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Abstract 
 
There is an increased incidence of young people with stroke (age ≤45years) in Human immunodeficiency 
virus (HIV) endemic countries; this has been largely attributed to hypertension. However, hospital based 
surveys in countries like Malawi and South Africa have shown that the prevalence of hypertension in 
these young people is lower than expected, but HIV infection is substantially higher, implicating HIV as a 
risk factor. 
 
For many years a link between HIV and stroke has been postulated, but the relationship is uncertain. 
Whilst HIV may be a risk factor for stroke directly through mechanisms linked with HIV-associated 
vasculopathy, or indirectly through opportunistic infections, the drugs that treat HIV infection may also 
increase the risk of stroke because of their metabolic effects. Many studies, almost all retrospective, 
have failed to separate the direct effect of HIV infection from the indirect effects, including combined 
antiretroviral therapy, on cerebrovascular risk. 
 
HIV infection increases the risk of stroke mimics such as intracranial toxoplasma infection.  The 
Recognition of Stroke in the Emergency Room (ROSIER) score is commonly used to screen for a stroke 
and triage patients for computer tomography (CT) of the brain.  However, the accuracy of the ROSIER 
score and CT brain to reliably differentiate a stroke diagnosis from those with a stroke mimic in people 
with HIV infection is uncertain.  I found that the ROSIER score and CT brain imaging had poor diagnostic 
accuracy in an HIV positive population.  Therefore, in my thesis, every patient with an acute neurological 
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symptom was fully assessed for a stroke as part of the screening process and confirmation was by 
magnetic resonance brain imaging.  
 
I subsequently investigated the risk factors and aetiology of stroke through a prospective case-control 
study in an HIV endemic country. Through this work, I showed that HIV infection is associated with 
cerebrovascular disease. Although hypertension was the leading risk factor in the population overall, HIV 
infection and its treatment was the second most important, and the most important in younger 
patients. Unexpectedly, I found that starting combined antiretroviral therapy in a subgroup of people 
living with HIV infection independently increased the risk of stroke. In this cohort, ischaemic stroke was 
the predominant stroke type and opportunistic infections only accounted for less than a third of these 
cases. 
 
The heterogeneity of HIV stroke with respect to risk factors for stroke, the degree of 
immunosuppression and HIV activity, and prior or current opportunistic infection has made it difficult to 
generalise epidemiological findings in some studies to populations at large. My study, to some extent 
unravels some of this ambiguity.  I  speculate that HIV related strokes evolves through the introduction 
of cART and then transitions into an aging population, accelerating atherosclerotic stroke and potentially 
contributing to an anticipated stroke epidemic in countries like Malawi. 
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Abbreviations and Notations 
 
3TC      Lamuvudine 
ACE     Angiotensin Converting Enzyme 
ACL    Anti-cardiolipin antibody 
aHR     Adjusted Hazard Ratio 
AIDS    Acquired Immunodeficiency Syndrome 
ANA     Antinuclear Antibody 
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CMV     Cytomegalovirus 
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CNS    Central Nervous System 
CSF     Cerebrospinal Fluid 
CT      Computed Tomography 
CXR      Chest Radiograph 
d4T     Stavudine 
DNA     Deoxyribonucleic Acid 
EIA     Enzyme Immunoassay 
ELISA     Enzyme Linked Immunosorbant Assay 
ENA     Extractable Nuclear Antigen 
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FBC     Full Blood Count 
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GDP    Gross Domestic Product 
HAND     HIV Associated Neurocognitive Disorder 
HBMECs    Human Brain Microvascular Endothelial Cells 
HDSS     Health and Demographic Surveillance Sight 
HIV    Human Immunodeficiency Virus 
HR     Hazard Ratio 
hsCRP     High-sensitivity C-reactive Protein 
HUVECS    Human Umbilical Vascular Endothelial Cells 
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ICAM-1    Intracellular Adhesion Molecule 1 
IDU     Intravenous Drug Use 
Ig     Immunoglobulin 
IHD      Ischaemic Heart disease 
IL6      Interleukin 6 
IQR      Interquartile Range 
IRIS      Immune Reconstitution Inflammatory Syndrome 
JCV     John Cunningham Virus 
LA     Lupus Anticoagulant 
LACI      Lacunar Infarct 
LACS      Lacunar Syndrome 
MCP-1    Monocyte Chemotatic Protein 1 
MI     Myocardial Infarction 
MLW     Malawi Liverpool Wellcome Trust Clinical Research Programme 
MRI     Magnetic Resonance Imaging 
MTB    Mycobacterium Tuberculosis 
NIHSS     National Institutes of Health Stroke Scale 
NNRTI     Non-nucleotide Reverse Transcriptase Inhibitor 
NRTI     Nucleotide Reverse Transcriptase Inhibitor 
NVP     Nevirapine 
OCSP     Oxfordshire Community Stroke Project 
OR     Odds Ratio 
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PACI     Partial Anterior Circulation Infarct 
PACS     Partial Anterior Circulation Syndrome 
PAF     Population Attributable Fraction 
PCR     Polymerase Chain Reaction 
PI     Protease Inhibitors 
PML     Progressive Multifocal Leukoencephalopathy 
POCI     Posterior Circulation Infarct 
POCS     Posterior Circulation Syndrome 
QECH     Queen Elizabeth Central Hospital 
RCC     Red Cell Count 
ROSIER    Recognition of Stroke in the Emergency Room 
RPR      Rapid Plasma Reagin 
Std. Err    Standard Error 
TACI    Total Anterior Circulation Infarct 
TACS     Total Anterior Circulation Syndrome 
TB      Tuberculosis 
TBM     Tuberculous Meningitis 
TOAST    Trial of Org 10172 in Acute Stroke Treatment 
TPPA     Treponema Pallidum Particle Agglutination 
Tp    Treponema  
UK     United Kingdom 
UN     United Nations 
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USA     United States of America 
VCAM-1    Vascular Cell Adhesion Molecule 1 
VDRL     Venereal Disease Research Laboratory 
VZV     Varicella Zoster Virus 
WCC    White Cell Count 
WHO     World Health Organisation 
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1 Introduction 
 
 
1.1 Overview 
Stroke is a common and devastating human disease. It is one of the leading causes of premature death 
and disability worldwide (Lozano et al. 2012; Murray et al. 2012). 
 
Stroke is clinically defined as “rapidly developing clinical signs or symptoms of focal (at times global) 
disturbance of cerebral function, lasting more than 24 hours or leading to death with no apparent cause 
other than vascular” (Hatano 1976). Once diagnosed a stroke is typed (e.g. ischaemic or haemorrhagic) 
using brain imaging. Ischaemic arterial stroke is the predominant type worldwide and accounts for 
approximately 80% of acute stroke events (C. Warlow 2007). The clinical presentation can be diverse 
such as dizziness or unilateral weakness. This can make the diagnosis challenging and delay treatment. 
 
The subtype of stroke is determined by the vascular territory involved and relates to outcome Figure 
1:1.  There are several causes of arterial ischaemic stroke and these are categorised by different 
aetiological classifications (Adams et al. 1993; Amarenco et al. 2009).  A commonly used example is the 
Trial of Org 10172 in Acute Stroke Treatment (TOAST) and includes the following: 1) large 
atherosclerosis 2) cardioembolism 3) small vessel disease 4) determined aetiology (e.g. infective 
disorders and coagulopathy), and 5) undetermined aetiology (Adams et al. 1993). Atherosclerosis is the 
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commonest cause of stroke worldwide and is strongly associated with established vascular risk factors 
such as hypertension, diabetes, and  smoking (Warlow et al. 2003). 
 
 
 
Figure 1:1: Subtype of stroke using the Oxfordshire Community Stroke Project (OCSP) classification: 
syndromes and imaging examples. Modified from Muir 2009 
 
Usually small vessel 
occlusion e.g. 
lenticiulostriate 
arteries. 
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Identification of causal stroke risk factors and implementing preventative therapies to reduce these risk 
factors at a population level can dramatically reduce stroke incidence. Rothwell and colleagues 
demonstrated a 40% decrease in stroke incidence in a UK community over a 10 year period; there were 
several speculations why this may have been the case, one important observation was the increased 
uptake of anti-hypertensive medication during this timeframe (Rothwell et al. 2004).  
 
1.2 Epidemiology of stroke  
In 2005 16 million individuals were estimated to have had a first-ever stroke and in the absence of public 
health interventions to reduce risk factors, this is expected to rise to 23 million by 2030 (Strong et al. 
2007). After ischaemic heart disease, stroke is the 2nd most important diagnosis of non-communicable 
diseases (Lozano et al. 2012). Deaths from non-communicable diseases, rose by just under 8 million 
between 1990 and 2010, accounting for two of every three deaths (34·5 million) worldwide (Lozano et 
al. 2012). On the basis of a systematic review of studies published between 1970-2008, there was a 42% 
decrease in stroke incidence rates in high-income countries, due to better recognition of stroke and 
improved primary and secondary interventions.  However, an increase in stroke incidence rates of  over 
100% was reported in  low-middle income countries (Feigin et al. 2009). As low-middle income countries 
develop economically, they will evolve through the ‘health transition’, this involves improved health 
services, better sanitation, reduced prevalence of infectious diseases and  rural to urban migration, as a 
result,  individuals will live longer. Because age is a strong predictor of stroke, stroke incidence will 
increase as the population ages. Established stroke risk factors are also associated with aging and 
urbanisation, and partly explains why emerging economies now suffer from the highest burden of stroke 
(Yusuf S 2001; Feigin et al. 2009).   
 
Introduction 
28 
 
Although stroke studies from sub-Saharan Africa are limited, the few that exist suggests that the 
incidence of young stroke (≤ 45 years-old) is more frequent compared to an industrialised country like 
the UK Table 1:1 (Connor et al. 2007; O'Donnell et al. 2010).  This interesting trend is thought to be 
largely explained by hypertension (O'Donnell et al. 2010). However, hospital based data from Malawi 
and South Africa shows that hypertension is less important (Kumwenda et al. 2005; Tipping et al. 2007; 
Heikinheimo et al. 2012). The disparity in the attribution of risk factors of young stroke, even within a 
continent, highlights the gaps in our knowledge (O'Donnell et al. 2010). 
 
 
 
 
 
 
 Figure 1:2 describes the distribution of important risk factors of common diseases, ranked globally and 
for each country. Specifically for stroke, risk factors included tobacco smoking, alcohol use, high fasting 
glucose, high total cholesterol, high blood pressure, high body mass index, abnormal diet (low in fruit, 
vegetable, whole grain or high in sugar, sodium) and physical inactivity.  The variation in the ranking of 
 Table 1:1: Age specific incidence of stroke per 100 000 population 
(Connor, Walker et al. 2007)
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these risk factors reflects the ‘health transition’ across the globe.  Whilst hypertension was ranked first 
globally and in many industralised countries it took a lesser rank in the poorer African countries.   
 
Sub-Saharan Africa also faces an enormous burden of infectious diseases, the impact of acute and 
chronic infection on the increasing burden of stroke is uncertain (Emsley et al. 2008; Lim et al. 2012). A 
better understanding of the risk factor profile in sub-Saharan African countries is needed to facilitate 
appropriate intervention strategies. 
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 Figure 1:2: Risk factors ranked by attributable burden of disease, 2010. Regions are ordered by 
mean life expectancy 
No data=attributable disability-adjusted life-years were not quantified (Lim, Vos et al. 2012). 
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1.3 Clinical features of stroke 
Stroke is usually characterised by acute focal neurological deficits, such as hemiparesis, aphasia, hemi- 
inattention or hemianopia, depending on the part of the brain that is affected. Figure 1:1 describes the 
subtypes of stroke (Oxford community stroke project classification) and relates this to the clinical 
presentation and brain imaging (Muir 2009). Almost any neurological symptom can be indicative of a 
stroke but when the symptoms are non-localising (e.g. loss of consciousness, psychiatric symptoms) and 
without clear-cut focal deficits, which is infrequent, the diagnosis then becomes challenging (Edlow et al. 
2011). There are also diagnoses that present like stroke but of non-vascular origin, these are referred to 
as stroke mimics and examples include migraine and focal epilepsy (C. Warlow 2007).  
 
1.4 Aetiology of stroke and mechanism of atherosclerosis 
Fifty percent of stroke is attributable to atherosclerosis, followed by small vessel disease (25%), 
cardioembolism (20%) and rare causes (5%); these proportions are typical of older (>45 years old) stroke 
patients (Warlow et al. 2003). Rarer causes of stroke, for example, primary vasculitis, infective vasculitis 
(e.g. varicella zoster) genetic disorders (e.g. Cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy) and coagulopathies (e.g. antiphopholipid syndrome) feature more in 
younger stroke patients but can still occur in the older cohort (Dichgans 2007; Gilden et al. 2009; Putaala 
et al. 2009; Urbanus et al. 2009). 
 
Atherosclerosis is the main cause of ischaemic stroke. When the arterial wall is irritated or injured by 
stimuli (such as dyslipidaemia, hypertension, diabetes, smoking or pro-inflammatory mediators) the cell 
biology of the arterial wall mal-adapts and this leads to plaque formation, narrowing of the luminal wall, 
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plaque instability, thrombus formation and ultimately ischaemia Figure 1:3. Distal embolisation of the 
ruptured plaque or thrombus is also likely to play an important role.  If this arose in the brain, the clinical 
manifestation would be an ischaemic stroke (Libby et al. 2011). Alternatively, hypertension associated 
arterial wall tension could give rise to microaneurysm formation and rupture, leading to a haemorrhagic 
stroke; there are many other causes of haemorrhagic stroke but this is the most common. 
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Figure 1:3: Stages in the development of atherosclerosis 
The normal muscular artery and the cell changes that occur during disease progression to thrombosis are 
shown. (Image A) The normal artery contains three layers. The inner layer, the tunica intima, is lined by a 
monolayer of endothelial cells that is in contact with blood overlying a basement membrane. In contrast to 
many animal species used for atherosclerosis experiments, the human intima contains resident smooth muscle 
cells (SMCs). The middle layer, or tunica media, contains SMCs embedded in a complex extracellular matrix. 
Arteries affected by obstructive atherosclerosis generally have the structure of muscular arteries. The arteries 
often studied in experimental atherosclerosis are elastic arteries, which have clearly demarcated laminae in the 
tunica media, where layers of elastin lie between strata of SMCs. The adventitia, the outer layer of arteries, 
contains mast cells, nerve endings and microvessels. (Image B) The initial steps of atherosclerosis include 
adhesion of blood leukocytes to the activated endothelial monolayer, directed migration of the bound 
leukocytes into the intima, maturation of monocytes (the most numerous of the leukocytes recruited) into 
macrophages, and their uptake of lipid, yielding foam cells. (Image C), Lesion progression involves the 
migration of SMCs from the media to the intima, the proliferation of resident intimal SMCs and media-derived 
SMCs, and the heightened synthesis of extracellular matrix macromolecules such as collagen, elastin and 
proteoglycans. Plaque macrophages and SMCs can die in advancing lesions, some by apoptosis. Extracellular 
lipid derived from dead and dying cells can accumulate in the central region of a plaque, often denoted the 
lipid or necrotic core. Advancing plaques also contain cholesterol crystals and microvessels. (Image D), 
Thrombosis, the ultimate complication of atherosclerosis, often complicates a physical disruption of the 
atherosclerotic plaque. Shown is a fracture of the plaque's fibrous cap, which has enabled blood coagulation 
components to come into contact with tissue factors in the plaque's interior, triggering the thrombus that 
extends into the vessel lumen, where it can impede blood flow (Libby et al. 2011).  
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1.5 Management and outcome 
There are several established risk factors for ischaemic stroke where data have shown reduction in 
stroke risk following intervention; this includes management of hypertension, and high cholesterol 
(Goldstein et al. 2006). Risk-assessment tools like the Framingham risk score or equivalent,  are 
important for assessing potential stroke risk to direct optimal management (Goldstein et al. 2006; 
D'Agostino et al. 2008).   
 
Following an acute stroke, secondary prevention such as aspirin (for those with ischaemic stroke) plus 
dipyridamole or clopidogrel, anticoagulation (for those that are high risk of a cardio-embolic stroke), 
carotid endarterectomy (for those with >70% carotid stenosis) and  administering blood pressure and 
cholesterol lowering drugs, have all been proven to reduce the incidence of recurrent stroke (Howells et 
al. 2010).  The risk of dying within the first 7 days, 1 month and 6 months after a first ever stroke are 
about 11%, 15% and 22% respectively, this is higher than the general population of equivalent age (C. 
Warlow 2007). Patients with haemorrhagic strokes, have a much higher early risk of dying than those 
with ischaemic strokes (C. Warlow 2007). 
 
Life saving and disability sparing interventions such as stroke units and thrombolysis  for ischaemic 
stroke, have revolutionised stroke care in the 21st century (Howells et al. 2010). Stroke units are now 
seen as an effective component of stroke services. A stroke unit is characterised by the presence of a 
multidisciplinary team (comprising medical, nursing, physiotherapy, occupational therapy, speech 
therapy, and social-work staff) who coordinate their work through regular meetings; in this forum they 
identify problems and set short and long-term recovery goals (Langhorne et al. 2002).  
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In contrast, the management of stroke in low-middle income countries provides several challenges 
including, poorer access to care and limited availability of secondary prevention strategies (Mendis et al. 
2005).  Furthermore, health systems are already stretched and specialist input scarce. Prioritising 
interventions that are resource appropriate combined with identifying vascular risk factors that are 
region/country specific are essential steps needed to overcome some of these difficulties. 
 
1.6 Malawi 
1.6.1 Demography and health indicators 
Malawi is situated in central southern Africa. In 2012 it had an estimated population of 13 million and 
this is predicted to rise to 26 million by 2030 (UNAIDS 2012).  The average life expectancy at birth  for 
males is 57 years and females 58 years (UNAIDS 2012). Malawi has a predominately young population 
with a median age of 17, 46% are less than 15 years and 6% greater than 60 years (UNAIDS 2012). As 
one of the poorest countries in the world, it has a gross domestic product (GDP) of US$357 per capita 
per year and is ranked 170/181 according to the human development index (UNdata).  
 
Blantyre, the commercial capital, is situated in the South of Malawi at an altitude of 1065m, it has a 
population of 1 million and two-thirds of these reside in urban dwellings.  Queen Elizabeth Central 
Hospital (QECH) is the main hospital for Blantyre district, as well as being the southern regional referral 
hospital.  In 1.5 years, QECH had in excess of 7000 adult medical admissions; median age was 37 years-
old, 50% were male, 26% were HIV positive (21% undiagnosed), the median stay in hospital was 5 days 
and in-hospital fatality 15% (Miguel A. SanJoaquin 2013).  
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The national adult HIV prevalence is 10.6%, however in urban Blantyre this is reported to be as high as 
18%; this makes it the top 10 of countries hardest hit by HIV/AIDS infection (Choko et al. 2011; UNAIDS 
2012). Heterosexual contact is the principal mode of HIV transmission in Malawi, while mother-to-child 
transmission of HIV accounts for approximately 25% of all new HIV infections (UNAIDS 2012). The 
Malawi demographic and health survey results shows that from 2004 to 2010 there was an upward shift 
in the HIV epidemic, suggesting that the HIV population was aging, there was also a gender variation 
Figure 1:4 (UNAIDS 2012). Since 2004 Malawi has had a free national programme to provide combined 
antiretroviral therapy (cART) for those living with HIV infection; up until 2011, the first-line treatment 
was a combination of nevirapine, stavudine and lamivudine but was later updated to three first line 
options; 1) nevirapine, stavudine and lamivudine 2) nevirapine, zidovudine and lamivudine 3) tenofovir, 
lamivudine and efavirenz (for pregnant, breastfeeding mothers and those already on TB treatment) 
(Malawi 2008; Malawi 2011). 
 
 
 
 
Figure 1:4: Prevalence of HIV infection by 5 years age bands and by sex, for 2004 and 2010 
 
W – woman, M – Male (Government 2012). 
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1.6.2 Stroke 
Stroke is among the top 10 diagnoses in the adult medical wards in Malawi (Miguel A. SanJoaquin 2013).  
Although the true incidence of stroke in this population is not clearly defined, neighboring countries like 
Tanzania show that the age adjusted incidence of stroke is substantially higher than the equivalent black 
American population (Walker et al. 2010).  Young stroke patients (≤45 years-old) account for 
approximately one-third of adult stroke admissions at QECH (Kumwenda et al. 2005; Heikinheimo et al. 
2012).  A high proportion of young patients with stroke has also been described in other sub-Saharan 
African countries (Kumwenda et al. 2005; Connor et al. 2007; Walker et al. 2010; Heikinheimo et al. 
2012).  
 
Cumulative hospital mortality post-stroke at 6 months and 1 year is 39% and 45% respectively; these 
rates are almost double those reported in high income countries (Bravata et al. 2003; C. Warlow 2007; 
Heikinheimo et al. 2012).  It is likely that these differences are related to design methodology (i.e. 
hospital versus community based study) but there is also the possibility of this being due to an increased 
incidence of stroke or poor quality of care post stroke.   
 
The WHO STEPS survey described the distribution of vascular risk factors in the general Malawian 
population.  They showed that within the 25-64 years age category, hypertension and smoking were 
more frequent (32.9% and 14.9% respectively) than diabetes, hypercholesterolaemia, and obesity (5.6%, 
8.7% and 4.6% respectively) (Msyamboza et al. 2011). Furthermore, the frequency of smoking, diabetes 
and hypercholesterolaemia was substantially lower compared to high income countries (O'Donnell et al. 
2010).  
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Figure 1:5 shows the distribution of stroke admissions by age at QECH. The early peak in stroke hospital 
admissions in the 25-45 years age-band mirrors the HIV epidemic in this country Figure 1:4. 
Furthermore, the prevalence of established vascular risk factors in this young stroke population is low 
and does not fully explain this peak, thus possibly implicating HIV infection as a stroke risk factor 
(Kumwenda et al. 2005; Heikinheimo et al. 2012).   
 
 
 
 
 
 
Long-term treatment with antiretroviral therapy has been linked to a high prevalence of hypertension 
and hypercholesterolaemia in Malawi (Muronya et al. 2011; van Oosterhout et al. 2012) . A better 
understanding of the risks associated with HIV infection and its treatment would give an insight into the 
drivers of stroke in Malawi. 
 
Figure 1:5: Distribution in age groups with HIV prevalence in 98 patients admitted with a recent stroke 
syndrome (Kumwenda, Mateyu et al. 2005) 
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1.7 Trends in HIV infection 
Sub-Saharan Africa suffers from the bulk of the world’s HIV epidemic and the incidence remains high in 
Malawi (Nel et al. 2012; UNAIDS 2012). The anticipated decline in HIV-associated mortality as observed 
in industrialised countries, owing to the widespread use of cART, will shift the landscape of HIV infection 
into an aging population.  This will be accompanied by an expansion of age-related diseases like stroke 
(Hasse et al. 2011). Furthermore, HIV infected individuals on long-term cART, who are virologically 
suppressed and immunocompetent, still suffer from premature death (Lewden et al. 2007). The concern 
being that accelerated vascular disease due to HIV infection may be the cause (Bozzette et al. 2003; 
Hasse et al. 2011). 
 
The transition of HIV infection from a terminal illness to a chronic disease is likely to dominate the HIV 
landscape for the foreseeable future. Thus, dissecting the relationship of HIV infection, its treatment and 
stroke risk is of urgent priority.  
 
1.8 HIV and stroke; current perspective  
1.8.1 Overview 
The incidence of stroke has increased by 100% in low-middle income countries in the last ten years 
(Feigin 2007; Feigin et al. 2009). While much of this increase is likely related to the health transition 
driven by the increasing burden of vascular risk factors and aging of the population, infectious causes of 
stroke may also add to the burden (Emsley et al. 2008; Walker et al. 2010). It is in these countries that 
the bulk of HIV infection is found (Quinn 1996). The two conditions may therefore be coincidental. 
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However, HIV infection potentially influences stroke risk and cause, and current HIV treatment results in 
vascular damage perhaps conferring an additional risk (Dobbs et al. 2009; Sen et al. 2012). 
 
Between 1–5% of HIV infected patients develop stroke in clinical series though a higher proportion have 
cerebral ischaemic lesions at autopsy (4–34%) (Moskowitz et al. 1984; Sharer et al. 1985; Anders et al. 
1986; Mizusawa et al. 1988; Berger et al. 1990; Kieburtz et al. 1993; Connor et al. 2000). There was little 
correlation between pathological evidence of cerebral ischaemic lesions and clinical manifestations prior 
to death in series that assessed this (Connor et al. 2000; Pinto 2005). In the United States, admissions of 
stroke patients with concurrent HIV infection has increased by 43% over nine years (Ovbiagele et al. 
2011). Despite this apparent association, surprisingly little research has assessed the impact of HIV 
infection on the burden and nature of stroke, the extent to which HIV increases stroke risk and the 
pathogenesis of stroke in HIV infected individuals (Berger 2004; Dobbs et al. 2009). 
 
The current mainstay of HIV treatment, combination antiretroviral therapy (cART), may also contribute 
to the risk of stroke directly by accelerating atherosclerosis and indirectly by increasing life expectancy 
(de Gaetano Donati et al. 2004). Inevitably, there will continue to be an increased exposure to 
conventional vascular risk factors (e.g. ageing, hypertension, diabetes mellitus, hypercholesterolaemia 
and cigarette smoking) as the HIV population lives longer. Furthermore, the continuous exposure to HIV, 
albeit at lower viral titre, and low-grade chronic systemic inflammation, may additionally add to the risk 
of stroke (Emsley et al. 2002; Lindsberg et al. 2003). 
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Quantifying the impact of HIV infection upon stroke has public health relevance, particularly when 
attempts are made to address the increased frequency of stroke in regions of high HIV prevalence.  
From a practical clinical perspective, when physicians in all regions are faced with an HIV infected 
patient who has had a stroke, they need to know the extent to which HIV infection and its treatment 
may impact upon the aetiology, clinical presentation and management of the stroke. Futhermore, the 
physician will need to consider a stroke presentation being the presenting feature of HIV infection.  
 
This review describes what is known about the risk of stroke in HIV infected individuals, the emerging 
theories of the mechanism of stroke in HIV infection, the impact of HIV on clinical stroke syndromes and 
implications for management. 
 
1.8.2 HIV infection and the risk of stroke 
Both HIV infection and cART may potentially increase an individual’s risk of stroke, therefore any 
assessment of the risk attributable to HIV infection must ideally have been assessed in an untreated 
population. The majority of studies have been retrospective or compared unmatched groups or cohorts, 
or the prevalence of HIV infection in stroke series compared to the general population of a similar age. 
Most were hospital based series, while some studies compared cerebral infarction (rather than clinical 
stroke) in HIV infected and unaffected brains at autopsy. No case controlled or cohort studies have 
prospectively assessed the risk of stroke in HIV infected populations and so the evidence to support the 
notion of an increased risk with HIV infection is based on very limited data.  
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Pre cART era 
A retrospective hospital based case-control study compared 113 young (19-44 years) stroke patients 
with 113 age and sex matched asthma patients with known HIV status in  South Florida, US, between 
1990-94. The study found that HIV infection was associated with a doubling of the risk of stroke (OR 2.3; 
95% confidence interval [CI], 1.0-5.3). The risk was higher for cerebral infarction (OR 3.4; 95% CI, 1.1-8.9) 
than cerebral haemorrhage (OR 1.3; 95% CI, 0.3-6.4). Eleven of the 25 HIV infected stroke patients (44%) 
had a coagulopathy (protein S deficiency) or meningitis (Qureshi 2005). 
 
 A population-based study from Baltimore, US, from 1988-1991 found that AIDS conferred an adjusted 
relative risk of 13.7 (95% CI, 6.1 to 30.8) for ischaemic stroke and 25.5 (95% CI, 11.2 to 58.0) for cerebral 
haemorrhage (Cole et al. 2004). This study included a small cohort of stroke patients with acquired 
immunodeficiency syndrome (AIDS) (n=12), ascertained retrospectively using discharge coding from 
multiple institutions. Several shortcomings may have resulted in surprisingly high relative risk ratios, 
including the selection of (by definition) patients with advanced HIV infection and therefore at 
particularly high risk of stroke, and under-reporting of AIDS in the study population (Berger 2004).  
 
Not all studies have found an association between HIV infection and stroke. An autopsy study from 
Florida (1986-87), retrospectively compared the brains of AIDS cases and non-AIDS cases between 20 
and 50 years of age. Cerebrovascular disease was present in 13 (8%) of 154 AIDS cases, and in a higher 
proportion of 25 of 111 (23%) of controls which suggested that stroke was not more common in AIDS 
cases at autopsy (Berger et al. 1990).   
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A hospital based study in Kwazulu Natal, South Africa found that the prevalence of HIV infection in a 
series of young patients with stroke was 16%, similar to the prevalence of HIV in the non-stroke 
population of a similar age (Hoffmann et al. 2000). However, it is questionable how generalisable this 
was to the population of Kwazulu Natal as the Durban Stroke Data Bank included around 12% black 
African stroke patients compared to a community proportion of 85% (Hoffman 1998).   
 
In a retrospective hospital-based study of 293 black African stroke patients aged between 15 and 44 
years, from the same region, HIV infection (present in 56) increased the risk of ischaemic stroke (OR 2.3 
CI 0.8 to 7.7; p = 0.09) though this finding was not statistically significant (Patel et al. 2005).  Patients 
with opportunistic infection were excluded from the study. However, almost a third of patients did not 
have HIV serology assessed. 
 
Post cART era 
No studies have prospectively assessed the impact of HIV infection on stroke risk since the introduction 
of cART (Dobbs et al. 2009; Sen et al. 2012).   
 
In a recent retrospective analysis of hospital admission data for all HIV infected individuals in Denmark 
(January 1995 to January 2010), the rate of cerebrovascular events was determined and compared to a 
sex and age matched general population, and stratified by Intravenous Drug Use (IDU) and conventional 
vascular risk factors.  HIV-infected individuals had an increased risk of cerebrovascular events compared 
with controls (non-IDU HIV adjusted Incidence Rate Ratio (IRR) 1.60; 95% CI, 1.32–1.94).  Risk of 
cerebrovascular events was greater when associated with intravenous drug use, low CD4+ T-lymphocyte 
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count pre-cART and treatment with abacavir (Rasmussen et al. 2011). Although arguably, this study 
provides the best evidence of risk of HIV for stroke, the retrospective nature of the study and lack of 
detailed prospective clinical assessment might have led to misclassification of cerebrovascular events in 
a population where stroke mimics are common. 
 
In the large US study that assessed population wide hospital stroke discharge diagnoses over nine years 
(1997-2006), there was a 43% rise in the number of HIV positive patients admitted with stroke, after 
adjustment for the population size. This increase was associated with a total increase in the proportion 
of ischaemic strokes in the HIV infected population and also coincided with the introduction of 
combination antiretroviral drugs in the mid-1990s (Ovbiagele et al. 2011).  It is impossible to tease out 
how much of this rise reflected an increase in the incidence of HIV infection, the impact of cART use on 
stroke risk in people with HIV infection, improved survival or indeed better recognition of stroke 
symptoms. However, the increase in HIV associated stroke admissions occurred simultaneously with an 
overall reduction in all stroke admissions (7%), suggesting but not confirming an association between 
HIV infection and stroke.  
 
1.8.3 Clinical presentation of stroke in patients with HIV infection 
Age 
Individuals with HIV infection and stroke are reported to be younger than non-HIV infected stroke 
patients. This could be a reflection of the population at risk of HIV infection or a sign that the 
mechanism of stroke in HIV is largely independent of classical vascular risk factors.  Ovbiagele et al 
described a median age of 42.9 years in 1997 and 48.4 years in 2006 of HIV infected stroke individuals in 
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the previously described retrospective analysis of hospital discharges in the US, and Ortiz et al found a 
median age of 42 years in a similar setting between 1997-2002 ((Ortiz et al. 2007; Ovbiagele et al. 2011). 
However, in lower income countries such as South Africa and Malawi HIV infected stroke patients are 
younger; a median age of 33.4 (n=61) years and 39.8 years (n=26) was described in Cape Town, South 
Africa (2000-2006) and Blantyre, Malawi (2008-2009) respectively (Tipping et al. 2007; Heikinheimo et 
al. 2012). One possible explanation for this global variation and the increase in median age seen in the 
US over a decade may be the use of cART, perhaps by delaying the time to stroke onset. 
 
Other Clinical Considerations  
Clinical descriptions of stroke in HIV infected and non-HIV infected patients are similar (Kumwenda et al. 
2005; Tipping et al. 2006; Bermel et al. 2009). While the sudden onset of a focal neurological deficit is 
typical, atypical stroke presentations are common in the context of HIV infection e.g. acute confusion, 
fever, acute loss of consciousness and stepwise focal neurological presentation over hours to days 
(Sharfstein et al. 2007; Bhagavati et al. 2008; Melica et al. 2009). An alternative cause or mimic of stroke 
should be excluded before a final diagnosis of HIV associated stroke is made. 
 
Stroke type and subtype 
Ischaemic stroke appears to be more frequent than cerebral haemorrhage in HIV infected patients, at 
least in hospital based series from sub-Saharan Africa, where it is reported in over 90% of HIV strokes 
(Mochan et al. 2005; Tipping et al. 2006; Ortiz et al. 2007). This trend was previously not supported by 
the literature (during the pre-cART era) in the US;  with near equal proportions of cerebral haemorrhage 
and ischaemic infarction in the Baltimore study described previously, but this is likely the reflection of 
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illicit drug use or hospital admission bias (Cole et al. 2004). However, Ovbiagele et al confirmed 
ischaemic stroke as the predominant pathological stroke type. This study found that the proportion of 
ischaemic stroke in HIV infected persons doubled between 1997 and 2006 (Ovbiagele et al. 2011).  
Whether this reflects the impact of cART or methodological factors is not clear. 
 
In a South African hospital based study, the subtype of ischaemic stroke using the Oxfordshire 
Community Stroke Project (OCSP) classification in the HIV positive group (n= 64), comprised lacunar 
stroke (n=13), partial anterior circulation stroke (n=33), total anterior circulation stroke (n=11) and 
posterior circulation stroke (n=7) (Tipping et al. 2007). The proportions of these subtypes follow similar 
trends to the original OCSP classification but posterior circulation stroke was less frequent in this HIV 
population though this is based on small patient numbers (Bamford et al. 1991). However, I will be able 
to accurately determine the proportions of stroke type and subtype in a community based HIV stroke 
population to avoid hospital admission bias that favours cerebral haemorrhage. 
 
1.8.4 Causes of stroke in people with HIV infection 
HIV infection can potentially cause stroke in many ways; indirectly through cardioembolism, 
coagulopathy, non-HIV infective vasculitis, or directly through HIV-associated vasculopathy. Table 1:2 
lists the possible mechanisms that may result in an ischaemic or haemorrhagic stroke.  
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Coagulopathy 
HIV infection may predispose to both arterial and venous thrombosis; however, it is not clear to what 
extent this is due to a coagulopathy. Protein C and S deficiency are sometimes associated with 
intracranial venous thrombosis but rarely with arterial stroke in non-HIV infected adults (Kenet et al. 
2010; Morris et al. 2010). Although Protein C and S deficiency have been described in HIV infected 
stroke patients, it is not clear whether this is an epiphenomenon or causal.  In one case series comparing 
unmatched stroke patients (n=33) with and without (n=33) HIV infection from South Africa, there was 
no significant difference in the proportion of patients with Protein S deficiency in the two groups 
(Mochan et al. 2005). 
 
Antiphospholipid antibodies have been infrequently described in people with stroke and HIV infection, 
but as transient elevated antiphospholipid antibody titres are commonly found with viral infection, 
elevated levels should only be considered significant in patients fulfilling the International Haematology 
Consensus statement criteria for antiphospholipid syndrome (Miyakis et al. 2006). This has only rarely 
been applied in studies investigating stroke and HIV infection and the true frequency of any association 
remains unclear (Mochan et al. 2003; Tipping et al. 2006; Giannakopoulos et al. 2009). Factor V Leiden is 
not associated with HIV related stroke. 
 
Cardioembolism 
Cardioembolism accounts for 4-15% of ischaemic strokes in an HIV infected population (Hoffmann et al. 
2000; Mochan et al. 2003; Ortiz et al. 2007). HIV-associated dilated cardiomyopathy is a commonly 
reported cause of cardiac disease particularly in sub-Saharan Africa (Magula et al. 2003; Ntsekhe et al. 
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2009; Sliwa et al. 2012). It may be associated with opportunistic infection and has been attributed to HIV 
itself although its pathogenesis is uncertain. I have therefore used a deliberately vague term ‘HIV 
associated cardiac dysfunction’ in Table 1:2.  Assessment of cardioembolic causes of stroke in patients 
with HIV in studies from sub-Saharan Africa is further complicated by the relatively high prevalence of 
non-ischaemic cardiomyopathy and rheumatic heart disease in the non-HIV infected population (Ntusi 
et al. 2009). Other potential causes of cardioembolism include bacterial and marantic endocarditis, and 
ischaemic heart disease (Barbaro et al. 2001; Barbaro 2002). 
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Opportunistic infections 
Some infections are well-established causes of stroke. Mycobacterium tuberculosis (TB), syphilis and 
Varicella zoster Virus (VZV) cause stroke in non-HIV infected patients, but immunosuppression due to 
HIV increases susceptibility to acquiring or reactivating these infections (Timmermans et al. 2004; Gilden 
et al. 2009; Lammie et al. 2009). TB related stroke is thought to be a complication of tuberculous 
meningitis and acute focal signs presenting as stroke may be the first manifestation (Berenguer et al. 
1992; Lammie et al. 2009). Therefore, actively looking for tuberculosis in HIV infected stroke patients, 
who are more at risk, is important. VZV infection may cause cerebral vasculitis and stroke in the 
immunosupressed and the skin manifestation can be absent in approximately a third of stroke cases at 
the time of presentation, making the diagnosis less obvious (Nagel et al. 2008; Gilden et al. 2009; 
Gutierrez et al. 2011).  The increased incidence of syphilis in HIV infected individuals could be related to 
one or more of the following factors; 1) immunosuppresion or 2) share the same mode of acquisition 
because both are sexually transmitted infections.  Co-infection with HIV compounds the difficulty in 
diagnosing neurosyphilis (Timmermans et al. 2004; Zetola et al. 2007). Furthermore, an increase in 
meningovascular complications has been described in the HIV population (Timmermans et al. 2004; 
Zetola et al. 2007; Chahine et al. 2011).  HSV-2 is another sexually transmitted infection that is known to 
infect the brain. However, it causes meningitis rather than stroke syndromes. 
 
Cytomegalovirus and Candida ablicans infections have been associated with HIV infection and stroke in a 
few case series and further evidence is needed to confirm this (Kieburtz et al. 1993; Anderson et al. 
2010). cART may unmask occult opportunistic infections that consequently cause a stroke. This should 
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be considered in all patients with an acute stroke or worsening of stroke symptoms following the 
initiation of cART (Lucas et al. 2008; Newsome et al. 2009; Pepper et al. 2009; Anderson et al. 2010). 
 
Even in high-income countries, opportunistic infection still accounts for significant mortality despite the 
use of cART and optimal diagnostic facilities (Lucas et al. 2008). Furthermore, infections outside the 
central nervous system may contribute to the development of a prothrombotic state potentially 
increasing the risk of ischaemic stroke (Emsley et al. 2008). 
 
HIV- associated vasculopathy 
HIV-associated vasculopathy is a relatively new and evolving term used to describe several arterial 
changes associated with HIV infection Figure 1:6. Some authors have distinguished aneurysmal arterial 
changes from vasculitis and others have suggested that given the uncertainty regarding pathogenesis of 
vasculitis, all arterial abnormalities thought to be associated with stroke are considered part of an HIV-
associated vasculopathy. A working definition would, in my opinion, be useful to both clinicians and 
pathologists. Based on the current literature, I propose that the term HIV-associated vasculopathy 
should include any abnormality of the intra or extracranial cerebral blood vessels that results directly or 
indirectly from HIV infection, but excludes opportunistic infection associated vasculitis or neoplastic 
involvement of the vessels Table 1:2. In the table, I suggest a classification of HIV-associated 
vasculopathy to include large and small vessel abnormality associated with aneurysm formation, 
vasculitis, accelerated atherosclerosis and other abnormalities including altered vascular reactivity and 
small vessel disease. Aneurysmal dilatation in HIV infected patients may be extracranial involving the 
carotid, aorta, iliac and other large arteries, or intracranial involving branches of the circle of Willis (Nair 
et al. 1999; Chetty et al. 2000; Modi et al. 2008). In a series of HIV positive stroke patients in Cape Town 
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(n=64), seven patients had an extracranial non-aneurysmal vasculopathy which manifested as either 
stenosis or occlusion of the internal carotid artery. Autopsy of one of the individuals who died from 
complications associated with their stroke had microscopic evidence of neovascularisation and vessel 
wall inflammation with a thrombus occluding the lumen. Six patients had radiological evidence of 
intracranial vasculopathy, typically involving the medium sized vessels with or without fusiform 
aneurysm or stenosis. One patient’s histology showed luminal thrombosis, concentric intimal 
hyperplasia with hyalinization and fragmentation of the elastic lamina (Tipping et al. 2007). In this case 
series, patients with an extracranial vasculopathy had a significantly higher CD4+ T lymphocyte count 
compared with those with intracranial vasculopathy (Tipping et al. 2007). Patients in this study were 
young and did not have evidence of atherosclerosis.  
Introduction 
52 
 
                                   
Table 1:2: Possible HIV related causes of stroke 
 
Ischaemic 
HIV-associated vasculopathy (abnormality of the cerebral blood 
vessels result directly or indirectly from HIV infection but excluding 
opportunistic infection vasculitis) 
 
 Associated with aneurysm formation 
- Intracranial 
- Extracranial 
 Vasculitis (where this is the direct result of HIV infection 
and opportunistic infections have been excluded) 
 Accelerated atherosclerosis  
 Other disease of cerebral blood vessels associated with 
HIV infection (including small vessel disease changes and 
altered vasoreactivity) 
 
Opportunistic infection / neoplasia 
 
 Opportunistic infection causing stroke e.g. tuberculous 
meningitis, Varicella Zoster Virus vasculitis, 
meningovascular syphilis 
 Neoplasia such as lymphoma involving cerebral blood 
vessels 
 
Cardioembolism  
 
 Bacterial endocarditis 
 Marantic endocarditis 
 HIV-associated cardiac dysfunction  
 Ischaemic Heart  Disease 
Other determined cause 
 
 Coagulopathy (e.g. antiphospholipid syndrome) 
 HIV associated hyperviscosity 
 
Haemorrhagic 
 
 HIV-associated vasculopathy (aneurysm or vasculitis 
associated) 
 
 HIV associated thrombocytopenia 
 
 Mycotic aneurysm (secondary to bacterial endocarditis 
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Figure 1:6: HIV-associated vasculopathy 
Aneurysmal HIV-associated vasculopathy (Image A) 
View of the ventral surface of the brain showing a 
thrombotic occlusion of the left internal carotid artery 
and evidence of vasculopathy of the left middle cerebral 
artery (arrows). (Image B) CT angiogram showing 
several fusiform aneurysms affecting the circle of Willis. 
(Image C) Haematoxylin and eosin stain of a cross-
section through an aneurysmal cerebral artery showing 
evidence of intimal hyperplasia, fragmentation of 
internal elastic lamina (arrow), and neutrophil infiltrate; 
note the absence of atherosclerosis. 
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In other studies, HIV infected patients with extracranial carotid aneurysms but without stroke, had 
evidence of a leucocytoclastic vasculitis of the vasa vasorum and periadventitial vessels without 
evidence of atherosclerosis or infection on culture of the blood or aneurysm wall (Nair et al. 1999; 
Chetty 2001). Whether this form of vasculitis is an initiating or pivotal event in the development of 
extracranial carotid artery aneurysm formation in HIV infection or one of several factors responsible is 
not clear. Fusiform intracranial cerebral aneurysms have been described in children usually as incidental 
findings but in some, associated with subarachnoid haemorrhage or ‘hemiparesis’ (Mazzoni et al. 2000; 
Bulsara et al. 2005).  
 
The term ‘vasculitis’ should be reserved for the histologically confirmed appearance of inflammatory 
cells in the blood vessel wall together with associated wall damage. In early pathological studies that did 
not exclude all potential causes of infective vasculitis other than HIV, cerebral vasculitis attributed to HIV 
was probably overestimated (Connor et al. 2000; Nogueras et al. 2002). However, a heterogenous array 
of extra-cerebral vasculitis of small, medium and large arteries has been described in HIV-infected 
patients (Chetty 2001). Although HIV antigen and particles have been described in perivascular cells in 
two patients and HIV-like particles in another suggesting direct HIV infection at least of perivascular 
tissue, this is far from certain (Gherardi et al. 1993; Chetty 2001). Other postulated mechanisms for 
vasculitis include immune deposition and indirect damage caused by T cell derived growth factors and 
cytokines (Chetty 2001). In clinical practice, histology is seldom available and the diagnosis of cerebral 
vasculitis is usually based on clinical and radiological findings and exclusion of other possible causes. In 
recent clinical case series HIV-associated arterial vasculitis (attributable to opportunistic infection or 
other known cause), accounted for 13-28% of ischaemic stroke patients (Mochan et al. 2003; Ortiz et al. 
2007; Tipping et al. 2007). In a patient presenting with typical clinical and radiological features of 
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vasculitis, in whom all other likely causes have been excluded, HIV-associated vasculitis is the most likely 
diagnosis.  
 
HIV infection may be associated with acceleration of large vessel atherosclerosis, potentially as a result 
of cART and associated metabolic complications such as dyslipidaemia, insulin resistance or diabetes 
mellitus, via low grade chronic systemic inflammation, or as a result of co-infections such as hepatitis C 
or cytomegalovirus (CMV) (Maniar et al. 2012; Sen et al. 2012).  Interactions between co-infections and 
cART in the context of HIV may be more complicated than currently appreciated. For example, one 
recent study suggested mitochondrial genomics may play a significant role in metabolic disorders and 
cardiovascular diseases in HIV/hepatitis C virus-coinfected patients on cART (Micheloud et al. 2011). 
Relatively little is known currently about the role of specific co-infections in atherogenesis in HIV 
infected individuals. It might even be relevant to consider infectious burden of a number of infectious 
microorganisms (for example Chlamydia pneumonia, Helicobacter pylori, CMV, herpes viruses 1 and 2) 
contributing to atherosclerosis rather than individual co-infections, as it appears to be in non-HIV 
infected individuals (Elkind et al. 2010). 
 
Other abnormalities of cerebral blood vessels such as altered vasoreactivity and small vessel 
abnormalities have been described (Connor et al. 2000; Sen et al. 2012). The significance of these 
abnormalities in the context of clinical stroke is not clear.  
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Other causes 
Although arterial changes in HIV infected patients may be associated with HIV or opportunistic infection 
(e.g. varicella zoster virus or tuberculosis), other unrelated aetiologies such as connective tissue disease 
and an arterial dissection should also be considered in this young population. Mycotic aneurysm 
resulting from bacterial endocarditis, HIV induced thrombocytopenia and complications of aneurysmal 
and vasculitic HIV-associated vasculopathy may result in cerebral or subarachnoid haemorrhage Table 
1:2. 
 
1.8.5 Pathogenesis of vasculopathy and atherogenesis in HIV (in the absence 
of cART) 
Much of our understanding of the potential pathogenesis of HIV infection and stroke comes from 
experimental studies using in vitro human brain microvascular endothelial cells (HBMECs), human 
umbilical vascular endothelial cells (HUVECs) models and HIV-transgenic animal models (Tinkle et al. 
1997; Chi et al. 2000; Hag et al. 2009). In vivo studies in humans have utilised various imaging modalities 
(e.g. carotid and transcranial-Doppler, magnetic resonance imaging and angiography) to demonstrate 
endothelial integrity indirectly. In addition, the use of circulating biomarkers has given us some insight 
into endothelial dysfunction in HIV infection (de Gaetano Donati et al. 2004).  
 
The vascular endothelium is a protective barrier, preventing arterial wall inflammation, coagulation, 
remodelling and ultimately, in some instances, stroke. Dysfunction of the endothelium is pivotal to the 
initiation and progression of vascular disease and may lead to occlusive thrombotic events mediated by 
leucocyte recruitment, platelet adhesion and aggregation, blood clotting activation, and fibrinolysis 
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derangement (Chi et al. 2000; Kline et al. 2008). This is believed to underpin the inflammatory process of 
atherosclerosis and similarities have been seen in HIV experimental models and individuals with stroke 
Figure 1:7 (Kline et al. 2008; Lo et al. 2012). I will explore the impact of HIV on the endothelium and its 
potential impact on chronic vascular inflammation and vessel wall remodelling.  
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Figure 1:7: Hypotheses on the mechanism of HIV-associated vasculopathy 
Mechanisms are specific to atheroma and potentially applicable to the other forms of HIV-associated 
vasculopathy. (1) Direct damage can occur through continuous exposure of the endothelium to HIV 
virion or viral particles (eg, GP120 or TAT) leading to endothelial dysfunction. (2) Indirect damage can 
arise from circulating infected monocytes freely transmigrating the endothelium as part of normal 
surveillance, with an impaired reverse transmigration, thus increasing the subendothelial population 
of HIV infected monocytes. The release of chemokines such as CCL2 from infected leucocytes attracts 
more leucocytes. (3) Several events lead to the progression of damage and propagation of 
atherogenesis: upregulation of cell adhesion molecules (eg, selectins), leading to increased adhesion 
of infected or non-infected leucocytes; release of HIV virions into the arterial smooth muscle and 
continued active replication of the virus in smooth muscle cells; inflammatory cytokine release from 
HIV-infected cells, leading to further recruitment and adhesion of leucocytes, increased production of 
reactive oxygen species, and derangement of the coagulation system, favouring a prothrombotic 
state. Underlying this continuing process is the remodelling of the vessel wall, involving intimal 
hyperplasia and fragmentation of the elastic lamina. (4) Thrombotic occlusion of the vessel wall lumen 
is one of the outcomes of this process. 
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The role of inflammation 
Although HIV-1 itself is unlikely to be vasculotropic, the virus affects endothelial homeostasis and 
function in important ways that could initiate and propagate atherogenesis. The vascular endothelium is 
continually exposed to stimuli such as HIV-1-infected cells (CD4+ T cells, monocytes, and macrophages), 
freely circulating HIV-1 viruses; HIV-1 proteins (i.e. Tat and gp120) that are released with host cell lysis 
or actively secreted, and viral-induced pro-inflammatory cytokines (Chi et al. 2000; Kuller et al. 2008). All 
these factors potentially activate the endothelium, damage and increase its permeability, facilitating 
leucocyte invasion into the vessel wall and chronic inflammation.  
 
HIV-1-induced cytokine endothelial activation may result in production of reactive oxygen species (ROS), 
expression of cell adhesion molecules (CAMs), and the release of chemoattractants at localised areas of 
vascular inflammation. Akin to the pathogenesis of atherosclerosis, chemoattractants such as 
chemokine ligand 2 (CCL2) may recruit leucocytes to the brain during HIV infection (Park et al. 2001; 
Eugenin et al. 2008).  CCL2 is also associated with an increase in HIV viral burden (Floris-Moore et al. 
2009). Plasma concentration of vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion 
molecule-1 (ICAM-1), and E-selectin, in addition to other markers of inflammation (high-sensitivity C-
reactive protein (hsCRP), interleukin (IL)-6 and cystatin) are significantly elevated in HIV-1-positive 
patients compared with controls (Schved et al. 1992; Chi et al. 2000; Ross et al. 2009; Neuhaus et al. 
2010). The activation of these biomarkers implicates HIV-1 virus in dysfunction of the endothelium and 
inflammation. Endothelial cell molecules involved in coagulation such as von Willebrand factor, 
thrombomodulin, plasminogen activator inhibitor-1 antigen, tissue factor and d-dimer are deranged in 
HIV infection, favouring a prothrombotic state (Schved et al. 1992; Neuhaus et al. 2010). Furthermore, 
some of these biomarkers of endothelial dysfunction and inflammation positively correlate with anti-
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p24 antibody levels and disease severity (Schved et al. 1992; Triant et al. 2011). This propagated 
inflammatory process could potentially accelerate atherosclerosis or independently initiate vascular 
disease. 
 
Monocytes continually migrate from the bloodstream across the vascular endothelium for systemic 
immune surveillance and maintenance of macrophage populations in the brain. CD163 is a novel marker 
of activated monocyte; it is elevated and associated with noncalcified coronary plaque in HIV-infected 
patients; implicating a role in the pathogenesis of HIV-associated atherogenesis (Burdo et al. 2011). 
 
Monocytes can perform reverse transendothelial migration across the endothelium, necessary for the 
movement of tissue monocytes/macrophages back into the bloodstream. HIV-1 infected macrophages 
have a reduced capacity to emigrate from the subendothelial extracellular matrix in vitro, indicating that 
the infected monocyte can easily move from the blood stream to the brain tissue but not the reverse 
(Westhorpe et al. 2009). Clinically, such an adaptation could promote establishment of viral reservoirs 
and increase the exposure of HIV-1 and its viral proteins to the vessel wall.  Since the vascular bed serves 
as the interface between the entry and exit of these monocytes, it is conceivable that this is where the 
greatest damage occurs.  In the context of vascular disease, it has been demonstrated that once the 
virus is subendothelial it can then infect coronary arterial smooth muscle in a CD4+ T cell, chemokine 
and endocytosis dependent manner and actively replicate in its new niche (Schecter et al. 2001; Eugenin 
et al. 2008).  
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Evidence of vessel wall remodelling  
Insights from animal models have shown a plausible link between endothelial dysfunction and 
vasculopathy. The well-characterised “murine AIDS” model of retroviral infection time-dependently 
decreased maximum aortic contractile responses and impaired endothelium-dependent relaxation 
(Clark et al. 2001).  Isolated aortas from infected mice also expressed higher levels of ICAM-1 and VCAM-
1 (Hag et al. 2009). These models also demonstrated independent HIV-associated vasculopathy (Tinkle 
et al. 1997; Baliga et al. 2005). Thus, the “murine AIDS” model strongly suggests that retroviral infection, 
similar to that of HIV-1 in humans, is capable of causing vasculopathy and endothelial dysregulation in 
mice. 
 
Some of these experimental findings have been corroborated in humans; brachial endothelial-
dependent flow mediated dilatation and carotid intimal medial thickness (cIMT) are functional and 
structural indicators of endothelial integrity. Impaired brachial endothelial-dependent flow mediated 
dilatation and increased cIMT are both associated with immunosuppression or increasing HIV viral levels 
(Solages et al. 2006; Oliviero et al. 2009; Seaberg et al. 2010).  Suppressed HIV replication is associated 
with less cIMT progression (a marker of subclinical atherosclesosis) (Baker et al. 2011).  Furthermore, 
thinning of the arterial media layer, a possible preclinical stage of HIV-associated vasculopathy has been 
described (Gutierrez et al. 2012). 
 
HIV-1 associated endothelial dysfunction likely compromises the central nervous system though 
whether or not this results in hard clinical outcomes such as stroke is unclear. It is plausible that HIV 
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initiates injury to the vascular tree or contributes to further injury to an already damaged vascular tree 
caused by atherosclerosis, predisposing to stroke.  
 
1.8.6 Role of cART in the pathogenesis of cerebrovascular disease and stroke 
More recently, the focus on stroke risk is not only on HIV infection but its treatment, cART.  De Gaetano 
Donati and colleagues proposed that cART could cause both direct tissue injury to arteries resulting in 
elevated markers of endothelial dysfunction or indirectly cause injury through lipid modification.  
However, it is still uncertain how relevant this is to cerebrovascular disease (de Gaetano Donati et al. 
2003).  Elevation of biomarkers indicating endothelial dysfunction should be interpreted with caution, as 
this could arise as a consequence of other factors, namely autoreactive cell destruction by an improved 
autoimmune system and/or the efficacy of the therapy destroying cells.   
 
In the short term cART might reduce the risk of ischaemic stroke and transient ischaemic attack, though 
this is based on retrospective data from only one study (Corral et al. 2009). However, there is increasing 
evidence suggesting that long-term cART results in endothelial toxicity and vascular dysfunction (Corral 
et al. 2009; Ross et al. 2009). Non nucleotide reverse transcriptase inhibitors (NNRTI), protease inhibitors 
(PI) but not nucleotide reverse transcriptase inhibitors (NRTI) are thought to cause inflammation and 
may increase cardiovascular risk. Again, little is known about the impact on cerebrovascular risk. 
Abacavir, a NRTI has been associated with an increased ‘high sensitivity’ (hs) CRP, IL-6 levels and in a 
retrospective cohort study, an increase in cerebrovascular events in an HIV infected population (Kuller et 
al. 2008; Rasmussen et al. 2011). However, a recent meta-analysis of published and unpublished 
Randomised Controlled Trials did not confirm an increased risk of cardiovascular events (mostly 
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myocardial infarction) with abacavir-containing cART regimens compared with other cART. How much of 
this extrapolates to cerebrovascular disease is unknown (Cruciani et al. 2011). More research is needed; 
specifically with cerebrovascular events as an endpoint. 
 
HIV related endothelial dysfunction and inflammation continues on cART; Ross and colleagues 
demonstrated enhanced endothelial activation, inflammation, and increased cIMT in HIV-infected 
patients despite cART; concluding that although cART is reducing the virulence of HIV, it has little anti-
inflammatory potential on the endothelium (Ross et al. 2009). Therefore, HIV infected individuals 
receiving cART are likely to live longer with prolonged endothelial and metabolic challenges that 
increase stroke risk. 
 
1.8.7 Management 
Stroke mimics are not uncommon in the HIV population. Of the ninety-eight consecutive patients 
presenting with an acute focal neurological deficit in Malawi, eleven were found to have another cause 
for their presentation (e.g. toxoplasmosis, neurocysticercosis, tuberculoma, brain tumour) (Kumwenda 
et al. 2005).  Brain imaging in HIV infected patients presenting with sudden onset focal signs and 
features suggestive of a stroke is therefore essential to the diagnosis as well as distinguishing between 
cerebral haemorrhage and ischaemic stroke.  
 
Once the diagnosis of stroke is confirmed, management should be directed towards acute stroke 
treatment, establishing the cause of the stroke, management of HIV infection and secondary prevention 
of stroke. Concomitant HIV infection raises doubt about extrapolating from evidence based treatment of 
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non-HIV related stroke. The role of intra-venous thrombolysis is uncertain in the absence of randomised 
controlled studies in HIV related stroke.  Often, the patient’s HIV status is not known at the time of 
presentation of the acute stroke and the decision whether or not to administer thrombolysis must be 
taken within a short time.  Although there is no clear evidence of harm and HIV infected individuals may 
well have a stroke unrelated to HIV infection, the pathogenesis of stroke may include HIV-associated 
vasculopathy, infective vasculitis, infective meningitis and other causes that may increase bleeding risk 
Table 1:2. Reassuringly, there are isolated reports of successful use of thrombolysis to treat myocardial 
infarction in HIV infected individuals (Boccara et al. 2003). However, how generalisable this is to patients 
with potentially diseased cerebral vessels and higher bleeding risk with thrombolysis is unclear. Until 
such data become available, acute therapy including the use of thrombolysis will have to be 
individualised and based on clinical judgment and of course patient choice.  
 
Investigation should be directed both at assessing for conventional causes of stroke and those 
associated with HIV (Table 1:2, with particular emphasis on finding treatable causes). Figure 1:8 provides 
an approach to management but in many areas where HIV infection is prevalent this will not be possible. 
In low resourced settings, investigation and treatment should be directed at finding treatable causes of 
stroke or stroke mimics such as tuberculosis, cryptococcus, toxoplasmosis, varicella zoster and herpes 
virus infection, perhaps by combining CT brain scan, chest x-ray, lumbar puncture (if not contraindicated 
and in the absence of an alternative cause e.g. an obvious cardioembolic source) and selected blood 
tests. Figure 1:8. Ancillary tests may be needed to establish the cause of the stroke e.g. sputum and 
cerebrospinal fluid (CSF) samples for tuberculosis (Kent et al. 1993; Nelson et al. 2011). Measuring 
intrathecal IgG against varicella zoster virus together with CSF DNA PCR improves the likelihood of 
identifying this potential cause (Nagel et al. 2008). The ideal test for neurosyphilis is controversial, 
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however CSF VDRL and when this is negative in a HIV positive patient, CSF fluorescent treponemal 
antibody (FTA) seems a reasonable approach (Marra et al. 2004; Timmermans et al. 2004). 
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Figure 1:8: Management approach for HIV infected patients with stroke 
TIA=transient ischaemic attack. cART=combined antiretroviral therapy. FBC=full blood count. ESR=erythrocyte 
sedimentation rate. ANA=antinuclear antibodies. ANCA=antineutrophil cytoplasmic antibodies. HSV-1=herpes 
simplex virus type 1. VZV=varicella zoster virus. CMV=cytomegalovirus. TB=tuberculosis. ECG=electrocardiograph. 
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Antineutrophil cytoplasmic antibodies (ANCA) assessed by immunofluorescence and enzyme-linked 
immunosorbent assay have been described in HIV infection but not necessarily in patients with 
vasculitis, autoimmune disease or specific opportunistic infection (Savige et al. 1993; Cornely et al. 1999; 
Jansen et al. 2005). A diagnosis of cerebral vasculitis in individuals with HIV infection should be based on 
the results of appropriate radiological and if possible histological features in a patient without any other 
potential cause of vasculitis (e.g. opportunistic infection). In this setting a positive ANCA may strengthen 
the diagnosis.  
 
In high resourced settings, the investigation should include detailed assessment of cerebral arteries 
including carotid doppler and CT or MR angiography depending on local expertise. In selected patients, 
perhaps those who have further events or comorbidity suggesting autoimmune or other disease, 
conventional angiography and or brain biopsy may be indicated. In low resourced settings without 
access to brain imaging, I advise basic stroke care using the approach outlined in the South African 
stroke guideline (Bryer et al. 2011).   
 
The role of immunosuppression with corticosteroids is far from clear (Bhagavati et al. 2008; Bermel et al. 
2009). In the absence of any evidence to guide management, it may be useful to follow this approach; if 
vasculitic HIV-associated vasculopathy is suspected and other potential autoimmune or infectious 
causes have been excluded, then the introduction of cART and addition of corticosteroid, if the patient 
has a poor response, seems reasonable.  
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There is convincing evidence that the introduction of cART results in reduction of all cause mortality in 
HIV infected patients (Bozzette et al. 2003; Bozzette 2011). Far less certain is whether cART, particularly 
exposure to protease inhibitors, increases the risk of stroke and myocardial infarction in the long term 
as a result of metabolic effects e.g. hypercholesterolaemia already described, and prolonged survival 
(aging is a risk factor for stroke and some HIV infected groups have a high prevalence of cigarette 
smoking) (Currier et al. 2008; Bedimo et al. 2011; Bozzette 2011). The risk-benefit ratio of cART on the 
basis of current knowledge appears favourable. However, given the concern about long-term stroke and 
cardiovascular disease risk, a pragmatic approach seems reasonable; identifying and managing risk 
factors, perhaps changing the class of cART regimen or considering a cholesterol lowering drug if 
appropriate (Holmberg et al. 2002; Bozzette et al. 2003; Kwong et al. 2006; Bozzette 2011; Islam et al. 
2012). 
 
None of the studies that currently guide the use of secondary prevention for stroke including use of 
antiplatelets, statins and blood pressure lowering therapy, can be directly extrapolated to the care of 
the HIV-infected stroke patients. However, general lifestyle factors and aiming for optimal reduction of 
vascular risk factors seems sensible.  
 
Finally, it is important to consider the mode of HIV infection relevant to the patient as this may influence 
the underlying stroke risk factors, cause and management. In sub-Saharan Africa the major mode of HIV 
transmission is heterosexual, intravenous drug use is rare (Ocama et al. 2011; Wamai et al. 2011). 
However, intravenous drug use is more common elsewhere and may be associated with several 
potential stroke causes including use of specific drugs (cocaine, amphetamines, sympathomimetic 
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drugs), infective endocarditis, and embolisation of particulate matter (C. Warlow 2007). In many regions, 
cigarette smoking is more common in people with HIV infection than the general population (Shurtleff 
et al. 2012). 
 
1.8.8 Conclusion 
The incidence of stroke is increasing in low and middle income countries and HIV infection, often 
prevalent in the same regions, may add to the risk, though data are very limited. While cART may 
decrease stroke risk in the short term, the impact of cART on the vasculature and long term stroke risk is 
unknown but may be significant. Certainly, cART has increased the lifespan of those infected with HIV 
infection but paradoxically this may increase their risk of stroke in the long term, particularly in the 
context of endothelial and metabolic side effects of current medication. The risk of stroke in HIV 
infection and further research to clarify burden, causes, pathogenesis, and management, is needed in 
areas with little or inadequate antiretroviral therapy. Equally, the need for further research exists in high 
income regions with populations of patients on long term antiretroviral therapy. The increased burden 
of stroke to patients and health services may only be realised in future decades.  
 
There are very little high calibre community based studies assessing the burden and nature of HIV 
related stroke. Epidemiological studies with detailed clinical assessment of stroke patients are needed 
both in high and low income regions. Ideally, these should include early imaging, clearly documented 
stroke types, subtypes, risk factors and causes, and importantly autopsy confirmation or exclusion of 
stroke. Improved knowledge about the mechanisms and causes of stroke should lead to improved 
investigation and treatment of patients. 
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1.9   Scope of thesis 
This thesis sets out to examine the relationship of HIV infection and stroke. HIV also increases the risk of 
stroke mimics such as intracranial toxoplasma infection.  To determine whether routine stroke screening 
tools such as the Recognition of Stroke in the Emergency Room (ROSIER) score and computer 
tomography of the brain reliably differentiate those with a stroke diagnosis from those with stroke 
mimics, I explored the diagnostic accuracy of both clinical tools in an HIV positive population.  Following 
the validation of these methods I was then able to answer the following questions: 
Is HIV infection a risk factor for stroke? 
Is there consensus on the aetiological case definitions of HIV infection and stroke? 
What is the aetiological spectrum and outcome of HIV related stroke and is this different from the non-
HIV stroke population? 
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2 Diagnostic accuracy of the Recognition of Stroke in the 
Emergency Room (ROSIER) score and CT brain scanning of 
people with HIV infection and suspected stroke  
 
 
2.1 Abstract  
Background 
HIV increases the risk of stroke mimics such as intracranial toxoplasma infection.  To determine whether 
routine stroke screening tools such as the Recognition of Stroke in the Emergency Room (ROSIER) score 
and computer tomography of the brain reliably differentiate those with a stroke diagnosis from those 
with stroke mimics, I explored the diagnostic accuracy of both clinical tools in an HIV positive 
population.  
 
 
Method 
In this retrospective diagnostic accuracy study, 56 HIV infected patients with stroke-like symptoms 
presented to the Infectious Disease Units in Liverpool and Manchester Hospitals, UK, during the study 
period of January 2007 to December 2009. Eighteen had a stroke and 38 had a stroke mimic. The clinical 
characteristics and diagnostic accuracy of routine clinical tools used to discriminate strokes from their 
mimics was studied. 
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Results 
The median age of patients with stroke and stroke mimics were 41-years and 38-years respectively. HIV 
status was unknown at presentation for 6/18 (33%) stroke patients and 18/38 (47%) stroke mimic 
patients. The sensitivity and specificity of combining ROSIER score and CT brain scan were 67% (95% CI 
30-92) and 90% (95% CI 68-98) respectively. 
 
Conclusion 
The ROSIER stroke score and CT brain imaging have a poor diagnostic accuracy in people with HIV 
infection.  A high proportion of undiagnosed HIV infection in this population adds to the difficulty in 
directing appropriate care. This study highlights the need for rapid HIV testing in young patients with a 
suspected stroke.  I therefore decided not to use ROSIER to help classify stroke in my study, and to focus 
on MRI scanning of the brain to help determine the aetiology of stroke. 
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2.2 Introduction 
The management of ischaemic stroke was revolutionised in the mid 1990s when thrombolytic therapy 
became available (Hacke et al. 1995; Hacke et al. 2008). One urgent step in managing such patients is 
the computed tomography (CT) brain scan which excludes haemorrhagic stroke and some stroke 
mimics, both contraindications to thrombolysis. The recognition of stroke in the emergency room 
(ROSIER) stroke score was devised in 2005 to allow patients with suspected stroke to be triaged rapidly 
for a CT brain scan. The score is based on easily accessible components from the history and physical 
examination. The presence of sudden asymmetric face, arm and leg weakness, speech disturbance and 
visual field deficit scores one point each; a point is subtracted if there is any seizure activity or loss of 
consciousness. Patients with scores greater than zero are highly likely to have had a stroke (Nor et al. 
2005).  Administration of the score takes less than 5 minutes.  In the general UK population, where this 
score was validated, it had a sensitivity of 92% and a specificity of 86% and a positive predictive value of 
86% (Nor et al. 2005). The ROSIER score is the most sensitive and specific rapid screening tool when 
compared with others and therefore, the most widely recommended (Whiteley et al. 2011) (NICE 2008). 
Although the ROSIER score is commonly used in industrialised countries, it has not been validated in 
many sub-Saharan African countries, including Malawi. Furthermore, little is known about the 
performance of this clinical tool in people with HIV infection.  
 
As discussed in chapter 1, HIV infection and its treatment, are thought to increase the risk of stroke, 
especially ischaemic stroke in young adults. However, HIV also increases the risk of stroke mimics such 
as intracranial toxoplasma infection (Kumwenda et al. 2005; Alkali et al. 2013). Correctly identifying such 
mimics, especially infections, is essential, because they have different management and are potentially 
treatable. However, the reliability of CT scan in identifying strokes and its mimics in people with HIV 
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infection is also uncertain. Thus, for people with HIV infection who present with a suspected stroke, 
both the role of the ROSIER stroke score in determining who needs an urgent CT, and the ability of the 
CT to identify stroke or its mimics are unclear.  
 
The objective of this study was to determine the diagnostic accuracy for recognition of stroke in the 
emergency room (ROSIER) score and computed tomography (CT) brain imaging in stroke and stroke 
mimic patients with HIV infection. 
 
2.3 Methods 
2.3.1 Clinical methods 
This retrospective study was conducted at the Infectious Disease units at the Royal Liverpool University 
Hospital and North Manchester General Hospital, which serve a combined HIV positive population of 
approximately 2600. I screened the hospital electronic databases for HIV positive patients from Jan 2007 
to Dec 2009 for patients with any neurological diagnosis.  Admission and discharge databases, discharge 
letters and clinic letters were explored. The medical records of patients with a neurological diagnosis 
were extracted and those that presented with acute stroke-like symptoms within 48 hours of symptom 
onset were included. Stroke-like symptom was defined as unilateral or bilateral motor impairment 
(including lack of coordination), unilateral or bilateral sensory loss, speech disturbance 
(aphasia/dysphasia), visual disturbance (hemianopia/forced gaze), perception deficit, dysphagia, 
confusion, personality change and seizure (WHO 2005).  A definitive diagnosis was defined as a 
consultant Infectious diseases or neurology physician’s final opinion, after an MRI head had been 
performed.  An MRI head was the gold standard in determining if the patient had a stroke or not, in 
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some cases, this was not performed (i.e. unable to tolerate the scan, died before imaging etc). In such 
cases the clinical history and examination and other gold standard tests (e.g. microbiologically 
confirmed blood and/or cerebrospinal fluid (CSF) infection, brain biopsy) were used. 
 
From this cohort, I was then able to determine definitive stroke group and a definitive stroke mimic 
group. I excluded patients without a clear diagnosis.  
 
This study was ethically approved by the Liverpool Northwest 4 Research Ethics Committee 
(10/H1005/9).    
 
2.3.2 Clinical and radiological tools 
 Age, gender, presence of vascular risk factors (hypertension, diabetes, hyperlipidaemia (defined as 
those on lipid lowering treatment on discharge), smoking, alcohol excess, ischaemic heart disease, HIV 
characteristics (i.e. duration of HIV infection, cART use, CD4+ T-lymphocyte count) and evidence of 
systemic inflammation (elevated peripheral white cell count and C-reactive protein) were collated from 
the case notes and recorded in the case record form. Each case patient was then scored by an 
independent (registrar level) physician, blinded to the definitive diagnosis, using the ROSIER scale; a cut 
off score > 0 was used to define a ROSIER diagnosis of stroke; if the score was ≤ 0, a ROSIER diagnosis of 
stroke mimic was made Figure 2:1 (Nor et al. 2005). The diagnosis made from the ROSIER score was then 
compared to the definitive diagnosis. 
 
Diagnostic accuracy of the Recognition of Stroke in the Emergency Room (ROSIER) score and CT brain scanning of people with 
HIV infection and suspected stroke 
76 
 
 
 
Figure 2:1: The Recognition of Stroke in the Emergency Room scale 
GCS=Glasgow Coma Scale; E=eye, M=motor; V=verbal component; BM=blood glucose; 
BP=blood pressure (mmHg) (Nor et al. 2005). 
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A list of CT brain characteristics that are associated with stroke or stroke mimics were compiled into a 
questionnaire; these variables included hypodensity, hyperdensity, cytotoxic oedema, vasogenic 
oedema, evidence of mass effect (presence of any of the following; loss of prominence of sulci/gyri, 
effacement of the lateral ventricles, loss of grey/white matter distinction or loss of patency of the basal 
cistern), multiple lesions and a normal image. The presence or absence of these variables were 
evaluated and recorded independently by two senior radiologists who then each made a final diagnosis 
of stroke, stroke mimic or normal scan.  The radiologists were blinded to the definitive diagnosis but had 
some clinical information to simulate a real-life setting and facilitate the interpretation of the brain scan 
(e.g. symptom type and affected side). One radiologist was a neuroradiologist working in a specialist 
neurology centre, the other was a general radiologist based in one of the teaching hospitals with the 
infectious diseases unit.  When there was disagreement in diagnosis between the two radiologists, the 
diagnosis from the original CT report was used.  
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2.3.3 Statistical methods 
Data were entered into a Microsoft Excel database, and statistical analysis was done using STATA 11.2. 
Categorical data were represented as proportions and continuous data as medians with interquartile 
ranges (IQR).   Univariate analysis was used on all variables and presented as proportions or odds ratios 
(OR) with 95% Confidence Intervals (CI).  Significance levels were taken at p ≤0·05. I calculated the 
sensitivity and specificity with 95% CI for the ROSIER score alone and in combination with a CT brain 
scan. Missing observations were included in the analysis by creating missing value categories. 
 
An inter-rater reliability analysis using unweighted Kappa statistic was used to determine the level of 
agreement between both radiologists (Brennan et al. 1992). 
 
2.4 Results 
2.4.1 Participants 
Among the population served by the two hospitals of approximately 2600 people with HIV infection, 152 
presented with acute stroke-like symptoms between January 2007 and December 2009. Clinical records 
were evaluated between January-March 2010. Of the 152 records 56 had complete data and therefore a 
definite diagnosis was made; 18 with a stroke, and 38 with a stroke mimic Figure 2:2.  In the remaining 
90, although there was a working diagnosis in some cases, it did not fulfil our strictly defined criteria. A 
definitive diagnosis was confirmed by MRI in 46 (82%) of the 56, by microbiological analysis of the 
blood/or cerebrospinal fluid (CSF) for all the infective aetiologies in 27 (48%), by brain biopsy in 2 (4% - 
this confirmed the diagnoses of lymphoma and HIV tumefactive demyelination), and by response to 
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treatment in 20 (35%). The subsequent clinical course of disease was consistent with the diagnosis for all 
56 patients. 
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Figure 2:2: Flow diagram detailing the selection process of patients 
*included varicella zoster encephalitis, neurocysticercosis, neurosyphilis, HIV tumefactive 
demyelination, aspergillus encephalitis, lymphoma, HIV dementia and cryptogenic epilepsy. The 
shaded box highlights the false negatives and positives respectively for the ROSIER score. 
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2.4.2 Clinical characteristics 
The age at presentation and gender were similar for patients with strokes and stroke mimics. Patients 
with strokes were more likely to have had a known HIV diagnosis for 12 months or more Table 2:1.  The 
prevalence of common vascular risk factors was similar between the two groups, though there was a 
non-significant trend towards hyperlipidemia being more common in patients with stroke. Twenty-six 
patients were diagnosed HIV-infected as a result of their acute stroke-like presentation: 6/18 (33%) had 
a stroke and 18/38 (47%) had a stroke mimic Figure 2:2.  
 
Patients with stroke were more likely to have had a CD4+ T lymphocyte count >200cells/mm3. There was 
no significant difference with cART use between the groups. Neither peripheral white cell count nor CRP 
(when requested) differentiated between a stroke or a stroke mimic Table 2:1.  
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Table 2:1: The demography and clinical characteristics of all patients categorised into strokes 
and stroke mimics* 
 
Definitive Diagnosis 
 
Stroke 
 (n=18) 
 
Stroke 
Mimic  
(n=38) 
  
(OR, 95% 
Confidence 
Interval) 
 
P value 
Demographics 
Age (Median, IQR) 40.5 (32,46) 38 (33,46) 1 (0.95-1.05) 0.970 
Male (%) 13 (72) 20 (53) 2.34 (0.70-7.86) 0.169 
     
HIV characteristics 
≥ 12 months duration of HIV positive 
diagnosis (%) 
10 (63) 12 (32) 3.61 (1.06-12.25) 0.039 
On cART (%) 11 (61) 16 (42) 2.16 (0.68-6.79) 0.188 
CD4+ >200cells/mm3 (%) 13 (72) 10 (29) 6.5 (1.83-23.04) 0.004 
     
Vascular risk factors 
Current Smoker (%) 2 (12) 5 (17) 0.64 (0.11 – 3.73) 0.620 
Diabetes (%) 0 2 (6) -  - 
Hypertension (%) 1 (5) 2 (6) 0.91 (0.08-10.79) 0.938 
Hyperlipidaemia (%) 5 (29) 3 (9) 4.49 (0.94-21.49) 0.060 
     
Evidence of inflammation 
Serum white cell count >5x10
9
/L (%) 8 (72) 14 (41) 3.81 (0.87-16.94) 0.079 
Serum CRP >5 (%) 1 (25) 14 (58)  0.23 (0.02-2.63) 0.242 
 
*Data were missing for some individuals; two for duration of HIV positive infection, 3 for CD4+ T-
lymphocyte count, 10 for smoking, 8 diabetes, 8 for hypertension, 6 hyperlipidaemia, 11 peripheral white 
cell count, 28 for CRP (this was not requested in all of the cases); these individuals were excluded from 
the denominator in percentage calculations. CD4+ - CD4+ T lymphocyte count. 
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2.4.3 Diagnostic performance of the ROSIER score and CT scan 
CT scans were reviewed for 40 (71%) of the 56 patients; 11 of these were from patients with stroke and 
29 were from patients with stroke mimics. For the 16 remaining patients either the scan was not 
available for review, or they had proceeded directly to MRI scan, and so no CT was performed. There 
was substantial agreement between the two radiologists for an overall diagnosis of stroke/stroke 
mimic/normal CT (88%). The overall unweighted Kappa (K) was 0.75 (Std. Err +/-0.16 p <0.0001). 
 
Both the sensitivity and specificity of the ROSIER stroke score alone was 68% Table 2:2.  When the 
ROSIER score was combined with a CT brain scan, the sensitivity was 67% and specificity 90%.    The 
standard algorithm of suspected stroke patients is to firstly screen by the ROSIER score and a positive 
score then determines the need for an urgent CT brain scan; I found that the ROSIER incorrectly 
categorised 12/38 (32%) stroke mimics as strokes. Of the 12, 11 had CT brain imaging available, 2/11 
(18%) would have had a confirmed diagnosis of stroke after the CT scan; both of these had treatable 
infectious aetiologies Figure 2:2.  The ROSIER also incorrectly categorised 5/18 (28%) definite strokes as 
stroke mimics; all had CT brain scans and in 2/5 (40%), a stroke diagnosis was confirmed, but 3/5 (60%) 
had a normal scan.  The presence of vasogenic oedema was the only CT brain characteristic, of the eight 
evaluated, that helped discriminate strokes from its mimics OR 0.11 95% CI 0.01-1.14 p=0.0045, this was 
consistent for both radiologists Table 2:3. 
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Table 2:2: Sensitivity and specificity of the Recognition of Stroke in the Emergency 
Room Score (ROSIER) alone and in combination with a CT brain scan 
 Sensitivity* Specificity* 
 
Test  (%) 95% CI % 95% CI 
ROSIER 68 43-87 68 51-82 
ROSIER and CT 67 30-92 90 68-98 
 
*A normal CT brain in a patient with an acute stroke-like symptom and ROSIER score 
positive was treated as a stroke in the sensitivity analysis.  However, if the working 
diagnosis was not a stroke (i.e. acute stroke-like symptom and ROSIER negative) then a 
normal CT brain scan was not considered a stroke. 
 
Table 2:3: CT brain scan characteristics in HIV positive strokes and stroke mimics 
 
CT characteristics 
 
Stroke 
 (n=11) 
 
Stroke Mimic  
(n=29) 
 
OR, 95% Confidence 
Interval 
 
P value 
 
Hypodensity 
 
4 (36) 
 
20 (69) 
 
0.26 (0.05-1.21) 
 
0.064 
     
Hyperdensity  3 (27) 4 (14) 2.34 (0.41-13.34) 0.323 
     
Vasogenic oedema 1 (9) 14 (48) 0.11 (0.01-0.94) 0.045* 
     
Cytotoxic oedema 1 (9) 3 (10) 0.87 (0.08-9.34) 0.906 
     
Evidence of mass effect 1 (9) 13 (45) 0.12 (0.01-1.09) 0.060 
     
Evidence of enhancement 1 (20) 7 (33) 0.50 (0.04-5.36) 0.567 
     
Multiple lesions (>2) 3 (27) 11 (38) 0.61 (1.13-2.81) 0.530 
     
Normal scan 4 (36) 7 (24) 1.79 (0.40-8.00) 0.442 
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2.5 Discussion 
The early distinction between a stroke and a stroke mimic is important with the increasing use of 
thrombolytic therapy. In an HIV positive population the proportion of stroke mimics presenting with 
acute stroke-like symptom is high (Kumwenda et al. 2005; Tipping et al. 2007).  An accurate and timely 
diagnosis is crucial for establishing appropriate treatment plans. 
 
In this retrospective study, I showed that the ROSIER score had a sensitivity and specificity of 68%; the 
score assigned a stroke diagnosis in three quarters of those who actually had one, but also one third of 
those with a stroke mimic.  A quarter of patients with definite strokes would not have had an urgent CT 
brain scan and therefore these individuals would have missed the narrow window of opportunity for 
thrombolysis.  Furthermore, one third of people with stroke mimics classified as strokes would have had 
a delay in appropriate investigations, such as an MRI scan, and cerebrospinal fluid analysis; this delay 
would have been compounded by the fact that almost 50% of this group had an unknown HIV diagnosis. 
 
Overall, the combination of ROSIER and CT brain had a sensitivity of 67% for detecting stroke, which is 
inadequate for a screening tool. Historically, CT brain imaging is known for its poor sensitivity in 
diagnosing strokes (Chalela et al. 2007; Brazzelli et al. 2009). I found that of the eight characteristics 
evaluated, vasogenic oedema was the only one that helped discriminate a stroke from its mimics and 
this was only present in half of the mimics and probably linked to the number of patients with 
toxoplasmosis.  Nonetheless, a CT is easier to operate, cost-effective and therefore widely used as part 
of the initial evaluation of patients presenting with acute stroke-like symptoms (Wardlaw et al. 2004).  In 
patients with HIV infection, an MRI brain especially when diffusion weighted magnetic resonance 
imaging is used, is superior to a CT scan in detecting strokes and their mimics but this will only be 
requested rapidly  if the patient’s HIV status is known (Maschke et al. 2004; Kidwell et al. 2010).  
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Another concern is that investigations that would normally indicate an alternative diagnosis to a stroke 
(e.g. peripheral white cell count and CRP (when requested), were also non-discriminatory in this 
population.  As in this study, HIV positive patients with stroke are younger than the general population 
with stroke, and young age at presentation should be a trigger for HIV testing (Ovbiagele et al. 2011).  
The British HIV Association guideline recommends HIV testing in patient with neurological symptoms in 
local populations where the HIV prevalence exceeds 2 in 1000 but this is often not adhered to (British 
HIV Association 2008; Palfreeman et al. 2009). MRI or CT brain scans are usually not accessible in 
resource poor settings, in such circumstances, the patients HIV status alone may be the only useful 
guide to appropriately managing their stroke syndrome. 
 
In the UK over 90,000 people are infected with HIV, a quarter of whom are unaware of their diagnosis, 
and this number continues to rise (HPA 2012).  In this study, stroke was a HIV-presenting condition; 33% 
of the definite stroke patients had a new HIV positive diagnosis. Other studies have reported rates as 
high as 42% (Tipping et al. 2007). In most cases the decision over thrombolysis is taken without 
knowledge of a patient’s HIV status and the consequence of this, is yet to be realised. 
 
The burden of stroke in an HIV positive population is still a problem as HIV infection not only increases 
the risk of ischaemic stroke through different mechanisms (e.g. vasculopathy and coagulopathy) but 
also, an aging population due to the success of cART, will further expose these individuals to other 
established vascular risk factors and thus increase their risk of stroke (Chapter 1).  
 
There is also the theoretical risk of patients with stroke mimics (e.g. toxoplasma, PML etc) receiving 
thrombolysis at the expense of appropriate therapy. Reassuringly, this would have only been applicable 
to 2/26 (6%).  
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There are two studies that have validated the ROSIER score in a low HIV-endemic population, both 
demonstrated a sensitivity of over 80% (Jackson et al. 2008; Whiteley et al. 2011).  However, this is the 
first study describing the diagnostic accuracy of routine triaging tools (i.e. ROSIER score and CT brain) for 
suspected stroke patients in an HIV population.  The study also utilised two Infectious Disease Units with 
a combined cohort of 2600 HIV infected individuals. The retrospective nature lends itself to coding bias 
especially since a portion of our cohort did not have a definitive diagnosis. However, this study 
generates hypotheses that would need to be followed up by a prospective study.  The study was also 
limited by the sample size; this was largely due to the low prevalence of HIV infection in this population 
and our strict criteria for establishing a definitive diagnosis. Nonetheless, establishing a definitive 
diagnosis using gold standard tests from which comparisons can then be made is easier to achieve in 
high income settings, where a lower HIV prevalence is often reported.  Misclassification of diagnoses 
was a concern in this study, however this bias was reduced by; 1) using a battery of gold standard 
diagnostic tests to help establish the definitive diagnosis (i.e. serological techniques, CSF PCR for 
pathogens, MRI imaging and in some cases brain biopsy), 2) blinding the scorer of the ROSIER stroke 
score/radiologists from the definitive diagnosis, and 3) having two radiologists report the CT imaging.   
 
In conclusion, the ROSIER stroke score and CT brain imaging had poor diagnostic accuracy in HIV 
infected patients presenting with stroke-like symptoms. For a large proportion of patients, this was their 
HIV-defining presentation and therefore knowledge of their status would direct the physician to rapidly 
request non-standard stroke investigations like MRI of the brain and CSF analysis.  This study also 
suggests that HIV testing in a young cohort presenting with acute focal neurological deficit could be 
helpful. I therefore decided not to use ROSIER to screen for the diagnosis of a stroke; instead, I fully 
assessed every patient with an acute stroke symptom as part of the screening process in my study.  I 
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also decided to focus on MRI scanning of the brain to help determine the aetiology of stroke, rather 
than CT scanning, especially as there was no scope for thrombolysis in Malawi.    
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3 Untreated HIV infection, antiretroviral treatment and stroke 
in Malawian adults: a case control study 
 
 
3.1 Abstract 
Background 
An increasing incidence of strokes, especially in young adults, has been noted in HIV endemic countries.  
This is postulated to relate to HIV infection.  I investigated HIV, its treatment and other risk factors for 
stroke in Malawi. 
 
Methods 
I performed a case-control study of 222 adults with acute stroke, confirmed by MRI in 86%, and 503 
population controls, frequency-matched for age, sex and place of residence, using Global Positioning 
System for random selection.  Multivariate logistic regression models were used for case–control 
comparisons. 
 
 
Results 
HIV infection (Population Attributable Fraction [PAF] 15%) and hypertension (PAF 46%) were strongly 
linked to stroke. HIV was the predominant risk factor for young stroke (≤45 years), with a prevalence of 
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67% and an adjusted odds ratio [aOR, 95%CI] of 5.57 [2.43,12.8]; PAF 42%. There was an increased risk 
of a stroke in patients with untreated HIV infection (aOR 4.48 [2.44,8.24 p<0.001]), but the highest risk 
was in the first 6 months after starting combined antiretroviral therapy (cART) (aOR 15.6 [4.21,46.6] 
p<0.001).  Stroke risk increased with declining CD4+ T-lymphocyte count (p=0.023). In older participants 
(HIV prevalence 17%) HIV was associated with stroke, but with a lower PAF (5%) than hypertension (PAF 
68%).   
 
Conclusion 
HIV infection is associated with an increased risk of stroke especially ischaemic stroke in young people; 
this also relates to the degree of immunosuppression. Although treatment is beneficial overall, the 
highest stroke risk is in the first 6 months of starting cART.  A better understanding of this risk is urgently 
needed in order to try and reduce it. 
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3.2 Introduction 
Stroke is one of the leading causes of premature adult death and disability worldwide (Lozano et al. 
2012; Murray et al. 2012). Identifying and treating risk factors for stroke is key to reducing the disease 
burden (Rothwell et al. 2004).  Across most of sub-Saharan Africa, the incidence of stroke is increasing 
(Feigin et al. 2013 ).  Much of this has been attributed to hypertension but the observation that in some 
countries, such as Malawi and South Africa, a substantial proportion of stroke  patients are young (i.e. 
age ≤45 years), and have a low prevalence of established risk factors such as hypertension, suggests 
other risk factors may be important (Kumwenda et al. 2005; Tipping et al. 2007; Heikinheimo et al. 
2012). 
 
HIV is postulated to be one such risk factor (Rasmussen et al. 2011).  The virus potentially causes stroke 
directly, for example through HIV-associated vasculopathy, or indirectly through opportunistic infections 
such as varicella zoster virus (VZV) (Chapter 1).  In addition, some drugs used in combined antiretroviral 
therapy (cART) for HIV are associated with metabolic syndromes, therefore increasing stroke risk with 
prolonged use (Friis-Moller et al. 2003).  
 
The recently published study by Walker et al made important observations on HIV infection and stroke 
(Walker et al. 2013). However, this study, like many that have preceded it, failed to separate the 
independent effects of HIV infection and its treatment on cerebrovascular risk (Chapter 1).  I therefore 
conducted a case-control study examining the role and impact of HIV and its treatment as risk factors for 
stroke in Malawian adults, together with other risk factors prominent in this setting. 
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3.3 Methods 
3.3.1 Study site 
Queen Elizabeth Central Hospital is the main hospital for Blantyre district (population 1 million), as well 
as being the referral hospital for the southern region of Malawi, which has an estimated adult HIV 
prevalence of 18.5% (Choko et al. 2011).   
 
3.3.2 Study design  
Adult (age >17 years) residents of the Blantyre district who presented to the hospital within seven days 
of the onset of symptoms that met the WHO case definition of stroke (Hatano 1976), were recruited 
between February 2011 and April 2012.  Participants were initially screened for the presence of an acute 
neurological symptom by the study nurse using a screening questionnaire, before I performed a detailed 
screening.  Scans were performed on a GE 0.35 Tesla Signa Ovation Excite Magnetic Resonance Imaging 
(MRI) scanner (Milwaukee, Wisconsin) within seven days of admission.  MRI sequences included a 
midline sagittal localising view of the brain - T1-weighted, axial diffusion-weighted, gradient echo, axial 
T2-weighted and a fluid attenuated inversion recovery sequence.  The images were reported at the time 
by a local radiologist and subsequently reviewed by a neuroradiologist and an infectious diseases 
radiologist. Patients with recurrent stroke were eligible for inclusion, provided they had not already 
participated in the study.  
 
Population controls were recruited from the local population in predefined residential neighbourhoods 
within the district of Blantyre, between January and November 2012. Two community controls were 
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selected at random for every case, using a modification of a previously described approach (Crampin et 
al. 2001).  The distribution of age (5 year age-bands), gender, and place of residence of the first 100 
cases was used to guide stratified recruitment, frequency-matching for age, gender and residential 
neighbourhood.  Individuals were included if they were > 17 years of age, patients with a past history of 
stroke were not excluded. I had rationalised not to exclude these patients, as reported stroke 
prevalence rates in similar settings to Malawi were low [e.g. 300/100 000 (95% CI, 250 to 357]) (Connor 
et al. 2004). Therefore, the likelihood of picking up a patient with a past history of stroke was also low. 
Other large case-control stroke studies in western populations have also used similar methods (Urbanus 
et al. 2009). 
 
 Random starting points and direction were overlaid onto high resolution satellite maps (March 2010 
images: Geo Eye-1/Eurimage SpA) using Google Earth pro software Figure 3:1.  Global Positioning 
System coordinates from the first dwelling intersected by any given randomly generated vector were 
recorded.  After sensitiziting the community about the project, dwellings were visited and all eligible 
potential control participants were identified. The control recruitment was undertaken by two qualified 
nurses. Both had undergone a period of training by myself prior to recruitment.  Standardized operating 
protocols for collecting data were used and their performance in adhering to this was regularly checked.  
If no one was home, dwellings were visited up to three times.  Where multiple individuals were eligible, 
the oldest individual was recruited.  If no eligible individual was identified, the next dwelling intersected 
was visited.  Recruitment continued in each residential neighbourhood until the pre-specified numbers 
of individuals in each age-gender category had been met.   
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Figure 3:1: Random sampling using Google Earth Pro 
 
Blantyre was defined by 16 residential neighbourhood; 9 urban and 7 rural (Image A). The boundaries 
defined a neighbourhood. Image B was an example of the neighbourhood Ndirande. Random starting 
points (Image C) and directions (Image D) were generated and exported into a Global Positioning System 
to facilitate sampling of the study participants. 
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3.3.3 Procedures 
For cases, the clinical subtype and severity of stroke were recorded using the Oxfordshire Community 
Stroke Project classification and National Institutes of Health Stroke Scale (NIHSS) criteria respectively 
(Brott et al. 1989; Bamford et al. 1991).  I determined the stroke diagnosis after a detailed history and 
examination. Ischaemic and haemorrhagic stroke types were determined by MRI brain scan findings. 
Patients were dual managed by myself and the admitting medical consultant using  standard hospital 
protocols (Zijlstra 2007). 
 
Demographic information and exposure to risk factors were obtained from the cases and controls using 
the same structured questionnaire (appendix).  Non-modifiable risk factors (i.e. age, sex, socioeconomic 
status and family history of stroke) and modifiable risk factors (HIV infection, HIV treatment and its 
duration, hypertension, diabetes, hypercholesterolaemia, acute infection, smoking, alcohol use, 
pregnancy and substance use [cannabis, cocaine and heroin]) were recorded.  Socioeconomic status was 
defined by education, occupation, place of residence and housing type (Cox et al. 2006; de Villiers et al. 
2011).  If the patient was dysphasic or unconscious, risk factors that could not be determined by 
examination or investigation were extrapolated from the guardian; if this was unclear this was marked 
as unknown.  In sub-Saharan Africa ascertaining the exact age can sometimes prove difficult, in such 
circumstances, age was confirmed by memory prompts (Paraiso et al. 2010).  Examination was 
performed to determine the waist-hip-ratio, a marker of abdominal obesity and blood pressure.  The 
admitting blood pressure for the cases was chosen for comparison with the international multi-site case-
control study; this explored the association of established vascular risk factors and stroke (O'Donnell et 
al. 2010).  Cases and controls were screened for diabetes, hypercholesterolaemia, and HIV infection, if 
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positive, the CD4+ T lymphocyte count was measured (BD FACS Count System, Becton, Dickinson, San 
Jose, CA). 
 
 
3.3.4 Definition of criteria used  
Stroke severity was classified as non-severe or severe using the NIHSS (Brott et al. 1989).  For cases and 
controls, HIV diagnosis was made from two rapid tests in parallel (Unigold, trinity Biotech, Ireland; 
Determine, Alere Medical Co Ltd, Japan  and SD Bioline, Standard Diagnostics, Korea, was used as a 
tiebreak).  CD4+ T lymphocyte count was classified as <200 cell/mm3, 200-349 cell/mm3, 350-500 
cell/mm3, >500 cell/mm3, which also determined cART eligibility (WHO 2010).  To explore the possible 
role of immune reconstitution syndrome, a cut-off of 6 months was used to classify the duration on 
cART (Shelburne et al. 2005).  The timing of cART was cross-checked with an electronic medical records 
system at QECH when there was ambiguity (Douglas et al. 2010).   Blood pressure was recorded at Day 0 
for both cases and controls, using clinically validated automated Omron M5-I upper arm monitors (El 
Assaad et al. 2003).  Three sequential readings were recorded and an average taken. Hypertension was 
defined as a composite of blood pressure >140/90mmHg or use of anti-hypertensive medication (Go et 
al. 2013).  Diabetes mellitus was defined as a non-fasting blood glucose of ≥11.1 mmol/L or use of 
glucose-lowering medication (American Diabetes Association 2010).  Patients were classified as having 
hypercholesterolaemia if they used lipid-lowering medication or had a non-fasting serum cholesterol 
concentration ≥6.2 mmol/L (NCEP 2001).  Waist-hip-ratio was calculated as tertiles from the control 
cohort (O'Donnell et al. 2010).  Recent infection was defined as  a fever or treated infection within 14 
days of the stroke (cases) or interview (controls) (Emsley et al. 2008). Young stroke was defined as ≤ 45 
years (Jacobs et al. 2002). 
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3.3.5 Ethical consideration 
The study was approved by the Liverpool School of Tropical Medicine, UK and the College of Medicine 
Research Ethics Committee, University of Malawi. All participants or guardians gave written informed 
consent. Individuals with newly diagnosed risk factors in the community (e.g. HIV infection, 
hypertension) were counselled by qualified fieldworkers and referred to an appropriate outpatient 
clinic. 
 
3.3.6 Statistical analysis 
The prevalence of potential risk factors was compared between cases and controls. Continuous variables 
were summarised using means and medians and compared using a Student independent-samples t-test 
or Mann Whitney U test as appropriate for the distribution properties of each variable.  
 
A sample size of 750 individuals (250 case-control sets each with one case and two controls) was 
estimated as providing 95% power to detect an odds ratio of 2 or greater (i.e. to detect a doubling of the 
risk of stroke) for HIV prevalence, assuming that 18% of the control individuals would be found to have 
HIV infection (Choko et al. 2011). 
 
A conceptual framework was used to divide all other potential risk factors into proximal determinants 
which have direct effects on stroke, and distal determinants which have indirect effects. Distal 
determinants were defined as age, gender, family history, socioeconomic status and season.  Proximal 
determinants were HIV status (also expanded or substituted by HIV treatment status and level of 
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immunosuppression in some of the analysis), hypertension, diabetes, hypercholesterolaemia, acute 
infection, abdominal obesity, alcohol and substance use.  The proximal determinants were initially 
evaluated individually (“univariate” model approach) after adjustment for age, sex and urban location 
(the variables used for frequency matching). Unconditional “multivariate” logistic regression models 
were then constructed based on this conceptual framework describing the hierarchical relationships 
between the matching, proximal and distal determinants. The role of each distal determinant was 
further assessed by comparing the model with or without, using the likelihood ratio test. Subtracting 
those from the model that were not significant (Victora et al. 1997).  This was repeated after stratifying 
by age and type of stroke.  Missing observations were included in the analysis by creating missing value 
categories. The findings from these models are reported as odds ratios with their 95% CIs. Population 
Attributable Faction (PAF) is defined as the proportion of disease cases over a specified time that would 
be prevented following elimination of the exposures, assuming the exposures were causal (Rockhill et al. 
1998). PAF was calculated using methods defined by Greenland and Drescher and it depended on the 
prevalence of the risk factor and the rate ratio (Greenland et al. 1993).  PAF presented are adjusted for 
confounders in a similar manner to the corresponding logistic regression models for odds ratio estimates 
and, where indicated, are stratified by subgroups of interest. The data were analysed with STATA 
version 11.2. 
 
3.4 Results 
I screened 553 patients with suspected stroke and 1686 households to obtain 222 stroke cases and 503 
controls Figure 3:2.  An MRI brain scan was performed in 190/222 (86%) cases, with findings consistent 
with 149 (78%) ischaemic and 41 (22%) haemorrhagic strokes. Ischaemic stroke subtype and severity are 
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summarised in Table 3:1. Cases and controls were well matched for age, sex, socioeconomic status and 
season of admission to the study Table 3:1.  
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Figure 3:2: Flow diagram of case and control recruitment 
QECH – Queen Elizabeth Central Hospital 
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Table 3:1: Baseline characteristics of cases and controls¶ **  
 
 
 Case-All Stroke (WHO defined)   
n=222 (%) 
Control  
n=503 (%) 
 
Median Age (IQR)* 
 
60 (42,70) 
 
57 (42,67) 
 
Sex (M) 
 
Urban location‡ 
 
HIV prevalence  
 
107 (48) 
 
143 (64) 
 
69 (31) 
 
249 (50) 
 
343 (68) 
 
95 (19) 
 
In formal employment 
 
69 (31) 
 
163 (32) 
 
Education 
Less than primary school 
Primary education 
Secondary  education 
Tertiary 
 
 
 
136 (61) 
53 (24) 
25 (11) 
4 (2) 
 
 
 
309 (61) 
125 (25) 
51 (10) 
18 (4) 
Type of housing 
Employers accommodation 
House/flat 
Shack 
 
0 
23  (10) 
189 (85) 
 
8 (1) 
48 (10) 
447 (89) 
Family history of stroke 37 (17) 67 (13) 
 
Season  
Jan-Mar 
Apr-Jun 
Jul-Sept 
Oct-Dec 
 
 
56 (25) 
54 (24) 
64 (29) 
48 (22) 
 
 
137 (27) 
120 (24) 
129 (26) 
117 (23) 
 
Subtype of Ischaemic stroke†(n=149)  
Total Anterior circulation Infarct 
Partial Anterior circulation Infarct 
Posterior circulation Infarct 
Lacunar Infarct 
 
 
37 (25) 
46 (31) 
6 (4) 
60 (40) 
 
 
NA 
 
 
Severity of Ischaemic stroke
¤
  (n=149)  
Non-severe (<14) 
Severe (≥14) 
 
 
 
93 (62) 
55 (37) 
 
 
NA 
 
*IQR=inter-quartile range 
**NA denotes not performed 
†Severity of stroke was defined by the National Institutes of Health Stroke Scale (NIHSS).18 
¤
Subtype of stroke was defined by Oxfordshire Community Stroke (OCSP) classification.17 
¶ Data were missing for the following cases and controls: one for HIV prevalence, 4 Education, 10 housing type 
and 1 stroke severity. 
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3.4.1 HIV and cART  
Stroke was strongly associated with HIV infection (aOR 3.28 [2.05,5.25] p<0.001; PAF 15% ). Timing of 
cART was important: starting ART in the first 6 months (aOR 15.6 [4.21,46.6] p<0.001) posed the 
greatest risk of strokeTable 3:2.  
 
The association of HIV infection and stroke was more evident in younger (≤45 years) individuals (PAF 
42%) compared to older individuals (combined PAF of 6%;Table 3:3) Although the prevalence of HIV was 
lower in the older participants (67% versus 18%) there was still a strong association with untreated HIV 
infection and early initiation of cART Table 3:3. 
 
To explore the role of CD4+ T-lymphocyte cell count and its interplay with HIV treatment status, we 
performed a subgroup analysis of the HIV positive population.  There was an independent relationship 
between the likelihood of stroke risk and decreasing CD4+ T-lymphocyte cell count Table 3:4. Although 
not significant, there was a trend towards a reduced stroke risk in the untreated HIV cohort after 
adjusting for CD4+ T-lymphocyte cell count Table 3:4. The stroke risk was partly reduced after adjusting 
for CD4+ T-lymphocyte cell count among those who initiated cART in the first 6 months. However, this 
still remained an independent risk factor of stroke (aOR 5.52 [1.22,25.0] p=0.026) Table 3:4. 
  
HIV infection was significantly associated with ischaemic stroke (aOR 4.36 [2.58,7.36] p<0.001) but not 
with haemorrhagic stroke (aOR 1.79 [0.63,5.05] p=0.274) Table 3:5. 
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There were 32 patients who did not have an MRI brain scan. When they were excluded from the 
analysis, the association between HIV infection and stroke remained significant (aOR of 4.36 [2.58,7.36] 
p<0.001).  
 
The national cART programme in Malawi uses standardised protocols, the 2008 edition was in use 
during the study period.  First line therapy for HIV infection was Stavudine[d4T], Lamivudine[3TC] and 
Nevirapine[NVP]) and alternative first line was Zidovudine [AZT],3TC and NVP) (Malawi 2008).  The 
prevalence of the Stavudine based regimen in cases and controls was 23 and 13 (64% and 36%; p 
<0.001) respectively.  
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Table 3:2: Univariate and multivariate analysis for modifiable risk factors in all patients with stroke¶ 
 Prevalence All Stroke (WHO definition) 
 Case  
n=222 (%) 
Controls  
n=503 (%) 
Univariate* OR (95% CI)  p value Multivariate OR** (95% CI) p value PAF
† 
 
(95% CI) 
 
HIV positive status 
 
69 (31) 
 
95 (19) 
 
2.33 
 
(1.58,3.48) <0.001 
 
3.28 
 
(2.05,5.25) <0.001 
 
15 (9,21) 
 
HIV treatment status 
 
HIV negative 
Untreated 
Had ART for <6 months  
Had ART for ≥6 months  
 
 
 
151 (68) 
38 (17) 
16 (7) 
14 (6) 
 
 
 
408 (81) 
47 (9) 
7 (1) 
38 (8) 
 
 
 
1 
2.85 
8.86  
1.14 
 
 
 
 
(1.70,4.77)  <0.001 
(3.42,22.9)  <0.001 
(0.59,2.02)  0.249 
 
 
 
1 
4.48 
15.6 
1.49 
 
 
 
 
(2.44,8.24)  <0.001 
(4.21,46.6)  <0.001 
(0.72,3.07)  0.280 
 
 
 
 
 
- 
 
Hypertension 
 
 
165 (74) 
 
273 (54) 
 
3.13 
 
(2.10,4.66) <0.001 
 
5.01 
 
(3.02,8.29)  <0.001 
 
46 (35,56) 
Other vascular risk factors 
 
Diabetes 
Hypercholesterolaemia  
Recent infection  
Current smoker 
 
Cannabis use
¤
 
Current alcohol drinker 
Pregnancy 
 
Abdominal obesity ∞ 
T1 
T2 
T3 
 
 
19 (9) 
18 (8) 
25 (11) 
41 (18) 
 
6 (3) 
34 (15) 
4 (2) 
 
 
49 (22) 
75 (34) 
93 (42) 
 
 
11 (2)  
28 (6) 
37 (7) 
63 (13) 
 
7 (1) 
92 (18) 
8 (2) 
 
 
150 (30) 
211 (42) 
141 (28) 
 
 
4.42  
1.69 
1.67 
1.66 
 
2.03 
0.79 
1.02 
 
 
1 
1.10 
2.07 
 
 
(2.05,9.53) <0.001 
(0.90,3.15) 0.102 
(0.98,2.87) 0.062 
(1.05,2.63) 0.029 
 
(0.66,6.23)  0.215 
(0.50,1.25)  0.322 
(0.29,3.64)  0.965 
 
 
 
(0.72,1.67) 0.661 
(1.35,3.16) 0.001 
 
 
3.41 
1.54 
1.38 
2.36 
 
1.23 
0.73 
1.67 
 
 
1 
0.83 
1.36 
 
 
(1.45,8.01)  0.005 
(0.77,3.08)  0.219 
(1.45,8.01)  0.005 
(1.34,4.13)  0.003 
 
(0.72,2.12) 0.447 
(0.52,1.02) 0.067 
(0.78,3.62) 0.194 
 
 
 
(0.51,1.35)  0.459 
(0.84,2.20)  0.208 
 
 
3 (1,6) 
2 (-1,5) 
3 (0.3,5) 
6 (2,11) 
 
0.5 (-0.8,2) 
-4 (-8,0.2) 
1 (0.1,2) 
 
 
 
-6 (-17,3) 
  5 (-5,14) 
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Table 3:2 
*Adjusted for frequency matched variables; age, sex and urban location. 
 **Adjusted for hypertension, recent infection, abdominal obesity, HIV positive status, smoking, current alcohol drinker, hypercholesterolaemia, cannabis use, age, sex, type of housing and 
urban location. 
† PAF= Population Attributable Fraction (%), When PAF was negative this was considered protective. For variables with more than 2 categories (i.e. HIV status and waist-hip-ratio) PAF was 
calculated from the reference category (e.g. T1 versus T2 and T1 versus T3).  
¶ Data were missing for the following cases and controls: one for HIV status, 6 HIV treatment status, 24 hypercholesterolaemia, 9 recent infection, 5 cannabis use, 13 alcohol use, 3 pregnancy 
and 6 abdominal obesity; these individuals were included in the analysis by creating missing value categories. 
¤ There was no exposure to other substance use such as heroin or cocaine. 
 ∞ Abdominal obesity (Waist-hip-ratio) tertiles (T) was calculated as tertiles from the control cohort. Cutoffs of 0.86 and 0.9 were used to divide participants into thirds 
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3.4.2 Hypertension 
Hypertension was strongly associated with stroke overall (aOR 5.01 [3.02,8.29] p<0.001); PAF 46%;Table 
3:2).  The risk was stronger for haemorrhagic stroke (aOR 9.35 [2.89,30.3] p<0.001) than for ischaemic 
stroke (aOR 3.66 [2.15,6.22] p<0.001). The effect of hypertension was more evident in those >45 years 
old than those ≤45 years (PAF 68% versus 11%;Table 3:3.  Of the 438 participants with hypertension, 
only 118 (27%) were on treatment. 
 
3.4.3 Other vascular risk factors 
Diabetes was associated with a small proportion of strokes overall (aOR 3.41 [1.45,8.01] p=0.005; PAF 
3%;Table 3:2).  This association was specifically with ischaemic and not haemorrhagic stroke (Table 3:5).  
Smoking (PAF 6%) and recent infection (PAF 3%) were also associated with stroke (Table 3:2). Waist-hip-
ratio cut-offs of 0.86 and 0.9 were used to divide participants into thirds.  At the highest tertile, there 
was an increased risk of ischaemic (aOR 2.01 [1.15,3.49] p=0.014) but not haemorrhagic stroke (Table 
3:5). There was no significant association between hypercholesterolaemia and stroke (Table 3:2, Table 
3:3, Table 3:5), and none of the case or control participants were on treatment for 
hypercholesterolaemia. Waist-hip-ratio, a marker of abdominal obesity, was calculated as tertiles (T) on 
the basis of the overall control data. Cutoffs of 0.86 and 0.9 were used to divide participants into thirds.  
At the highest tertile (T3), there was an increased risk of ischaemic (aOR 2.01 [1.15,3.49] p=0.014) but 
not haemorrhagic stroke Table 3:5.  Smoking (PAF 6%), recent infection (PAF 3%) were also associated 
with stroke overall Table 3:2.  
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Table 3:3: Multivariate analysis for modifiable risk factors in younger and older stroke patients 
 
 
Prevalence Younger (≤45years) stroke
¶
  
(WHO definition) 
Prevalence Older (>45years)  stroke
‡
   
(WHO definition) 
 Cases 
 n=61 (%) 
Controls 
 n=151 (%) 
Multivariate*  
OR (95% CI) p value 
PAF
†
 
(95% CI) 
Cases  
n=161 (%) 
Controls 
n=352 (%) 
Multivariate**  
OR (95% CI) p value 
PAF
†
 
(95% CI) 
 
HIV positive status 
 
41 (67) 
 
41 (31) 
 
5.57 
 
(2.43,12.8) <0.001 
 
42 (20,58) 
 
28 (18) 
 
48 (14) 
 
2.10 
 
(1.10,4.01) 0.024 
 
6 (0.3,10) 
 
HIV treatment status 
 
HIV negative 
Untreated 
Had ART for <6 months  
Had ART for ≥6 months  
 
 
 
20 (33) 
24 (39) 
12 (20) 
5 (8) 
 
 
 
104(69) 
29 (19) 
4 (3) 
13 (9) 
 
 
 
1 
5.04 
22.8 
3.27 
 
 
 
 
(1.99,12.8) 0.001 
(4.91,106) <0.001 
(0.88,12.1) 0.077 
 
 
 
 
 
 
 
 
131 (81) 
14 (9) 
4 (2) 
9 (6) 
 
 
 
304 (86) 
18 (5) 
3 (1) 
25 (7) 
 
 
 
1 
2.93 
15.9 
1.31 
 
 
 
 
(1.18,7.27) 0.020 
(2.03,124) 0.008 
(0.52,3.28) 0.591 
 
 
 
 
 
 
Hypertension 
 
 
21 (34) 
 
46 (31) 
 
1.92 
 
(0.84,4.36)  0.119 
 
11(-4,24) 
 
 
144 (89) 
 
227 (64) 
 
 
8.57 
 
(4.31,17.0) <0.001 
 
68 (52,79) 
Other vascular risk factors 
 
Diabetes 
Hypercholesterolaemia  
Recent infection  
Current smoker
 
 
 
Abdominal obesity∞ 
 
T1 
T2 
T3 
 
 
1 (2) 
4 (7) 
14 (23) 
8 (13) 
 
 
 
13 (21) 
26 (43) 
21 (34) 
 
 
1 (1)  
3 (2) 
11 (7) 
16 (11) 
 
 
 
63 (42) 
60 (40) 
28 (19) 
 
 
4.83 
4.66 
2.87 
0.73 
 
 
 
1 
1.29 
3.05 
 
 
(0.23,100)   0.308 
(0.71,30.8)  0.110 
(0.98,8.42)  0.054 
(0.18,2.87)  0.655 
 
 
 
 
(0.52,3.21) 0.579 
(1.14,8.18) 0.026 
 
 
1 (-2,4) 
3 (-1,7) 
9 (-1,17) 
-2(-11,6) 
 
 
 
 
3 (-18,22) 
15 (-0.6,28) 
 
 
18 (11) 
14 (9) 
11 (7) 
33 (21) 
 
 
 
36 (22) 
49 (30) 
72 (45) 
 
 
10 (2) 
25 (7) 
26 (7) 
47 (13) 
 
 
 
87 (25) 
151 (43) 
113 (32) 
 
 
2.79 
1.32 
1.36 
2.65 
 
 
 
1 
0.59 
1.04 
 
 
(1.17,6.65) 0.021 
(0.62,2.80) 0.465 
(0.97,1.91) 0.077 
(1.40,5.03) 0.003 
 
 
 
 
(0.33,1.05) 0.072 
(0.59,1.83) 0.886 
 
 
4 (1,7) 
1 (-3,4) 
2 (0.2,5) 
8 (3,13) 
 
 
 
 
-13 (-25,-1) 
 -1 (-14,11) 
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Table 3:3 
*Adjusted for hypertension, recent infection, abdominal obesity, HIV positive status, smoking, current alcohol drinker, hypercholesterolemia, cannabis use, age, sex and urban location. 
** Adjusted for hypertension, recent infection, abdominal obesity, HIV positive status, smoking, current alcohol drinker, hypercholesterolemia, cannabis use, age, sex, type of housing and urban location. 
† PAF= Population Attributable Fraction (%), when PAF was negative this was considered protective. For variables with more than 2 categories. (i.e.waist-hip-ratio) PAF was calculated from the reference 
category (e.g.T1 versus T2 and T1 versus T3). 
¤ There was no exposure to other substance use such as heroin or cocaine.  
¶For the younger stroke patient’s analysis, data were missing in the following cases and controls: One HIV treatment status, 4 hypercholesterolaemia, 2 cannabis use, 3 alcohol use and 1 abdominal 
obesity; these individuals were included in the analysis by creating missing value categories.  
‡ For the older stroke analysis, data were missing in the following cases and controls: One HIV positive status, 5 for HIV treatment status, 20 hypercholesterolaemia, 9 recent infections, 3 cannabis use, 10 
alcohol use, 3 pregnancy and 5 abdominal obesity.  Missing observations were included in the analysis by creating missing value categories. 
∞ Abdominal obesity (Waist-hip-ratio) tertiles (T) was calculated as tertiles from the control cohort. Cutoffs of 0.86 and 0.9 were used to divide participants into thirds 
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Table 3:4: Exploring the interplay of HIV treatment status and immunosuppression in an HIV subpopulation 
 Prevalence All Stroke (WHO definition) 
  
HIV+ Cases 
n=69 (%) 
 
HIV- Controls 
n=95 (%) 
 
Univariate*  
OR (95% CI) p value            
 
Multivariate**  
OR (95%CI)  p value 
 
 
HIV treatment status 
Had ART for ≥6 months  
Untreated 
Had ART for <6 months  
 
CD4+ T-lymphocyte cell count
‡
 
>500 cell cells/mm
3
 
350-500 cells/mm
3
 
200-350 cells/mm
3 
< 200 cells/mm
3 
 
 
 
14(20) 
38 (55) 
16 (23) 
 
 
4 (6) 
11 (16) 
17 (25) 
31 (45) 
 
 
 
38 (40) 
47 (49) 
7 (7) 
 
 
27 (28) 
23 (24) 
18 (19) 
21 (22) 
 
  
 
1 
2.01 
6.89 
 
 
1 
3.69 
7.95 
11.47 
 
 
 
 
 
 (0.90,4.50)  0.091 
(2.11,22.5)  0.001 
 
 
 
(0.97,14.0)  
(2.14,29.5)      <0.001 
(3.27,40.3)   
  
 
 
1 
1.56 
5.52 
 
 
1 
1.92 
6.06 
6.97 
 
 
 
 
 
(0.55,4.45)  0.409 
(1.22,25.0)  0.026  
 
 
 
(0.42,8.75)  
(1.42,25.8)      0.023 
(1.63,29.8)  
 
 (0.86,78.7)  
 
 
       
*Adjusted for frequency matched variables; age, sex and urban location. 
** Adjusted for hypertension, recent infection, abdominal obesity, HIV treatment status, smoking, current alcohol drinker, CD4+ T-lymphocyte count, 
hypercholesterolaemia, cannabis use, age, sex, type of housing and urban location. 
‡ A combined p-value was calculated using a likelihood ratio test for variables with > 3 categories.  
¶ Data were missing for the following cases and controls: Four HIV treatment status, 12 CD4+ T-lymphocyte cell count, 2 recent infection, 2 Waist-hip-ratio, 1 ETOH, 8 
pregnant, 1 substance use. Missing observations were included in the analysis by creating missing value categories. 
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Table 3:5: Multivariate analysis for modifiable risk factors in ischaemic and hemorrhagic stroke patients 
 
 
 
 
Prevalence Ischaemic stroke * 
(WHO definition) 
 
Prevalence Haemorrhagic stroke **  
(WHO definition) 
 
 Cases 
n=149 (%) 
Controls 
n=503 (%) 
Adjusted OR (95% CI) p value Cases 
n=41 (%) 
Controls 
n=503 (%) 
Adjusted OR (95% CI) p value 
 
HIV positive status 
 
57 (38) 
 
95 (19) 
 
4.36 
 
(2.58,7.36) <0.001 
 
8 (20) 
 
95 (19) 
 
1.79 
 
(0.63,5.05) 0.274 
 
HIV treatment status
‡
 
 
HIV negative 
Untreated 
Had ART for <6 months  
Had ART for ≥6 months  
 
 
 
92 (62) 
34 (23) 
13 (9) 
9 (6) 
 
 
 
408 (81) 
47 (9) 
7 (1) 
38 (8) 
 
 
 
1 
6.31 
20.2 
1.56 
 
 
 
 
(3.27,12.1)  <0.001 
(6.31,64.4)  <0.001 
(0.65,3.69)    0.314 
 
 
 
32(78) 
3   (7) 
2   (5) 
3   (7) 
 
 
 
408 (81) 
47 (9) 
7 (1) 
38 (8) 
 
 
 
1 
2.27 
5.17 
1.42 
 
 
 
 
(0.45,11.4) 0.410 
(0.56,48.0) 0.119 
(0.36,5.66) 0.200 
 
Hypertension
¶
 
 
103 (69) 
 
273 (54) 
 
3.66 
 
(2.15,6.22)  <0.001 
 
35 (85) 
 
273 (54) 
 
 
9.35 
 
(2.89,30.3) <0.001 
Other vascular risk factors 
 
Diabetes 
Hypercholesterolaemia 
Recent infection  
Current smoker
¥ 
 
 
Abdominal obesity ∞ 
T1 
T2 
T3 
 
 
12 (8) 
12 (8) 
18(12) 
30 (20) 
 
 
29(19) 
52 (35) 
67 (45) 
 
 
11 (2)  
28 (6) 
37 (7) 
63 (13) 
 
 
150 (30) 
211 (42) 
141 (28) 
 
 
3.70 
1.65 
1.53 
2.48 
 
 
1 
0.93 
2.01 
 
 
(1.42,9.63)   0.007 
(0.76,3.61)   0.208 
(1.07,2.19)   0.020 
(1.34,4.61)   0.004 
 
 
 
(0.53,1.61)  0.788 
(1.15,3.49)  0.014 
 
 
1  (2) 
5  (12) 
6  (15) 
6  (15) 
 
 
15 (36) 
9 (22) 
17 (41) 
 
 
11 (2) 
28 (5) 
37 (7) 
63 (13) 
 
 
150 (30) 
211 (42) 
141 (28) 
 
 
0.33 
1.62 
2.02 
3.12 
 
 
1 
0.36 
0.73 
 
 
(0.03,3.59) 0.365 
(0.47,5.57) 0.441 
(1.28,3.19) 0.002 
(0.85,11.5) 0.087 
 
 
 
(0.13,0.97) 0.044 
(0.30,1.80) 0.500 
Untreated HIV infection, antiretroviral treatment and stroke in Malawian adults: a case control study 
111 
 
 
 
 
Table 3:5 
*Adjusted for hypertension, recent infection, abdominal obesity, HIV positive status, smoking, current alcohol drinker, hypercholesterolaemia, cannabis use, age, sex, type of housing 
and urban location. 
**Adjusted for hypertension, recent infection, abdominal obesity, HIV positive status, smoking, current alcohol drinker, hypercholesterolaemia, cannabis use, age, sex, type of housing, 
level of schooling and urban location. 
†For ischaemic stroke analysis - data were missing in the following cases and controls: One HIV positive status, 4 HIV treatment status, 18 hypercholesterolaemia, 6 recent infection and 
2 abdominal obesity.  
‡For haemorrhagic stroke - data were missing in the following cases and controls: Four for HIV treatment status, 10 hypercholesterolaemia, 5 recent infections and 1 abdominal obesity.  
Missing observations were included in the analysis by creating missing value categories. 
∞Waist-to-hip ratio tertiles (T) was calculated as tertiles from the control cohort. Cutoffs of 0.86 and 0.9 were used to divide participants into thirds.  
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3.5 Discussion 
This large prospective case-control study has confirmed that HIV infection is an independent risk factor 
for all strokes in Malawian adults (adjusted odds ratio of 3.2).  Surprisingly, I also found that  for patients 
who had started HIV treatment in the previous 6 months, the risk of stroke was even higher (adjusted 
odds ratio of 15.6).   Although hypertension was the leading risk factor in the population overall (PAF 
46%), HIV infection and its treatment were the second most important risk factor (PAF 15%), and the 
most important in younger patients (PAF 42%). In the older cohort, HIV was associated with stroke but 
was less important (PAF 6%) than hypertension (PAF 68%). 
 
Whereas most previous studies of HIV infection and stroke have been retrospective (Chapter 1) one 
recent prospective study made important observations in HIV infection and stroke (Walker et al. 2013) 
but it was limited by missing data and lacked a definitive case definition of stroke (O'Donnell et al. 2013).  
As a consequence, there is still considerable uncertainty over the relationship between HIV infection and 
stroke. My prospective study, with well defined cases, carefully selected population controls, and 99% 
ascertainment of HIV status, provides the clearest data yet that HIV is indeed an important risk factor for 
stroke.   We found that HIV infection was associated with ischaemic but not haemorrhagic stroke. A 
variety of mechanisms might be implicated: HIV infection is known to cause endothelial dysfunction 
resulting in a vasculopathy which can manifest in several forms (e.g. accelerated atherosclerosis, 
aneurysmal or non-aneurysmal disease and small vessel disease); in addition, opportunistic infections 
such as VZV, which are more common in HIV infection, can also cause a vasculopathy (Chapter 1).  
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Importantly, I found that that the risk of stroke was much higher in the first 6 months of cART.  This is a 
new finding, not reported in any previous studies (Walker et al. 2013) (Chapter 1). Clinical deterioration 
in the first 6 months of starting cART suggests an immune reconstitution inflammatory syndrome (IRIS)-
like process (Martin-Blondel et al. 2011).  IRIS is thought to be the consequence of an over-whelming 
pathogen-specific, cell-mediated immune response; arising  either through unmasking of an occult 
infection or, a paradoxical deterioration following HIV treatment (Martin-Blondel et al. 2011).  In the 
latter, the recovering immune response is thought to target persisting pathogen-derived antigens or, 
possibly, self-antigens, causing tissue damage (Martin-Blondel et al. 2011).  Although 
immunosuppression is a risk factor for IRIS, I found that the risk of stroke in the first 6 months of starting 
cART was independent of CD4+ T-lymphocyte count.  However, monitoring the number of circulating 
CD4 +T-lymphocyte cells after initiating cART is not always reliable at predicting IRIS and thus immune 
dysregulation is still an important mechanism to consider (Martin-Blondel et al. 2011).  There is also the 
possibility of other simultaneous or independent mechanisms occurring, such as stavudine toxicity.  
Insights from the large prospective D:A:D study (Data Collection on Adverse Events of anti-HIV Drugs) 
support my findings; in that study there was an increased risk of cardio- and cerebrovascular disease 
events for 5 years after starting cART; although it was not highlighted at the time, the data indicate the 
rate of vascular events was greatest in the first year, which we suspect may have been related to 
initiation of ART (d'Arminio et al. 2004).  
 
Ideally, HIV viral load would have been a better correlate of HIV disease activity however; I was limited 
by the study budget to pursue this routinely.  Instead, I have used CD4+T-lymphocyte cell count as a 
surrogate marker of HIV disease activity.  I found that a higher CD4+T-lymphocyte cell counts (a function 
of cART) was associated with reduced stroke risk, suggesting that HIV treatment is indeed beneficial 
overall.  Whilst initiating cART is necessary for improved HIV related outcome, the apparent increase in 
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early stroke risk needs investigating further; a better understanding of the mechanisms may point to 
empirical antimicrobial treatment of occult infection and/or initiation of anti-inflammatory agents at the 
time of starting cART. 
 
 
Hypertension exceeded all risk factors and should not be neglected. Of highest concern is the double 
burden of two epidemics as HIV infection and hypertension overlap.  Lessons should be learnt from the 
success of cART programs and surveillance and treatment of hypertension should  be integrated into 
these services to reduce the burden of stroke (Ibrahim et al. 2012).  In Malawi, hypertension was an 
important risk factor in older, but not younger, stroke patients. This finding is different to the multi-
national inter-stroke study which attributed most young strokes in low-middle income countries to 
hypertension; however in that study only one fifth of the patients were from sub-Saharan Africa, and 
most of these were from wealthier African countries (O'Donnell et al. 2010).  Malawi is one of the 
poorest countries in the world, and a low prevalence of diabetes and hypercholesterolaemia has been 
reported from other studies (Msyamboza et al. 2011; Muronya et al. 2011).   
 
My study had several limitations. I cannot completely exclude recall bias, but the prospective nature and 
objective measurement for most of the important risk factors has considerably reduced this possibility. 
Equally, ascertainment bias was kept to a minimum by training the study team to use standard 
operating procedures, measuring clearly defined outcomes and managing the patients using 
standardised hospital protocols (Zijlstra 2007).  I was able to perform an MRI head scan in 86% of 
suspected stroke patients. This helped to further define my cases and reduced the possibility of 
misclassifying mimics of stroke. 
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 Recruiting from the hospital alone could have selected for known HIV positive patients but over 50% 
were newly diagnosed. Selection bias could also be argued for those who were untreated HIV positive 
individuals or who recently started cART.  There are two possible scenarios which could have arisen: 1) 
untreated HIV infected individuals or those recently starting cART had mild or severe stroke and thus did 
not present to hospital. This could have potentially underestimated this stroke risk, assuming that the 
control prevalence was accurate 2) the cohort that refused to enter the study were untreated HIV 
positive individuals or had recently started treatment, potentially overestimating stroke risk associated 
with these factors. However, the refusal rate for entering the study was low (14%) and most of these 
were based on religious beliefs. Importantly, the HIV prevalence in my control cohort was consistent 
with a previous study in this setting (Choko et al. 2011); this consistency inadvertently validated my 
control selection process. Therefore, the latter scenario was less likely to have occurred.  
 
 Because age, sex and urban location are important confounders of stroke and HIV infection, we 
adopted a stratified approach for these variables. This was especially important in our setting because 
the age of stroke patients was considerably greater than the median age of Blantyre residents. This 
stratification minimised selection bias but also limited our ability to comment on these factors. 
 
The population attributable fraction can be calculated from  using the distribution of risk factors among 
the cases alone, independent of the control population (Bruzzi et al. 1985).  The formula assumes that 1) 
the estimation of the PAF is unbiased; 2) the exposure is causal; and 3) elimination of the risk factor has 
to have no effect on the distribution of other risk factors. Although the evidence associating HIV 
infection and stroke is increasing this is not definitive and therefore the assumption of causality limits 
our interpretation of PAF. 
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Access to health care is a problem in Malawi, diabetes and hypertension are often poorly controlled, 
even for patients on treatment (Cohen et al. 2007). Therefore, we assumed that treatment did not 
modify stroke risk for these conditions.  
 
This study has important public health implications, particularly demonstrating the dangers of 
extrapolating findings from high income countries, even within the same continent, to inform policy on 
stroke risk reduction in lower income countries.  Whereas hypercholesterolaemia, diabetes and 
abdominal obesity are each important risk factors for stroke in industrialised countries, I found 
population attributable fractions to be very low in this setting, with far greater risk attributable to HIV 
infection and starting cART.   
 
In conclusion, HIV infection is an important risk factor for stroke in Malawi, especially ischaemic stroke 
in young people. Importantly, although being on cART reduced the risk of stroke overall, there was a 
markedly increased risk of ischaemic stroke in the first 6 months after starting treatment.   A better 
understanding of the mechanism of stroke in the first 6 months of cART is urgently needed to guide 
appropriate interventions. 
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4 Ischaemic stroke in HIV infected individuals: defining the 
aetiologies using a hierarchal approach for research studies. 
 
 
4.1 Abstract 
Background 
In chapter 3 I showed that untreated HIV infection and recent combined antiretroviral therapy (cART) 
initiation were associated with an acute ischaemic stroke; this reinforces the global priority to improve 
our understanding of HIV infection and vascular complications in an era of an aging HIV infected 
population. There are several potential aetiologies related to HIV infection and stroke (e.g. opportunistic 
infection and HIV-associated vasculopathy), many of which are treatable. However before I could 
examine the causes of stroke in my cohort I needed a robust classification framework to help me ascribe 
aetiologies. The development of such a framework forms the subject of this chapter. 
 
Methods 
To address these issues I convened an international working group of experts in the field and related 
field to develop a consensus statement for ischaemic stroke in HIV infected individuals. I developed a 
working template to enable discussions between experts. Ideas and proposals were discussed, 
deliberated, clarified, and modified based on published literature.  When published evidence was 
limited, expert opinion was used. 
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Results 
Case definitions for the major aetiologies in HIV related strokes were refined in the context of HIV 
infection and in some cases new case definitions were described. The level of certainty of a definition 
was confirmed or probable depending on the quality of diagnostic modality used. These case definitions 
provided a framework for a hierarchical algorithm to help assign a final diagnosis.  
 
Conclusions 
I provided a framework of case definitions for the different aetiologies to facilitate standardised 
reporting by using a hierarchical approach.  This chapter contains a pragmatic way forward as a starting 
point to guide the evolution of this disease. Importantly, it will provide guidance in determining the 
aetiologies in the large cohort of HIV infected patients with stroke that I studied in Malawi. 
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4.2 Introduction 
In chapter 3 I showed that untreated HIV infection and recent combined antiretroviral therapy (cART) 
initiation was associated with acute ischaemic stroke. These risk factors will undoubtedly contribute to 
the increasing reports of vascular complications in an aging HIV-infected population (Bozzette et al. 
2003; Ovbiagele et al. 2011; Freiberg et al. 2013). There are several potential aetiologies related to HIV 
infection and stroke (e.g. opportunistic infection and HIV-associated vasculopathy), many of which are 
treatable. However, before I could examine the causes of stroke in my cohort I needed a robust 
classification framework to help me ascribe aetiologies. The development of such a framework forms 
the subject of this chapter. 
.  
Stroke is a complex syndrome with multiple aetiologies and mechanisms.  The Trial of Org 10172 in 
Acute Stroke Treatment (TOAST) and Atherosclerosis-Small vessel disease-Cardiac source-Other cause 
(A-S-C-O) are widely used stroke classifications, but they were not defined with HIV infection in mind. 
Under these classifications many potentially treatable aetiologies (e.g. HIV-associated vasculopathy, 
coagulopathy, opportunistic infection etc), fall into the generic categories of other determined, other 
cause and undetermined. Furthermore, multiple aetiologies frequently occur in HIV related strokes and 
under the current stroke classification it would be assigned as underdetermined.  Ideally, researchers 
(and clinicians) should have guidance in classifying these vague categories and thus identify; 1) 
recognisable established causes and 2) patterns and phenotypes which we recognise as occurring but 
with as yet uncertain evidence to support the mechanism.  
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Furthermore, causes of stroke that occur more frequently in HIV infected individuals need to be 
considered in the context of HIV infection; for example, diagnosing VZV vasculopathy with CSF 
Immunoglobulin G (IgG) or PCR can be complicated by HIV infection. A positive result from either test 
could reflect blood brain barrier breakdown, caused by HIV infection, with leakage from blood to CSF, 
subclinical reactivation secondary to HIV infection without causing disease or pathological disease 
(Reiber et al. 1991; Cinque et al. 1997).  
 
While a non-uniform approach may be acceptable for clinical practice, research studies should strive for 
standardised diagnoses to obtain greater consistency and accuracy across studies.  A hierarchical 
approach of diagnostic tests has proved useful recently for defining another microbial related 
neurological syndrome (encephalitis) and thus facilitating large prospective cohort studies (Granerod et 
al. 2010; Granerod et al. 2010).    
 
With international experts in the field I therefore developed a pragmatic approach to defining the 
different causes of stroke in an HIV infected stroke population that will facilitate standardised reporting 
by using a hierarchical approach, allow for comparison of data and ultimately improve the standard of 
care of patients with HIV infection and stroke.  
 
4.3 Methods 
 HIV related stroke classifications were primarily defined based on informal discussions with my 
supervisory and collaborator team to produce Table 1:2. 
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However it was clear that further refinement was needed and therefore involved multidisciplinary 
experts.  With the assistance of one of my supervisors I identified and invited experts in the field or 
related field of HIV infection and stroke to contribute to this document.  The working group included 
specialist in neurology, stroke, neuroradiology, pathology, infectious disease, general medicine, 
haematology, microbiology and virology.  The collaboration also encompassed those working in high, 
middle and low income countries.  The first step was to determine the main aetiologies of interest for 
HIV related ischaemic stroke; this was largely based on the classification described in chapter one (i.e. 
opportunistic infections, HIV-associated vasculopathy, cardio-thromboembolism and coagulopathy) 
Table 1:2.  I then determined the level of certainty of each case definition based on the accuracy of the 
diagnostic test used.  A confirmed definition was defined as direct evidence of disease based on gold 
standard diagnostic tests.  A probable definition was defined as indirect evidence of disease based on 
less sensitive tests or clinical information. The case definitions where then built into a hierarchical 
algorithm by ranking them on the following criteria 1) prognosis 2) understanding of disease mechanism 
3) availability of definitive treatment.  A minimum workup of investigation was defined to allow for 
classification and an optimum work-up gave the best chance of classifying any aetiology. I developed a 
working template of case definitions and a hierarchical algorithm to enable discussions between the 
group members.   For 6 months, ideas and proposals were discussed in group e-mails received by 
members, and were deliberated, clarified, and modified based on e-mail input from all participants. 
Each of the experts were asked to comment on the working template presenting their evidence based 
on the published literature and also to provide expert opinion when there was no published evidence.  
This formed the basis of a document outlining the case definitions with probable and confirmed 
certainty and a hierarchical algorithm for the different aetiologies in HIV related stroke.  
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4.4 Rationale behind the case definitions for the different aetiologies of 
HIV stroke 
Stroke is a clinical diagnosis that is usually based on history and examination, confirmed by brain 
imaging and the exclusion of stroke mimics.  Aetiological case definitions, as derived by myself and the 
panel of experts, for the different mechanisms of stroke in HIV infected individuals are displayed in 
Table 4:1, Table 4:2, Table 4:3 and Table 4:4. These definitions apply to all cases of HIV infected arterial 
pre-cerebral and cerebral ischaemic stroke. The rationale for each of the case definition used is 
discussed in turn. 
 
4.4.1 Opportunistic infections 
As discussed in chapter 1 TBM, VZV and syphilis are key opportunistic infections that are closely linked 
to stroke in people with HIV infection, thus we recommend routinely screening for these infections.   
 
TBM 
TBM is common in many HIV endemic countries.  Early diagnosis remains a challenge and suspicion of 
the diagnosis is often based on clinical symptoms (sub-acute presentation: feeling generally unwell, tired 
and irritable, gradually worsening headache, vomiting, neck stiffness and fever) and CSF abnormalities 
(lymphocytosis, elevated protein, and reduced glucose levels). In an immunosuppressed HIV infected 
individual the clinical symptoms and CSF abnormalities may be subtle but it is more the difficulty in 
isolating tubercle bacilli in the brain/CSF, that makes diagnosing TBM challenging (Lammie et al. 2009; 
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Marais et al. 2010). Marias and colleagues have attempted to overcome this diagnostic challenge by 
developing and validating a scoring algorithm based on clinical, CSF, imaging and evidence of TB 
elsewhere. This scoring algorithm does not rely on isolating the tubercle bacilli and can also be applied 
to HIV infected stroke patients (Marais et al. 2010). It is worth noting that this scoring algorithm was 
validated in TB endemic regions and will need to be further validated in countries where TBM is less 
common (Marais et al. 2011). 
 
Syphilis 
When syphilis causes stroke this is often because of the meningovascular complications of infection.  A 
positive blood result using treponemal or non-treponemal methods can be a challenge to interpret, 
especially in the context of HIV infection; for example, both HIV and antiphospholipid syndrome (APS) 
can give false positive results using non-treponemal methods (Chahine et al. 2011).  The Centre for 
Disease Control  recommends that a screening treponemal test (e.g. serum syphilis IgG), followed by a 
confirmatory test (e.g. Venereal Disease Research Laboratory [VDRL] or Rapid plasma reagin  [RPR]) in 
the blood should be used in combination with an elevated CSF protein or white cell count, and a positive 
CSF VDRL/RPR to confirm the diagnosis of neurosyphilis (Centers for Disease Control and Prevention 
(CDC) 1997). CSF VDRL/RPR can be negative during the early stages of neurosyphilis but one study 
showed that the diagnostic sensitivity can be improved by testing CSF FTA-ABS (fluorescent treponemal 
antibody-absorbed) or CSF-FTA (fluorescent treponemal antibody) and the specificity can be improved 
by combining this with CSF B lymphocyte cell count in fresh and cryopreserved samples, using flow 
cytometry (Marra et al. 2004).  However the validated performance of CSF-FTA-ABS/CSF-FTA has been 
variable, depending largely on the choice of controls used and few studies included subjects with HIV 
infection (Harding et al. 2012).  HIV and other opportunistic infections can independently cause CSF 
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abnormalities (e.g. low glucose, raised white cell count), therefore, in the absence of a positive CSF 
VDRL/RPR, neurosyphilis is still probable but exclusion of an alternative infectious diagnosis is especially 
important.  While there are no clear recommendations regarding the interpretation of CSF white cell 
count in HIV-infected individuals, some series have suggested a cut-off of ≥20 CSF white cells as opposed 
to ≥5 cells in non-HIV infected patients (Marra et al. 2004).  
 
VZV  
 One third of patients with VZV vasculopathy do not have a rash at the time of presentation, this often 
leads to missed diagnosis (Nagel et al. 2008). Currently a diagnosis is confirmed by CSF VZV IgG or PCR 
(Nagel et al. 2008; Gutierrez et al. 2011). Although VZV PCR testing is still commonly used, recent 
evidence shows that IgG detection in the CSF is more sensitive (Nagel et al. 2008).  In the context of HIV 
infection, caution should be taken in measuring CSF VZV IgG, as elevated levels may also reflect an 
impaired blood brain barrier with leakage of blood antibody into the CSF rather than intrathecal VZV IgG 
production (Reiber et al. 1991).  We therefore recommended that in HIV infected individuals, screening 
for VZV vasculopathy should involve calculating the antibody index by comparing the serum/CSF ratio of 
anti-VZV IgG antibody to the serum/CSF ratio of albumin and total IgG, thus discriminating between 
blood derived and pathology brain-derived antibody (Reiber et al. 1991; Winchester et al. 2011).  The 
specificity of CSF VZV PCR alone in HIV infected individuals is also questionable, because a positive result 
may also be associated with subclinical activation, reaffirming the utility of CSF VZV IgG index in HIV 
infected individuals (Cinque et al. 1997). Therefore, a positive CSF VZV PCR should confirm rather than 
determine the diagnosis of VZV vasculopathy in an HIV infected individual. 
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Table 4:1: Diagnostic criteria for opportunistic infection of the central nervous system  found  in 
arterial ischaemic stroke in  HIV infected individuals 
 
Aetiology 
 
Confirmed 
 
Probable 
 
 
Varicella-zoster virus 
(VZV)  
Ischaemic stroke 
 
And 
1 out of 2 pathology/laboratory criteria: 1) 
Brain histopathology evidence of vasculitis 
and isolation of VZV virus particle by in 
situ hydribidisation, PCR or antigen 
detection using immunohistochemistry, 2) 
Intrathecal VZV IgG production +/- DNA 
VZV PCR in the CSF (Nagel et al. 2008; 
Gilden et al. 2009). 
 
And 
Exclusion of alternative diagnosis. 
Ischaemic stroke 
 
And 
1 out of 2 clinical/laboratory criteria: 
1)Trigeminal or cervical zoster distribution 
within the 6 weeks prior to the onset of 
stroke, in the absence of histology or 
laboratory confirmation (Gilden et al. 2009), 
2) Negative Intrathecal VZV IgG production 
and positive DNA VZV PCR in the CSF. 
 
And 
Exclusion of alternative diagnosis. 
 
 
Tuberculosis infection 
Ischaemic stroke 
 
And 
Brain histopathology or CSF AFB, culture 
or PCR positive for MTB with associated 
endarteritis obliterans (Marais et al. 
2010). 
 
And 
Exclusion of alternative diagnosis. 
Ischaemic stroke 
 
And 
Score ≥ 10 (without CT/MRI brain) or ≥ 12 
(with CT/MRI brain) based on the uniform 
case definition for tuberculous meningitis. 
Case definition encompasses clinical, CSF, 
evidence of MTB elsewhere +/- imaging 
(Marais et al. 2010). 
 
And 
Exclusion of alternative diagnosis. 
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Table 4:1: Diagnostic criteria for opportunistic infection of the central nervous system  found  in 
arterial ischaemic stroke in HIV infected individuals. 
 
Aetiology 
 
Confirmed 
 
Probable 
 
 
Syphilis 
Ischaemic stroke 
 
And 
3 out of 3 Laboratory criteria; 1) Reactive 
non-treponemal test (i.e., VDRL or RPR), 
and a reactive treponemal test (i.e. Tp EIA, 
TPPA) in the blood (Centers for Disease 
Control and Prevention (CDC) 1997), 2) 
Positive CSF RPR/VDRL or FTA-ABS /FTA 
+/- elevated CSF B-cell count (in the 
absence of substantial contamination of 
CSF with blood) (Centers for Disease 
Control and Prevention (CDC) 1997; Marra 
et al. 2004), 3) CSF leucocyte >20 
cells/mm
3
 or CSF protein >0.45 g/l, or IgG 
index >0.6 (Centers for Disease Control 
and Prevention (CDC) 1997; Timmermans 
et al. 2004; Chahine et al. 2011).  
 
Or 
 
Brain histopathology confirmation of Tp 
spirochaetes by immunohistochemistry 
with associated endarteritis obliterans.  
 
And 
Exclusion of alternative diagnosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ischaemic stroke 
 
And 
3 out of 3 Laboratory criteria; 1) Reactive 
non-treponemal test (i.e. VDRL or RPR), and 
a reactive treponemal test (i.e. Tp EIA, 
TPPA) in the blood, 2) Negative CSF 
confirmation of syphilis (or substantial 
contamination of CSF with blood), 3) CSF 
leucocyte >20 cells/mm
3
 or CSF protein 
>0.45 g/l, or IgG index >0.6 (Centers for 
Disease Control and Prevention (CDC) 1997). 
  
Or 
3 out of 3 Laboratory criteria; 1) Reactive 
non-treponemal test (i.e. VDRL or RPR), and 
a reactive treponemal test (i.e.Tp  EIA, 
TPPA) in blood, 2) Positive CSF EIA/TPPA 
confirmation of syphilis (or substantial 
contamination of CSF with blood), 3) CSF 
leucocyte >20 cells/mm
3
 or CSF protein 
>0.45 g/l, or IgG index >0.6 (Centers for 
Disease Control and Prevention (CDC) 1997).  
 
Or 
3 out of 3 Laboratory criteria; 1) Reactive 
non-treponemal test (i.e. VDRL or RPR), and 
a reactive treponemal test (i.e. Tp EIA, 
TPPA) in blood, 2) Positive CSF RPR/VDRL or 
FTA-ABS/FTA +/- elevated CSF B-cell count 
(in the absence of substantial 
contamination of CSF with blood), 3) CSF 
leucocyte ≤20 cells/mm
3
 or CSF protein 
≤0.45 g/l, or IgG index ≤0.6 (Brown et al. 
2006).  
 
And 
Exclusion of alternative diagnosis. 
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Table 4:1:  Diagnostic criteria for opportunistic infection of the central nervous system  found  in 
arterial ischaemic stroke in HIV infected individuals 
Opportunistic 
infections 
Minimum work-up 
TB: CSF microscopy and biochemistry or unenhanced CT/MRI and chest x-ray 
Syphilis: non-treponemal and a treponemal blood test, CSF microscopy and biochemistry 
VZV: nil 
Optimum work-up 
TB: CSF/brain histopathology/sputum - TB culture or AFB stain or TB PCR and CSF 
microscopy and biochemistry and CT/MRI with contrast and CXR 
Syphilis: non-treponemal and a treponemal blood test, CSF microscopy and biochemistry 
and CSF VDRL/RPR, FTA-ABS/FTA and B cell count. Brain histopathology 
VZV: CSF VZV IgG index and PCR, brain histopathology. 
Case definitions refer exclusively to the brain; retinal and spinal cord infarction fall out with the scope of these 
definitions. CSF – Cerebrospinal fluid, VDRL – Venereal Disease Research Laboratory, RPR – Rapid Plasma Reagin, 
Tp EIA – Treoinema Enzyme immunoassay, TPPA – Treponema pallidum particle agglutination, FTA-ABS - 
Fluorescent Treponemal Antibody-Absorbed), FTA - Fluorescent Treponemal, MTB- Mycobacterium Tuberculosis, 
TB-Tuberculosis, AFB – Acid fast bacilli,  CXR – chest radiograph. 
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4.4.2 HIV-associated vasculopathy 
Vasculopathy is defined as significant thickening of the intima, usually from intimal hyperplasia, more 
than expected for age. In chapter 1, HIV-associated vasculopathy was defined as an abnormality of the 
cerebral blood vessels that result directly or indirectly from HIV infection but excluding opportunistic 
infection, vasculitis and lymphoma. This definition was deliberately inclusive, in an attempt to 
encompass the several cerebrovascular changes described in HIV infection. Each of these will now be 
discussed in turn. 
 
Atherosclerotic and non-atherosclerotic vasculopathy 
Intimal hyperplasia is the hallmark of atherosclerosis.  It is usually typified by plaque formation and 
consists of form cells, a lipid core and a fibrous cap (Libby et al. 2011). While the mechanism of 
accelerated atherosclerosis by chronic inflammation owing to HIV infection or from dyslipidaemia 
associated with HIV treatment is more certain, the mechanism of a non-atherosclerotic group is not.  
The latter is typically found in young stroke patients and these patients usually have evidence of 
aneurysmal/ non-aneurysmal intracranial/extracranial asssociated strokes (Friis-Moller et al. 2003; 
Tipping et al. 2006; Tipping et al. 2007; Gutierrez et al. 2011; Ovbiagele et al. 2011; Rasmussen et al. 
2011) (Chapter 1). 
 
The mechanism of non-atherosclerotic vasculopathy may differ, however their phenotypes overlap and 
are sometimes difficult to differentiate without histopathology and optimal imaging; neither of which 
are readily available in resource-poor settings where the highest burden of HIV infection exists.  Young 
age is the most important predictor of this phenotype and was therefore used to define this non-
atherosclerotic group; a cut-off of 45 years was chosen to discriminate from the typical atherosclerotic 
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related strokes (Tipping et al. 2006; Tipping et al. 2007) (Chapter 1).  This cut-off was based on the age 
distribution of histologically supported case series (Nair et al. 1999; Tipping et al. 2006; Tipping et al. 
2007; Delgado Almandoz et al. 2013).  Although we envisage that our knowledge will expand in this field 
and thus guide a refined classification of this non-atherosclerotic group, we suggest this pragmatic 
definition as a starting point to guide the evolution of this emerging syndrome. 
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Table 4:2: Diagnostic criteria  for HIV-associated vasculopathy found  in arterial ischaemic stroke in HIV 
infected individuals 
 
Aetiology 
 
Confirmed 
 
Probable 
 
 
Non-atherosclerotic 
Stroke 
Ischaemic stroke 
 
And 
1 out of 4 pathology/radiology criteria: 1) 
Brain histopathology evidence (macro- 
and microscopic demonstration) of 
vasculopathy (significant thickening of the 
intima, usually from intimal hyperplasia, 
more than expected for age) of the 
arterial wall in the absence of 
atherosclerosis and vasculitis, 2) Patients 
with stenosis (or complete occlusion) 
≥50% in an intra-/or extracranial artery 
supplying the ischaemic field +/- luminal 
thrombus, 3) a mobile thrombus in the 
aortic arch; 4) occlusion with imaging 
evidence of vasculopathy in an intra-/or 
extracranial artery supplying the 
ischaemic field (Tipping et al. 2006; 
Tipping et al. 2007; Gutierrez et al. 2011).  
 
And  
Age ≤45 years  
 
And 
Exclusion of alternative diagnosis. 
 
 
Ischaemic stroke 
 
And 
A history of intermittent claudication, 
Transient Ischaemic Attacks (TIAs) in the 
same vascular territory, a carotid bruit, or 
diminished peripheral pulses.  
And  
Age ≤45 years  
 
And 
Exclusion of alternative diagnosis.† 
 
 Minimum work up: nil 
Optimum work up: Carotid/vertebral duplex ultrasound/echography. CT-angiography or 
MR-angiography or Digital-subtraction angiography (Adams et al. 1993; Amarenco et al. 
2009) . Brain histopathology. †There should be careful consideration for a psycogenic 
cause of symptoms in those without brain imaging or a normal unenhanced CT within 
24hours of index stroke. 
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Table 4:2:  Diagnostic criteria  HIV-associated vasculopathy found  in arterial ischaemic stroke in HIV 
infected individuals 
 
Aetiology 
 
Confirmed 
 
Probable 
 
 
Atherosclerotic 
Stroke 
Ischaemic stroke 
 
And 
1 out of 4 pathology/radiology criteria: 1) 
Brain histopathology evidence (macro- 
and microscopic demonstration) of 
atherosclerotic disease of the arterial wall, 
with or without local thrombus, 2) 
Patients with stenosis (or complete 
occlusion) ≥50% in an intra-/or 
extracranial artery supplying the 
ischaemic field +/- luminal thrombus, 3) A 
mobile thrombus in the aortic arch; 4) 
occlusion with imaging evidence of 
atherosclerosis in an intra-/or extracranial 
artery supplying the ischaemic field 
(Adams et al. 1993; Amarenco et al. 2009). 
 
And  
Age >45 years  
 
 And 
Exclusion of alternative diagnosis. 
Ischaemic stroke 
  
And 
A history of intermittent claudication, 
Transient Ischaemic Attacks (TIAs) in the 
same vascular territory, a carotid bruit on 
auscultation or diminished peripheral pulses 
(Adams et al. 1993; Amarenco et al. 2009). 
 
And  
Age >45 years  
 
And 
Exclusion of alternative diagnosis.† 
 
 Minimum work up: nil 
Optimum work up:  Carotid/vertebral duplex ultrasound/echography. CT-angiography or 
MR-angiography or Digital-subtraction angiography (Adams et al. 1993; Amarenco et al. 
2009).  Brain histopathology. †There should be careful consideration for a psycogenic 
cause of symptoms in those without brain imaging or a normal unenhanced CT within 
24hours of index stroke. 
 
Case definitions refer exclusively to the brain; retinal and spinal cord infarction fall out with the scope of these 
definitions. CT – Computer tomography. 
 
Ischaemic stroke in HIV infected individuals: defining the aetiologies using a hierarchal approach for research studies. 
132 
 
Vasculitis  
 The association of HIV and cerebral vasculitis has been reported in a few case series (Nogueras et al. 
2002; Taylor et al. 2008; Bermel et al. 2009; Melica et al. 2009). Vasculitis can either be caused by 
infection, where direct invasion of the pathogen leads to proliferation and inflammation of the vessel 
wall (e.g. VZV) or by non-infectious mechanisms (Jennette et al. 2013).  Although a pathogen may be 
involved in the latter, this type of vasculitis does not have direct vessel wall invasion; this is suspected to 
be the likely mechanism for HIV-associated vasculitis. Most of the case series that describes HIV-
associated vasculitis meets the Chapel Hill criteria of single organ vasculitis (i.e. the vasculitis is limited 
to the brain) (Jennette et al. 2013). Diagnoses of single organ vasculitis is usually one of deduction, firstly  
by identifying the characteristic clinical and radiological features and then excluding alternative 
aetiologies (); neoplasia (e.g. lymphoma, leukaemia, lung cancer), infections (VZV, syphilis, TB, 
neuroborreliosis, fungal infection - aspergillosis, nocardiosis, cryptococcus, histoplasmosis, hepatitis B 
and C) and inflammatory disorders (e.g. Behcet’s disease, scleroderma, polyarteritis nodosa, Sjogren’s 
syndrome, antiphospholipid antibody syndrome, Wegener’s granulomatosis, systemic lupus 
erythematosis, Crohn’s disease, Kohlmeier-Degos disease, Cogan’syndrome, sarcoid granulomatosis and 
angiitis, urticarial hypocomplementemic) (Hajj-Ali et al. 2011) Table 4:2. Investigations to exclude these 
alternative diagnoses should be directed by clinical history and in some cases, the regional endemicity of 
the condition.  
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Table 4:2: Diagnostic criteria  HIV-associated vasculopathy found  in arterial ischaemic stroke in 
HIV infected individuals 
 
Aetiology 
 
Confirmed 
 
Probable 
 
Vasculitis  
 
 
Ischaemic stroke 
 
And  
The presence of either classic 
angiographic or histopathology features of 
angiitis within the central nervous system 
(Chetty 2001; Nogueras et al. 2002; Kuker 
2007; Melica et al. 2009; Hajj-Ali et al. 
2011).  
 
And 
Exclusion of alternative diagnosis
+
 
 
Ischaemic stroke 
 
And 
CT/MRI confirmation of acute and/or 
chronic ischeamic changes in more than one 
vascular territory, involving any or all of 
cortical, subcortical and deep white matter 
distribution. In the absence of an embolic 
source (Kuker 2007; Hajj-Ali et al. 2011). 
 
And 
Exclusion of alternative diagnosis 
 Minimum work up: unenhanced CT/ MRI (T1, T2, FLAIR and DWI sequences) and exclude 
VZV and TB and syphilis and CXR (Wardlaw et al. 2013). 
Optimum work up:  CT (with contrast)/ MRI (minimum T2, T2*and DWI sequences) and 
 CT-angiography or MR-angiography or Digital-subtraction angiography.   Histopathology 
examination.  
 
†Alternative diagnosis should be excluded; for inflammatory disorders,  ANA antibodies 
(if positive ENA, DNA antibodies), or C3/C4, or ANCA, or cryoglobulins or rheumatoid 
factor or serum/CSF angiotensin-converting enzyme (ACE) and APS screen (as above) and 
CXR; for  Infections, VZV, TB, syphilis, hepatitis B and C  and Lyme’s disease (especially in 
regions endemic for ticks) (Hajj-Ali et al. 2011).  
Case definitions refer exclusively to the brain; retinal and spinal cord infarction fall out with the 
scope of these definitions. CT – Computer tomography, MRI – Magnetic resonance imaging, VZV – 
varicella zoster virus, TB – mycobacterium tuberculosis, CXR – chest radiograph, ANA –Antinuclear 
Antibody, ENA – Extractable Nuclear Antigen, C3/4 – Complement C3/4, ANCA – Anti-neutrophil 
cytoplasm antibody. 
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Small vessel disease 
Small vessel disease is a type of stroke.  As a term, small vessel disease covers many pathologies, the 
main causes of small vessel disease  described in pathology series are those thought to be associated 
with chronic hypertension, hyaline arteriolosclerosis and lipohyalinosis, and cerebral amyloid angiopathy 
(Pantoni 2010).  Lacunar infarcts and white matter lesions are easily detected by neuroimaging but small 
vessel disease due to vessel wall alteration is not.  Therefore, neuroimaging classification of recent 
infarct (<20mm in size) restricts the definition to ischaemic lesions and might be misleading (Pantoni 
2010; Wardlaw et al. 2013). The Edinburgh cohort of 183 case autopsy series showed that SVD  does 
indeed exist in an HIV infected population however, these were  largely asymptomatic cases, 
characterised by hyaline small vessel wall thickening, perivascular space dilatation, rarefaction and 
pigment deposition with vessel wall mineralization and occasional perivascular inflammatory cell 
infiltrates and associated with microinfarcts (Connor et al. 2000).  Further work is needed to confirm if 
stroke syndromes are the only entity of small vessel disease in patients with HIV infection. Especially as 
small vessel disease may be implicated in neurological disorders such as cognitive impairment (Wright et 
al. 2010). 
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Table 4:2: Diagnostic criteria  HIV-associated vasculopathy found  in arterial ischaemic stroke in HIV 
infected individuals 
Aetiology Confirmed Probable 
 
 
Small Vessel Disease 
 
Ischaemic stroke 
 
And 
1 out of 2 pathology/clinical/radiology 
criteria. 1) Brain histopathology evidence 
of small vessel disease characterised by 
hyaline arteriolosclerosis, lipohyalinosis or 
amyloid angiopathy (Connor et al. 2000; 
Wardlaw et al. 2013), 2) At least one 
traditional clinical lacunar syndromes
*
 in 
the absence of cortical involvement
** 
and 
CT/MRI demonstration of a relevant 
brainstem or subcortical lesion with a 
diameter of less ≤20mm (Bamford et al. 
1987; Adams et al. 1993; Wardlaw et al. 
2013).  In the absence of cardio-
thromboembolic source and/or ≥50% 
ipsilateral carotid stenosis.  
 
And 
Exclusion of alternative diagnosis. 
 
 
 
 
 
 
 
 
Ischaemic stroke 
 
And 
A least one traditional clinical lacunar 
syndromes* in the absence of cortical 
involvement**, in the absence of cardio-
thromboembolic source and/or ≥50% 
ipsilateral carotid stenosis (Adams et al. 
1993; Amarenco et al. 2009).  
 
Or 
 
A least one traditional clinical lacunar 
syndromes* in the absence of cortical 
involvement** and normal unenhanced CT 
within 24 hours of index stroke, in the 
absence of cardio-thromboembolic source 
and/or ≥50% ipsilateral carotid stenosis 
(Adams et al. 1993; Amarenco et al. 2009).  
 
  
And 
Exclusion of alternative diagnosis.
†
 
 
Minimum work up: nil 
Optimum work up: MRI (T1, T2, FLAIR, T2*GRE, DWI) (Wardlaw et al. 2013). 
*
The following 4 syndromes were recognised: pure motor stroke, pure sensory stroke, 
sensorimotor stroke, and ataxic hemiparesis. 
**
The presence of a visual field defect, 
evidence of higher cerebral dysfunction (e.g. dysphasia, visuospatial disturbance, 
predominantly proprioceptive sensory loss) on standard clinical testing, or features that 
clearly localize the lesion in the vertebrobasilar distribution (e.g. gaze palsies or crossed 
deficits, though not nystagmus or dysarthria) exclude the diagnosis of lacunar syndrome 
(Bamford et al. 1987). 
 
†There should be careful consideration for a psycogenic cause of symptoms in those 
without brain imaging or a normal unenhanced CT within 24hours of index stroke. 
 
Case definitions refer exclusively to the brain; retinal and spinal cord infarction fall out with the scope 
of these definitions. CT – Computer tomography, MRI – Magnetic resonance imaging, T1- T1 weighted 
sequence T2 – T2 weighted sequence,  DWI – diffusion weighted imaging, GRE- gradient ECHO, FLAIR – 
fluid attenuated inversion recovery.  
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4.4.3 Cardioembolism 
The criteria we devised for cardio-thromboembolism were based largely on the TOAST classification 
(Adams et al. 1993). We modified this to also include marantic endocarditis in the high risk group Table 
4:3 (Berger et al. 1990). 
 
 
  
Table 4:3: Diagnostic criteria  for cardio-thromboembolism found  in arterial ischaemic stroke in HIV 
infected individuals 
 
Aetiology 
 
Confirmed 
 
Probable 
Cardio-
thromboembolism 
Ischaemic stroke 
 
And 
Identification of high-risk cardio-
thromboembolic lesions (Mechanical 
prosthetic valve, Mitral stenosis with atrial 
fibrillation, Atrial fibrillation (other than 
lone atrial fibrillation), Left atrial/atrial 
appendage thrombus, Sick sinus 
syndrome, Recent myocardial infarction 
(<4 weeks), Left ventricular thrombus, 
Dilated cardiomyopathy, Akinetic left 
ventricular segment, Atrial myxoma, 
infective and marantaric endocarditis) 
(Adams et al. 1993). 
 
And 
Exclusion of alternative diagnosis 
Ischaemic stroke 
 
And 
Identification of medium-risk cardio-
thromboembolic lesions (Mitral valve 
prolapsed, Mitral annulus calcification, 
Mitral stenosis without atrial fibrillation, 
Left atrial turbulence (smoke), Atrial septal 
aneurysm, Patent foramen ovale, Atrial 
flutter Lone atrial fibrillation, Bioprosthetic 
cardiac valve, Nonbacterial thrombotic 
endocarditis, Congestive heart failure, 
Hypokinetic left ventricular segment, 
Myocardial infarction [>4 weeks, <6 months 
of stroke event]) (Adams et al. 1993).  
 
And 
Exclusion of alternative diagnosis† 
Minimum work-up 
ECG and auscultation by a cardiologist 
Optimum work-up 
ECG/telemetry/Holter ECG and Trans-thoracic echography or Trans-oesophageal 
echography or cardiac CT/MRI (Amarenco et al. 2009). †There should be careful 
consideration for a psycogenic cause of symptoms in those without brain imaging or a 
normal unenhanced CT within 24hours of index stroke. 
 
 
Case definitions refer exclusively to the brain; retinal and spinal cord infarction fall out with the scope 
of these definitions. ECG – electrocardiogram. 
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4.4.4 Coagulopathy 
Antiphospholid syndrome (APS) is a prothrombotic disorder.  Greater than 20% of cases can present as a 
stroke (Ruiz-Irastorza et al. 2010).  The revised classification criteria for APS (2006) specify that at least 
one of the clinical criteria and laboratory criteria are met (Miyakis et al. 2006).  A patient presenting with 
an ischaemic  stroke (confirmed by  brain imaging)  automatically meets the clinical criteria but they will 
also need to have anti–β2-glycoprotein I (β2GP1) or anticardiolipin (ACL) antibodies or lupus-
anticoagulant (LA), detected by enzyme-linked immunosorbant assay (ELISA) in their blood and 
persistence of medium to high titers of these antibodies for >12 weeks Table 4:4.  More recent evidence 
shows that the anti–β2GP1 and LA are strongly associated with incident stroke (Urbanus et al. 2009).  
However, the evidence demonstrating the utility of ACL as a predictor of APS and stroke is conflicting 
(Brey et al. 2003; Urbanus et al. 2009).  HIV infection is associated with ACL and LA but not anti– β2GP1 
(Petrovas et al. 1999). As anti–β2GP1 appears to be specific in stroke individuals with APS in both HIV 
positive and negative populations, the consensus was to refine the laboratory definition to include the 
detection of anti- β2GP1 in combination with ACL or LA in those with HIV infection.  
 
The definition of a confirmed APS is defined by time therefore precluding a diagnosis at the acute stage 
of the patient’s presentation.  Part of the definition requires a repeat blood test at 12 weeks to confirm 
or refute this diagnosis. Other coagulopathies like Protein C and S deficiency have been implicated in HIV 
infection but these are associated with venous and not arterial strokes.  
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Table 4:4: Diagnostic criteria  anti-phospholipid syndrome found  in arterial ischaemic stroke in HIV 
infected individuals 
 
Aetiology 
 
Confirmed 
 
Probable 
Coagulopathy 
Anti-phospholipid syndrome 
 
Ischaemic stroke.
†
 
 
And 
1 out of 2 laboratory criteria: 1) Lupus 
anticoagulant present in plasma 2) 
Anticardiolipin antibody of IgG or IgM 
isotype, present in serum or plasma, in 
medium or high titer (i.e. >40 GPL or 
MPL units, or > 99th percentile) (Miyakis 
et al. 2006). 
 
And  
Anti-β2-glycoprotein 1 antibody of IgG 
or IgM isotype, present in serum or 
plasma, in titer >99th percentile 
(Petrovas et al. 1999).  
 
All present on two or more occasions, at 
least 12 weeks apart. 
 
And 
Exclusion of alternative diagnosis. 
Ischaemic stroke 
 
And 
1 out of 2 laboratory criteria: 1) Lupus 
anticoagulant present in plasma 2) 
Anticardiolipin antibody of IgG or IgM 
isotype, present in serum or plasma, in 
medium or high titer (i.e. >40 GPL or 
MPL units, or > 99th percentile) 
(Miyakis et al. 2006). 
 
And 
Anti-β2-glycoprotein 1 antibody of IgG 
or IgM isotype, present in serum or 
plasma, in titer >99
th
 percentile 
(Petrovas et al. 1999). 
 
Present at one time-point, or on two 
occasions separated by less than 12 
weeks.  
 
And 
Exclusion of alternative diagnosis.†  
Minimum work-up: Lupus anticoagulant or Anticardiolipin antibody and Anti-β2-
glycoprotein 1 
Optimum work-up:  MRI (T1, T2, FLAIR sequences); CT-angiography plus CT-
venography or MR-angiography plus MR-venography (Hajj-Ali et al. 2011; Kaichi et 
al. 2013). Lupus anticoagulant or Anticardiolipin antibody and Anti-β2-glycoprotein 
1. Brain histopathology examination. 
 
†
histopathology confirmation is not essential for a confirmed diagnosis but if used, 
thrombosis should be present without significant evidence of inflammation in the 
vessel wall (Miyakis et al. 2006). †There should be careful consideration for a 
psycogenic cause of symptoms in those without brain imaging or a normal 
unenhanced CT within 24hours of index stroke. 
 
 
Case definitions refer exclusively to the brain; retinal and spinal cord infarction fall out with the scope of 
these definitions. CT – Computer tomography, MRI – Magnetic resonance imaging, T1- T1 weighted 
sequence T2 – T2 weighted sequence, DWI – diffusion weighted imaging, FLAIR – fluid attenuated 
inversion recovery, IgG-immunoglobulin G, IgM – immunoglobulin M. 
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4.4.5 Other determined aetiology 
Although we have described the common aetiologies encountered in HIV related  stroke, this is by no 
means an exhaustive list. There are aetiologies where the mechanism of HIV stroke may be biologically 
plausible but there was minimal evidence in the literature to support an association (e.g. systemic 
vasculitidies and precerebral/cerebral arterial dissection, hyperviscosity syndrome). There are also 
aetiologies described in young populations that may co-occur in HIV infected individuals (e.g. hereditary 
causes of stroke and drug-induced vasculopathy).  A thorough clinical history and examination, with 
diagnostic studies such as blood tests and brain imaging should reveal these less frequently described 
causes of stroke.  
 
4.4.6 Stroke mimics 
In an HIV endemic population one quarter of patients presenting with an acute focal neurological deficit 
will have a stroke mimic (Kumwenda et al. 2005). Frequently occurring mimics include toxoplasma 
infection, progressive multifocal leukoencephalopathy, viral encephalitidies (e.g. HSV-1, CMV) and 
fungal infections (Chapter 2). The selection of appropriate imaging (at least a CT scan with contrast or 
preferably an MRI with a minimum sequence of T1, T2, FLAIR and DWI) is essential for the exclusion of 
stroke mimics (Chapter 2). 
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4.5 Building the hierarchical framework  
 
The starting point of this framework was defined as: 
 
1) Stroke - rapidly developing clinical symptoms lasting more than 24 hours or leading to death, 
with no apparent cause other than a vascular one (Hatano 1976). 
2) HIV infection – based on a positive antibody test which either involves HIV enzyme 
immunoassay (EIA) or rapid HIV antibody test, a positive result requires confirmation with 
western blot, antigen test or PCR test. However, in resource-poor settings confirmation is 
usually with a second antibody test using a different manufacturer system. 
 
When possible, this was accompanied by brain imaging to type the stroke and exclude stroke mimics. 
The aetiological definition was based on clinical, laboratory, radiology and brain histopathology findings; 
a minimum work-up of investigations (in addition to clinical history and examination) was needed for a 
diagnosis to be established. The level of certainty “confirmed” or “probable” was based on the quality of 
diagnostic evidence.  
 
A complete assessment of all the potential causes preceded the use of our proposed algorithm. The 
selected aetiologies were based on those with good evidence or plausible mechanisms that linked HIV 
infection and stroke; this included opportunistic infection (i.e. VZV, syphilis, TB), coagulopathy (i.e. 
antiphospholipid syndrome [APS]), cardio-thromboembolism and HIV-associated vasculopathy (Chapter 
1). 
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The hierarchical placement of the different aetiologies was based on several factors 1) poor prognosis 2) 
our confidence of the underlying mechanism of the disease in the context of HIV infection (based on 
current evidence) 3) availability of definitive treatment. Those that satisfied all three criteria were 
placed higher up in the algorithm.  The highest aetiology in the hierarchy with a “confirmed diagnosis” 
was taken as the final diagnosis even if there were multiple confirmed aetiologies. However, a “probable 
diagnosis” was only allocated as the final diagnosis if there was one option; otherwise this was defined 
as undetermined  Figure 4:1.  We considered several scenarios to justify the rationale behind the 
placement of the different aetiologies; 1) if after an assessment of all the possible causes, the patient 
had a confirmed CNS VZV infection and confirmed vasculitis; it was likely that VZV caused the vasculitis 
and without treatment of the VZV infection the patient would  have a worse prognosis  therefore CNS 
VZV infection was placed higher than vasculitis in the hierarchy: 2) If after an assessment of all the 
possible causes, the patient was found to have both confirmed cardio-thromboembolic and 
atherosclerotic stroke, those with cardio-thromboembolic stroke were more likely to have recurrent 
events thus a poorer prognosis (Grau et al. 2001; Gilden et al. 2009).  In the latter scenario, the timely 
initiation of long-term anti-coagulation is an important consideration.  In the era of thrombolysis, a non-
infectious cardio-thromboembolic stroke would be considered for treatment, as long as there were no 
contraindications therefore, short-term management does not necessarily differ between the two 
aetiologies but long-term management does, justifying the higher placement of cardio-thromboembolic 
stroke; 3) although antiphosholipid syndrome is well characterised in the non-HIV population as a cause 
of young stroke, and has a plausible mechanism of a pro-thrombotic state in HIV infected individuals, 
there is little evidence that demonstrates an association with APS and HIV stroke (Maclean et al. 1990; 
Urbanus et al. 2009) (Chapter 1). Furthermore, treatment interventions in the non-HIV and HIV infected 
populations are uncertain (Brey et al. 2003). For this reason, this was placed lower down in the hierarchy 
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but ahead of small vessel disease.  Small vessel disease requires the exclusion of APS for a diagnosis to 
be made and does not have a definitive treatment (Pantoni 2010) Figure 4:1.  
 
A diagnosis was defined as “undetermined” when; 1) more than two probable cause was identified at 
the same level of “probable” diagnostic certainty 2) the diagnosis was ”uncertain” (following a minimum 
work-up for all aetiologies) 3) the diagnosis was ”incomplete” (this arose when one or more of the 
aetiologies did not have a minimum work-up) or classified as “other determined” when rarer causes of 
HIV stroke were found (Amarenco et al. 2009). 
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Figure 4:1: Hierarchical approach to defining the aetiology of arterial ischaemic stroke in HIV 
infected individuals 
APS: Anti-phospholipid syndrome 
 
 
Ischaemic stroke in HIV infected individuals: defining the aetiologies using a hierarchal approach for research studies. 
144 
 
4.6 Discussion 
The preliminary classification of HIV related stroke in chapter one was based on several phenotypes 
reported in the literature. In this chapter I further refined definitions in the context of HIV infection and 
developed new definitions as in the case of non-atherosclerotic stroke, a form of HIV-associated 
vasculopathy.  
 
These case definitions and hierarchical algorithm are timely and underscores the global priority to focus 
on HIV infection and vascular diseases (Ullrich et al. 2011). A better understanding of the pathogenesis 
and interventions to reduce this stroke burden is of top priority. 
 
We intentionally deviated from the horizontal type algorithm seen in past stroke classifications, largely 
to enforce a diagnosis (Adams et al. 1993; Amarenco et al. 2009).  The vertical hierarchical algorithm 
assumes that the top aetiology is the likely causative agent/ mechanism and this is deduced from the 
systematic investigation of common aetiologies found in HIV related stroke.  This concept is 
straightforward except for when multiple aetiologies arise which may or may not have the same 
underlying mechanism. For infective organisms such as VZV, TB, syphilis it can be convincingly argued 
that all these infections can potentially  cause  vasculitis, vasculopathy, cardioembolic stroke (especially 
for syphilis) and small vessel disease and therefore,  can be placed higher in the algorithm. However, 
aetiologies like atherosclerotic stroke, cardio-thromboembolism, vasculitis, small vessel disease may 
coexist and have related mechanisms or be entirely exclusive. In this instance, we adopted a logical 
approach i.e. what would be useful for the clinician? The consensus was that the prognosis and 
availability of definitive treatment were important components in managing any patient with a stroke 
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thus, we priortised those with poorer prognosis and availability of definitive treatment above those 
without. We were also cautious not to prioritise aetiologies which logically should be higher up in the 
algorithm but limited evidence supporting the mechanism in HIV related stroke prevented this (e.g. 
APS).  
 
Most studies will benefit from this stringent approach which maximises on the specificity but at the 
expense of sensitivity.  Validation studies in existing and prospective cohorts will advance this approach 
and optimise its sensitivity, specificity, and accuracy.  We also envisage that once validated that this can 
also be used in a clinical setting. 
 
The intention of this algorithm was not to stop investigating at the point of diagnosis but rather, to 
perform a complete assessment of all the frequently occurring aetiologies in HIV related stroke. We 
developed a minimum assessment which collectively included (blood tests – ACL, LA, B2GP1, syphilis IgG 
or Tp EIA, VDRL or RPR, CXR, CSF – microscopy, biochemistry, bacterial culture and unenhanced CT); if a 
probable diagnosis occurred, these investigations, which are mostly resource appropriate, should 
capture the diagnosis. The optimum work-up, when resource allows will confirm a definitive diagnosis if 
it existed. This is in addition to the standard work-up of stroke patients (i.e. fasting glucose, fasting 
cholesterol, full blood count and urea and electrolyte) (Chapter 1). 
 
The heterogeneous nature of HIV stroke and the limited number of studies to extrapolate evidence from 
made the development of this consensus statement challenging. The number of specialties needed to 
develop this document also highlighted the diversity of aetiologies in HIV infected stroke patients. 
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Within the working group we had contributors from Malawi and Cape Town; authors from these centers 
were working on probably the largest prospective cohort of HIV stroke in Sub-Saharan Africa at the time 
of writing and insight from these databases helped in bringing this document together.  Furthermore, 
contribution from these regions also ensured that poorer countries, which suffer from the highest 
burden of HIV infection, were sensitively considered with regards to diagnostic modalities. 
 
HIV infection and stroke is an emerging field and we have some way to go in understanding the different 
causes of stroke and their pathogenesis in this population.  However, this chapter contains a pragmatic 
way forward as a starting point to guide the evolution of this disease.  My next step, covered in the next 
chapter, was to use these case definitions to determine the aetiologies in the large cohort of HIV 
infected patients with stroke that I studied in Malawi. 
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5 Aetiology and HIV predictors of outcome at six months in 
HIV related stroke in Malawi; a prospective case series 
 
 
5.1 Abstract 
Background 
Untreated HIV infection and recently starting combined antiretroviral therapy (cART) are important risk 
factors for stroke in HIV endemic regions. However there is uncertainty about the aetiology, clinico-
pathological presentation and the predictors of a poor outcome in HIV related stroke. 
 
Methods 
The cohort of adults (age >17 years) with acute stroke described in chapter 3 were investigated by MRI 
brain imaging, cardiac and carotid ultrasound scan, electrocardiogram, blood and CSF screening for 
infectious and inflammatory aetiologies,  and histopathology examination of the brain when possible. 
HIV positive ischaemic stroke cases were classified according to the aetiologies defined in chapter 4. 
Survivors of stroke were followed up for 6 months. 
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Results 
Seventy-eight of the 252 (31%) confirmed stroke patients were HIV positive (64 had an ischaemic 
stroke). Their median age and CD4+ T-lymphocyte count was 41 years (IQR;32,54) and 192 cells/mm3 
(IQR; 66,342) respectively.  Among those with an Ischaemic stroke: 34/64 (53%) had HIV-associated 
vasculopathy (32% were undetermined), 18/64 (28%) had opportunistic infections, 7/64 (11%) had anti-
phospholipid syndrome and 5/64 (8%) had cardioembolism. Thirty-four (44%) were on cART, of these, 
19 had recently started within 6 months (15 had an ischaemic stroke).   Among those starting cART 
within 6 months of an ischaemic stroke only 4/15 (27%) had an opportunistic infection and 11/15 (73%) 
were dead or missing by 6 months. One case with a histologically-proven diagnosis had evidence of HIV-
associated vasculitis after starting cART.  Advanced immnuosuppression (adjusted hazard ratio [aHR] 
8.22 (1.85, 36.48) was associated with a poor outcome but initiating cART within the previous 6 months 
prior to a stroke (aHR 1.33(0.30, 6.01) was not. 
 
Conclusion 
Less than a third of HIV related strokes are due to opportunistic infections.  Although HIV-associated 
vasculopathy was the predominant aetiology, this cohort needs to be further characterised. It is possible 
that in a subpopulation of HIV infected individuals, cART initiation exacerbates an ongoing pro-
inflammatory state however; a better understanding of this subpopulation is urgently needed to guide 
appropriate interventions. 
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5.2 Introduction 
As discussed in chapter 3, HIV infection is an important risk factor for young stroke in HIV endemic 
regions. Several aetiologies have been described which are directly (e.g. HIV-associated vasculopathy) or 
indirectly (e.g. opportunistic infection) related to HIV infection (Chapter 1). 
  
HIV-associated vasculopathy is a term that encompasses the different HIV-associated cerebrovascular 
diseases in the absence of opportunistic infection vasculitis and lymphoma. Accelerated atherosclerosis 
in HIV infected individuals is a more accepted cause of HIV-associated vasculopathy (Chapter 1).   
However, the mechanism of non-atherosclerotic stroke, found especially in younger HIV infected 
patients, is less clear (Chapter 4).  Furthermore, age is a strong predictor of stroke, and as the HIV 
positive population ages on treatment it is uncertain if accelerated atherosclerosis will become the 
dominant mechanism of HIV related stroke. 
 
In chapter 3, I showed that untreated HIV infection is associated with ischaemic stroke which is mostly 
mediated by immunosuppression but more importantly, that there was an independent risk of 
developing a stroke within 6 months of starting combined antiretroviral therapy (cART). The 
characteristics of this subgroup and their underlying aetiology are undefined. 
 
Because of the clinico-pathological uncertainties about HIV related stroke, especially in those recently 
starting antiretroviral treatment, I prospectively investigated the clinical, radiological and pathological 
characteristics of patients presenting with HIV related stroke in Malawi. I determined the aetiology of 
ischaemic stroke, using the definitions described in chapter 4. I also examined the variation in 
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phenotype compared to stroke patients who did not have HIV infection as well as determine the HIV 
characteristics that predicted a poor outcome at 6 months. 
 
5.3 Methods 
5.3.1 Patients  
This study was conducted at the Queen Elizabeth Central Hospital in the cohort of adults (age >17 years) 
with acute stroke described in chapter 3. The 30 patients that were excluded for residing outside the 
Blantyre district were included in this analysis (Chapter 3). All patients that met the WHO criteria of a 
stroke and presented to hospital between February 2011 and April 2012 were included in this case 
series, the eligibility criteria were previously described (Chapter 3). The study was approved by the 
Liverpool School of Tropical Medicine, UK and the College of Medicine Research Ethics Committee, 
University of Malawi. All participants or guardians gave written informed consent. 
 
5.3.2 Procedures 
I took a full history, including details of clinical demographics, clinical features of the stroke 
presentation, exposure to potential vascular risk factors and drug history from each patient. I also 
performed a detailed clinical examination, including a full neurological examination. Stroke severity at 
baseline was assessed with the National Institutes of Health Stroke Scale (NIHSS) and classified as non-
severe (NIHSS<14) or severe (NIHSS≥14) and stroke subtype was assessed using the Oxfordshire 
Community Stroke Project classification, both were performed within 7 days of the index stroke (Brott et 
al. 1989; Bamford et al. 1991). Blood pressure and waist-hip-ratio were assessed as previously described 
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(Chapter 3). Ankle brachial index was measured using HI Dop Vascular Doppler (Ana Wiz Ltd UK), 
peripheral vascular disease was defined as an ankle brachial index <0.9 (Hirsch et al. 2006).  Brain 
imaging was performed on a GE 0.35 Tesla Signa Ovation Excite Magnetic-resonance (MRI) scanner 
(Milwaukee, Wisconsin) within seven days of admission. Routine MRI brain sequences included a 
midline sagittal localising view of the brain - T1-weighted, axial diffusion-weighted images, gradient 
echo, axial T2-weighted and a fluid attenuated inversion recovery sequence.  The images were 
immediately reviewed by a radiologist and subsequently validated by two other radiologists (one 
neuroradiologist and one Infectious disease radiologist). Electrocardiogram was performed and 
interpreted by the physician and a 2D-mode echocardiogram and duplex carotid doppler (Philips HD3) 
were performed and interpreted by a radiologist. When possible, blood samples and cerebrospinal fluid 
(CSF) were taken soon after admission. The blood samples were tested for full blood count, random 
blood glucose, random cholesterol and HIV infection at Malawi-Liverpool-Wellcome Trust Clinical 
Research Programme (MLW) diagnostic facilities; previously described cut-off parameters were used 
(Chapter 3).  Specialist tests for Anti-phospholipid syndrome (APS) included, anti-cardiolipin antibody 
and β2-glycoprotein, these were performed in batches at the Royal Liverpool diagnostic laboratory using 
a commercial ELISA kit (Cambridge Life Sciences Ltd, Cambridgeshire, UK). Rapid plasma reagin (RPR), 
Treponema (Tp) enzyme immunoassay (EIA), Treponema Pallidum Particle Agglutination (TPPA) were 
tested for syphilis at the Public Health of England (PHE) clinical diagnostic laboratory, London. Each 
patient’s CSF had microscopy for white and red cells, and CSF gram stain.  CSF bacterial culture, protein 
and glucose were also performed. Additional tests such as indian ink stain and cryptoccocal antigen 
were performed in all CSFs from HIV positive patients. Staining and microscopy for acid fast bacilli and 
culture for Mycobacterium Tuberculosis (MTB) were performed in the CSF of those with white cell count 
≥5cells/mm3.  RPR, TPPA and Tp EIA were tested in the CSF of those with a positive serum  and VZV 
intrathecal index was determined by comparing the serum/CSF ratio of anti-VZV IgG antibody to the 
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serum/CSF ratio of albumin and total IgG at the PHE clinical diagnostic laboratory, London (Reiber et al. 
1991; Winchester et al. 2011). Limited brain autopsy was performed in deceased HIV positive patients 
(when possible) by a local pathologist. Brain tissue was stored in 10% formalin and shipped to the 
University of Edinburgh for processing. The tissue sections were stained with hematoxylin and eosin and 
Zeihl-Neelsen stain.  Additional staining to assess for evidence of HIV-associated encephalitis included 
CD8, CD68 and CR3. The results were interpreted by a neuropathologist and general pathologist with an 
interest in HIV infection. 
 
Patients were managed by the admitting medical team according to standard hospital protocols, which 
included starting anti-hypertension treatment if hypertension was present after day 5 post-stroke and 
commencing on anti-glycaemic agents, if diabetes was diagnosed. All patients with ischaemic stroke 
were commenced on aspirin if no contra-indications.  On discharge, patients were referred to the 
appropriate ART, diabetes or hypertension out-patient clinic if indicated.  
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5.3.3 Aetiological diagnosis 
All patients were classified using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification. 
For ischaemic HIV positive patients the case definitions for opportunistic infections (VZV, TB, syphilis), 
cardio-thromboembolism, HIV-associated vasculopathy (i.e. atherosclerosis, non-atherosclerosis, 
vasculitis and small vessel disease) and anti-phospholipid syndrome were applied and the final 
diagnoses was then determined using the  hierarchical algorithm I developed in Chapter 4. 
 
5.3.4 Follow-up 
At the point of in-patient death or discharge,  at 3 months and at 6 months, the modified Rankin score 
[mRS] was recorded using validated structured questions (Janssen et al. 2010). The modified rankin scale 
classifies the level of disability and death in stroke patients where 0=no symptoms, 1=no significant 
disability, 2=slight disability, 3=moderate disability, 4=moderately severe disability 5=severe disability 
and 6=death (Janssen et al. 2010).  The assessment was performed over the phone at 3 months and in 
person at 6 months.  Because mobile phone use was widespread in Malawi I used this as a way to 
communicate with the patients. I obtained two numbers (the second usually being another family 
member or neighbour) to maximise ascertainment at follow-up.  Patients were called up to 5 times on a 
weekly basis with text message communication at the point of follow-up. If unsuccessful, they were 
classified as lost-to-follow-up after this intensive period of ascertainment. Death was confirmed in 
hospital or by verbal notification (over the phone) by the patient’s guardian, relative or neighbour. 
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5.3.5 Statistical analysis 
This case series was largely descriptive. Clinico-pathological information was described in detail for 2 
patients and clinico-radiological for 3. Univariate analysis was performed to identify significant 
differences between the clinical characteristics and outcome of ischaemic HIV and non-HIV patients, 
stratified by age and the different aetiologies. Continuous variables were compared using the Student t-
test or Mann-Whitney U test and categorical variables were compared by Pearson Chi-Squared and 
Fisher Exact tests.  After checking that the assumption of proportionality was satisfied, a cox 
proportional hazard model was used to assess the association of HIV characteristics (untreated 
infection, <6 months treatment, ≥6 months treatment and advanced immunosuppression; 
<200cells/mm3) and death within 6 months for the survivors of stroke patients post-discharge. The 
following variables were included in the model: HIV characteristics, NIHSS classification, gender and age 
at stroke onset. All patients were censored at 6 months of follow-up or 13th October 2012 for those that 
were missing.  Missing covariates were included in the analysis by creating missing value categories. I 
reported hazard ratios with 95% CIs. The data were analysed with STATA version 11.2 and GraphPad 
Prism version 6, GraphPad Software Inc., California, USA. Two-sided values of P≤0.05 was considered 
statistically significant. 
 
5.4 Results 
I identified 300 suspected stroke patients. Two-hundred and sixty out of 300 (87%) had an MRI scan. I 
excluded 48 (16%) patients with a stroke mimic, the aetiology was unknown in 27 (56%), other causes 
found included brain tumours 7 (15%), old strokes 5 (10%), toxoplasma 3 (6%), subdural haemorrhage 2 
(4%), meningitis 2 (4%), tuberculoma 1 (2%) and an inflammatory disorder 1 (2%).  For the overall stroke 
cohort; an MRI confirmed 172 ischaemic strokes, 45 haemorrhagic and 35 unknowns. The ischaemic 
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stroke subtype was predominantly lacunar infarct (72; 42%), followed by partial anterior circulation 
infarct (51; 30%), total anterior circulation infarct (42; 24%) and posterior circulation infarct (8; 4%). 
Sixty-three (37%) of the ischaemic strokes were severe (NIHSS ≥14).  The median age was 60 years 
(Interquartile range; 43, 70) and 117/252 (46%) were male.  In-patient mortality was 43/252 (17%) and 
the cumulative mortality for survivors post discharge was 51/209 (24%) at 6 months. Thirty-nine out of 
209 (19%) were lost to follow-up. 
 
Seventy-eight of the 252 (31%) confirmed stroke patients were HIV positive. Of these MRI brain 
confirmed 64 ischaemic strokes,9 haemorrhagic and 5 did not have a scan. The median age was 41 years 
(IQR; 32, 54) and 36 (46%) were male. Thirty-four (44%) were on cART, of these, 19 had started within 6 
months. The median CD4+ T-lymphocyte count was 192 cells/mm3 (IQR; 66,342). The ischaemic stroke 
subtype was predominantly lacunar infarct (26; 40%), followed by partial anterior circulation infarct (19; 
29%), total anterior circulation infarct (16; 25%) and posterior circulation infarct (4; 6%). Twenty out of 
64 (31%) of the ischaemic stroke were severe (NIHSS ≥14).  In-patient mortality was 13/78 (17%), the 
cumulative mortality for survivors post discharge was 13/65 (20%) at 6 months. Seventeen out of 65 
(26%) were lost to follow-up. 
 
5.4.1 Phenotype of HIV related stroke 
Being a young stroke patient was strongly associated with HIV infection (median 41 years versus 65 
years in the HIV negative cohort; p <0.001).  Ischaemic stroke type was predominant in HIV infected 
individuals compared with HIV negatives (p=0.025).  Although haemorrhagic stroke was less frequent, 
the burden increased with age and had similar proportions to the non-HIV participants from 55 years 
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Figure 5:1. There were no significant differences in subtype and severity of HIV reated ishcaemic stroke 
compared to the equivalent HIV negative cohort. The aetiology differed substantially between the HIV 
positive and negative stroke patients (p<0.001).  The causes of HIV stroke was defined by the TOAST 
classification. The aetiologies were less diverse in the younger age-bands (e.g. other determined cause 
predominated). This transitioned to a more heterogeneous spectrum from age 45 years and included 
large atherosclerosis, cardio-thromboembolism, small vessel disease and undetermined cause.  In the 
non-HIV stroke cohort, undetermined aetiology predominated Figure 5:1. The prevalence of 
cardiovascular risk factors in HIV related stroke participants were hypertension 28 (42%), diabetes 2 
(3%), hypercholesterolaemia 5 (8%), smoking 6 (9%), acute infection 12 (18%), peripheral vascular 
disease 8 (12%), heating houses with wood 10 (15%) and abdominal obesity 26 (40%). Only heating 
houses with wood was significantly associated with HIV related stroke (15% versus 10%; 0.027), while 
hypertension, diabetes and smoking were significantly associated with non-HIV stroke.  There were no 
significant differences in the prevalence of peripheral vascular disease in HIV positive and negative 
participants (12% versus 13%; p=0.384). 
   
5.4.2 Aetiology of ischaemic HIV related stroke 
The aetiology of HIV related ischaemic stroke was based on case definitions of confirmed or probable 
certainty Table 5:1. I described several aetiologies; HIV-associated vasculopathy 34 (53%), opportunistic 
infection 18 (28%), anti-phospholipid 7 (10%) and cardio-thromboembolism 5 (8%) Table 5:2. There was 
a trend towards an association in the age distribution for the different aetiologies (p=0.066); those with 
opportunistic infection were younger (median age 35) than those with HIV-associated vasculopathy, 
anti-phospholipid syndrome and cardio-thromboembolism (median age 41, 43 and 54 respectively). 
There was no association between the different ischaemic aetiologies and gender, having additional 
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symptoms to a focal neurological deficit, severity of stroke, full blood count, in-patient mortality and 
death within 6 months Table 5:2.  APS and opportunistic infections were associated with a lower CD4+ T-
lymphocyte count compared with the other aetiologies, and a significantly higher proportion were 
untreated  (71% and 72% respectively) compared to those with HIV-associated vasculopathy and cardio-
thromboembolism (47% and 60% respectively) Table 5:2. 
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Figure 5:1: Describes the age distribution (Image A) and stroke type stratified by HIV positive status (Image 
B) 
 
A 
B 
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Figure 5:2: Describes the subtype (image A) and aetiology (Image B) of ischaemic stroke stratified by HIV 
positive status. 
Stroke subtype was defined by the Oxford Community Stroke  Project classification.  Aetiology of stroke 
was defined by TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification. TACI – Total anterior 
circulation infarct, PACI – Partial anterior circulation infarct, POC – Posterior circulation infarct, LACI – 
Lacunar infarct.  
 
A 
B 
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Table 5:1: Aetiologies of HIV ischaemic stroke and their degree of certainty (n=64) 
 
 
Aetiological 
classification 
 
Sub-classification 
 
 
 
No. 
 
Certainty of diagnosis 
 
HIV-associated 
vasculopathy 
 
Atherosclerosis [AS] (6) 
Non-Atherosclerosis [Non-AS](7) 
Small vessel disease [SVD] (2) 
Vasculitis [VA] (8) 
Undetermined disease [UD](11) 
 
 
34 
 
Confirmed  
AS -3, Non-AS-4, SVD-2, 
 
Probable 
AS-3, Non-AS-3, VA-8 
 
Opportunistic 
infection 
 
 
Varicella Zoster Virus [VZV] (9) 
Mycobacterium Tuberculosis [MTB] (5) 
Syphilis (4) 
 
18 
 
Confirmed 
VZV-9, MTB-1 
 
Probable 
MTB-4, Syphilis-4 
 
Cardioembolism 
 
- 
 
5 
 
Confirmed -5 
 
APS 
 
- 
 
7 
 
Probable-7 
    
AS-Atherosclerosis, Non-AS - Non-Atherosclerosis, SVD - Small vessel disease, VA – Vasculitis, UD - 
Undetermined disease. (5) Inconclusive aetiology, (9) Haemorrhagic stroke. 
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Table 5:2:  Clinical features and outcome for the different aetiologies of HIV positive iscahemic strokes 
 
 HIV-associated 
vasculopathy 
(n=34) 
 
Opportunistic 
infection 
(n=18) 
Anti-
phospholipid 
syndrome (n=7) 
Cardio-
thromboembolism 
(n=5) 
P value 
Median age (IQR) 41 (31,50) 35 (28,40) 43 (32,60) 54 (42,62) 0.066 
Male (%) 18 (53) 7 (39) 4 (57) 2 (40) 0.732 
Not on cART (%) 16 (47) 13 (72) 5 (71) 3 (60) 0.019* 
CD4+ T-lymphocyte count 221 (90,323) 133 (55,266) 89 (63,120) 302 (240,558) 0.038* 
 
Additional symptoms to 
focal neurological deficit: 
 
Seizure 
GCS ≤ 8 
Headache 
Fever 
 
Severity of stroke 
(Median NIHSS) 
 
 
 
 
0 
8 (25) 
15 (48) 
5 (15) 
 
12 (8,16) 
 
 
 
 
0 
3 (17) 
9 (52) 
5 (28) 
 
13 (8,16) 
 
 
 
 
0 
1 (14) 
5 (71) 
1 (17) 
 
10 (7,12) 
 
 
 
 
0 
3 (60) 
2 (40) 
0 
 
9  (8,11) 
 
 
 
 
- 
0.218 
0.680 
0.479 
 
0.369 
 
Blood result 
 
Median white cell count 
Median Haemaglobin 
Median Platelet 
 
 
 
5 (4,6) 
13 (10,14) 
257 (183,317) 
 
 
 
6 (4,6) 
12 (10,13) 
223 (182,297) 
 
 
 
5 (4,5) 
10 (9,12) 
258 (211,299) 
 
 
 
5 (5,6) 
13 (12,14) 
281 (203,333) 
 
 
 
0.735 
0.299 
0.702 
 
CSF result  
 
Median white cell count 
Median red cell count 
Median glucose 
Median protein 
 
 
 
0 (0,2) 
3 (0,23) 
3.1 (2.8,3.9) 
0.7 (0.4,0.9) 
 
 
 
0 
12 (0,200) 
2.6 (1.6,3.2) 
0.8 (0.5,2.5) 
 
 
 
0 
0 (0,80) 
2.6 (2.3,3.1) 
0.6 (0.6,1.4) 
 
 
 
0 (0,2) 
45 (7,5800) 
3.2 (2.9,3.7) 
0.4 (0.3,0.7) 
 
 
 
0.458 
0.141 
0.035* 
0.212 
 
Outcome of stroke 
 
In-patient mortality 
 
 
Survivors post discharge  
 
Cumulative mortality at 6 
months  
Missing data  
 
 
 
 
5 (15) 
 
 
 
 
 
11 (32) 
7 (21) 
 
 
 
3 (17) 
 
 
 
 
 
7 (39) 
6 (33) 
 
 
 
1 (14) 
 
 
 
 
 
3 (43) 
1 (14) 
 
 
 
1 (20) 
 
 
 
 
 
2 (40) 
0 
 
 
 
0.990 
 
 
 
 
 
0.661 
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5.4.3 HIV-associated vasculopathy 
This term encompasses several mechanisms and the frequency of the different types among those with 
ischaemic stroke were atherosclerosis 6/34 (18%), non-atherosclerosis 7/34 (20%), vasculitis 8/34 (24%), 
small vessel disease 2/34 (6%), undetermined 11/34 (32%). I had limited access to HIV stroke deceased 
brain for histopathological examination. However, those that were available showed distinct 
mechanisms of HIV-associated vasculopathy. Some illustrative material from individual patients is 
described here Figure 5:4, Figure 5:5, Figure 5:6. For example Patient 218 was found at autopsy to have 
a diagnosis of extensive atherosclerosis, despite his relatively young age (age 50 years).  He also had 
borderline elevated hypercholesterolaemia Figure 5:4.  For Patient 219 the cause of her stroke, which 
was exacebated 5 days after starting cART, was unknown; based on her admission clinical features and 
progress.  However at autopsy, she was found to have an extensive HIV-associated vasculitis in the 
absence of background HIV encephalitis or other infections on histopathological examination Figure 5:5. 
In three patients, one with undetermined and two with a non-atherosclerosis diagnoses, I demonstrated 
evidence of extra-cranial with or without intra-cranial disease from MRI imaging and duplex carotid 
doppler Figure 5:6. 
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Figure 5:3: Patient 218 case report 
NIHSS – National Institutes of Health Stroke Scale, CXR – chest radiograph, MRI – magnetic 
resonance imaging, CSF – cerebrospinal fluid, TB – Mycobacterium Tuberculosis VZV – varicella 
zoster virus, CNS cART – combined antiretroviral therapy, IgG – immunoglobulin. 
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Figure 5:4: Patient 219 case report 
NIHSS – National Institutes of Health Stroke Scale, CXR – chest radiograph, MRI – magnetic 
resonance imaging, DWI-diffusion weighted imaging, T1 – T1 weighted imaging, T2 – T2 weighted 
imaging, CSF – cerebrospinal fluid, TB – Mycobacterium Tuberculosis VZV – varicella zoster virus, 
CNS – central nervous system, cART – combined antiretroviral treatment, IgG – immunoglobulin. 
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Figure 5:5: Case reports of HIV-associated vasculopathy with extra-cranial manifestation 
NIHSS – National Institutes of Health Stroke Scale, CXR – chest radiograph, MRI – magnetic resonance 
imaging, DWI-diffusion weighted imaging, T1 – T1 weighted imaging, T2 – T2 weighted imaging, CSF – 
cerebrospinal fluid, TB – Mycobacterium Tuberculosis VZV – varicella zoster virus, CNS – central nervous 
system, cART – combined antiretroviral therapy, mRS – modified rankin score, ACL – anticardiolipin 
antibody, β2 –GP1 – Beta 2 glycoprotein 1. 
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5.4.4 Clinical features in patients who recently initiated cART 
Although the spectrum of the final diagnoses in those who recently initiated cART was diverse, the 
majority 8/15 (53%) had HIV-associated vasculopathy. Only 4/15 (27%) had opportunistic infections.  
Twelve out of 15 (80%) were on stavudine based cART regimens. Arguably, the level of 
immunosuppression was variable but the majority were immunosupressed; the median CD4+ T-
lymphocyte count was 113 (Interquartile range; 63, 218). Ten out of 15 (67%) had initiated cART within a 
month and most, 11/15 (73%) died (8) or were missing (3) by six months Table 5:3. 
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Table 5:3: Clinical features of 15 patients with an ischaemic stroke that recently initiated cART 
 
ID Age Sex Approximate 
date of 
stroke 
cART 
initiated 
within a 
month of 
index 
stroke 
On 
Stavdine 
based 
regimen 
CD4+ 
count 
NIHSS 
score 
on 
admiss
ion 
CSF characteristics Final diagnosis Outcome 
21 50 M Mar 2011 Yes Yes 15 27 WCC 0 cells/mm3, RCC 30 
cells/mm3, glucose  2.89mg/L, 
protein  0.75mg/L 
HIV-associated vasculopathy – 
small vessel disease 
Died in hospital 
32 17 F Apr 2011 Yes Yes 305 22 WCC 0  cells/mm3, RCC 0 
cells/mm3, glucose 2.48  mg/L, 
protein  0.2mg/L 
HIV-associated vasculopathy – 
confirmed non-atherothrombosis 
mRS 4 at discharge, died at 3 
months 
46 42 M Apr 2011 Yes Yes 12 18 WCC  26 cells/mm3, RCC 15 
cells/mm3, glucose 3.07 mg/L, 
protein  0.69 mg/L 
HIV-associated vasculopathy – 
probable vasculitis 
mRS 3 at discharge, died at 3 
months 
50 52 F Apr 2011 Yes Yes 133 12 WCC 0 cells/mm3, RCC 0 
cells/mm3, glucose 3.04 mg/L, 
protein  0.84 mg/L 
Opportunistic infection – 
confirmed VZV 
mRS 4 at discharge, died at 3 
months 
75 30 M May 2011 Yes Yes 50 13 WCC 640 cells/mm3, RCC 0 
cells/mm3, glucose  1.37mg/L, 
protein  1.55mg/L 
Opportunistic infection – probable 
TB 
mRS 4 at discharge, mRS 3 at 
3 months, missing at 6 
months 
85 31 M Jun 2011 Yes Yes 82 13 WCC 0 cells/mm3, RCC 15 
cells/mm3, glucose  2.90mg/L, 
protein  0.95mg/L 
HIV-associated vasculopathy – 
probable vasculitis 
mRS 3 at discharge, missing at 
3 and 6 months 
87 42 F Jun 2011 No Yes 362 12 WCC  0 cells/mm3, RCC 10 
cells/mm3, glucose  4.13 mg/L, 
protein  0.36 mg/L 
Cardio-thromboembolism mRS 4 at discharge and mRS 1 
at 6 months 
118 62 F Aug 2011 Yes - 63 10 WCC  0 cells/mm3, RCC  20 
cells/mm3, glucose  2.65mg/L, 
protein  0.9 mg/L  
Antiphospholipid syndrome mRS 3 at discharge, died at 3 
months 
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ID Age Sex Approximate 
date of 
stroke 
cART 
initiated 
within a 
month of 
index 
stroke 
On 
Stavdine 
based 
regime 
CD4+ 
count 
NIHSS 
score 
on 
admiss
ion 
CSF characteristics Final diagnosis Outcome 
129 34 F Aug 2011 Yes Yes 128 27 WCC  0 cells/mm3, RCC 8 
cells/mm3, glucose  2.54 mg/L, 
protein  16mg/L 
Opportunistic infection – 
confirmed TB 
Died in hospital 
190 29 F Nov 2011 Yes Yes 88 12 WCC  0 cells/mm3, RCC 3 
cells/mm3, glucose  2.49 mg/L, 
protein  0.98mg/L 
HIV-associated vasculopathy – 
probable vasculitis 
mRS 3 at discharge, died at 6 
months 
215 39 M Dec 2011 No Yes 92 13 WCC 15 cells/mm3, RCC 44  
cells/mm3, glucose  1.91 mg/L, 
protein  1.38 mg/L 
HIV-associated vasculopathy – 
probable vasculitis 
mRS 2 at discharge and 0 at 6 
months 
220 32 F Dec 2011 No Yes 156 12 WCC 0  cells/mm3, RCC  0 
cells/mm3, glucose  3.21mg/L, 
protein  0.37 mg/L 
HIV-associated vasculopathy – 
undetermined 
mRS 3 at discharge and 0 at 6 
months 
268 52 M Mar 2012 No Yes 113 7 WCC  0 cells/mm3, RCC  80 
cells/mm3, glucose  0.56 mg/L, 
protein  1.35 mg/L 
Anti-phospholipid syndrome mRS 3 at discharge, died at 3 
months 
278 45 M Mar 2012 Yes - 218 17 WCC  0 cells/mm3, RCC 0 
cells/mm3, glucose  3.7mg/L, 
protein  0.51mg/L 
HIV-associated vasculopathy – 
confirmed non-atherothrombosis 
mRS 4 at discharge and 4 at 6 
months 
293 27 F Apr 2012 No - 623 14 WCC  0 cells/mm3, RCC 800 
cells/mm3, glucose  3.08 mg/L, 
protein 0.7 mg/L 
Opportunistic infection – probable 
syphilis 
mRS 3 at discharge, missing at 
3 and 6 months 
M – male, F – female, ID – patient identifier, WCC – white cell count,  RCC – red cell count  TB – Mycobacterium Tuberculosis VZV – varicella zoster virus, , cART – combined 
antiretroviral treatment, mRS – modified rankin score, CD4+ count – CD4+ T-lymphocyte count, “-“ missing. 
-  
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5.4.5 HIV characteristics that are predictors of mortality within 6 months 
After adjusting for age, sex and severity of disease, advanced immunosuppression (CD4+ T-lymphocyte 
count <200cells/mm3) was a significant predictor of death within 6 months in those with ischaemic 
stroke (adjusted hazard ratio [aHR] 8.22 [1.85, 36.5].  Although being on cART for ≥6 months showed 
trends towards predicting death within 6 months, it was not significant Figure 5:7.  Over 85% of newly 
diagnosed HIV positive stroke survivors were initiated on cART within a month of discharge. 
Interestingly, untreated HIV positive patients who survived a stroke, showed trends towards a favorable 
outcome at 6 months (HR 0.37 [0.06, 2.14]). However, ten out of 32 (31%) were missing at 6 months. 
The aetiology of this missing individuals included (4) HIV-associated vasculpathy, (4) opportunistic 
infection (1) antiphospholipid syndrome (1) inconclusive Figure 5:7. 
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Figure 5:6: HIV characteristics that predict death among discharged survivors of ischaemic stroke 
Advanced immunosuppression was defined as a CD4+ T-lymphocyte count <200 cells/mm3. Loss to 
follow-up was found in the following categories: 6/25 advanced immunosuppression, 1/8 among 
participants on cART for ≥ 6 months,  3/13 among those on cART for < 6 months, and 10/32 
untreated HIV infected participants. 
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5.5 Discussion 
HIV related stroke is an emerging disease and threatens to worsen the increasing burden of stroke in 
low and middle income countries.  Current knowledge about the mechanisms of disease in those 
initiating cART and the transition of the different phenotypes as the HIV population ages is uncertain.  
Importantly, I have shown that only a third of stroke patients that had been initiated on cART in the first 
6 months prior to developing a stroke had opportunistic infections, most were on stavudine based 
therapy and most died within 6 months of their stroke. My work further characterises the spectrum of 
the different aetiologies in HIV positive and negative stroke patients and shows that the aetiologies are 
distinct in the young but converges from the age of 45 years. 
 
In chapter 3, I described the association with recent cART initiation and ischaemic stroke.  The data in 
this chapter gave some understanding about the possible mechanisms, and prognosis:  Opportunistic 
infections occurred in less than a third and although HIV-associated vasculopathy was the most common 
aetiology, this phenotype needs better characterisation.  Furthermore, most of these patients died 
within 6 months of their stroke.  A large cohort study in Uganda evaluating adverse events in those 
initiating cART reported a high mortality of 18% in the first year, but without routine neuroimaging of 
these participants, it was not clear how much of this can be attributable to stroke (Castelnuovo et al. 
2009).  I also found that the timeframe from starting cART to developing a stroke was within one month. 
Uncontrolled or interrupted HIV infection is associated with increased levels of tissue factor, interlukin-
6, D-dimer and nonclassic [CD14(+) CD16(++)] and classic [(CD14++) CD16(+) monocyte activation. Non-
HIV infected individuals with acute vascular events also have similar activation profiles (Kuller et al. 
2008; Funderburg et al. 2012). It is conceivable that starting cART in a subpopulation of HIV positive 
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individuals exacerbates this process. There is also the possibility of other simultaneous or independent 
mechanisms; namely nucleotide reverse transcriptase inhibitor (i.e. stavudine) toxicity.   
 
The concept that starting cART exacerbates an ongoing pro-inflammatory state in a subgroup of 
individuals was supported by the case report of the young woman who improved from a stroke whilst 
on anti-inflammatory therapy. She developed worsening symptoms and consequently died soon after 
starting cART, histopathological examination of the brain confirmed a florid HIV-associated vasculitis, 
her MRI prior to commencing HIV treatment showed a uni-focal lesion. It is possible that a previously 
localised HIV-associated vasculitis was exacerbated by starting cART. Whereas the case of the 50-year-
old man on HIV treatment for ≥ 6 months, supports the concept of an accelerated atherosclerosis 
induced by chronic HIV infection.  He also had borderline hypercholesterolaemia. Progressive 
hypercholestrolaemia can occur rapidly on stavudine based cART, as shown by the 9% increase in 
prevalence between 12-24 months of routine surveillance in Malawi and thus an additive risk of stroke 
in this population (van Oosterhout et al. 2012).  
 
Stroke is not the only vascular entity that has been linked with HIV infection. Recently, in a large USA 
based cohort, HIV infection was associated with a 50% increased risk of acute myocardial infarction after 
taking account of recognised vascular risk factors (Freiberg et al. 2013). Peripheral vascular disease was 
not uncommon in the HIV positive participants. I would have expected a significantly higher prevalence 
in the older non-HIV stroke cohort but instead, I showed no significant difference compared to the 
young HIV stroke patients; this may indicate a link with HIV infection.   
 
As this study was hospital based, our data were limited for individuals with mild strokes and silent 
infarcts, who were less likely to come to hospital. The latter could be especially relevant to HIV infection, 
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as a previous review of a large series of autopsies on brains of HIV positive people showed evidence of 
widespread small vessel ischaemia in an asymptomatic cohort (Connor et al. 2000).  Mild strokes and 
silent infarcts are associated with subtle physical and cognitive deficits; the latter may be relevant to the 
increased prevalence of mild to moderate HIV-associated neurocognitive impairment in the cART era 
(Vermeer et al. 2007; Schouten et al. 2011). I was unable to explore the role of HIV co-infection with 
other chronic infections such as hepatitis B and C and although hepatitis C is associated with stroke risk, 
hepatitis B is not (Sung et al. 2007; Lee et al. 2010). However, HIV and hepatitis C co-infection rates are 
low in Malawi (0.1%) and thus unlikely to have had an impact on our findings (Chasela et al. 2012). 
Although we showed a favourable trend between untreated infected stroke patients and outcome at 6 
months, the high loss to follow-up in this cohort, could have substantially underestimated this risk. 
 
In conclusion, in this chapter I found a variety of aetiologies associated with HIV infection.  Importantly, 
less than a third of HIV related strokes were due to opportunistic infections.  Although HIV-associated 
vasculopathy was the predominant aetiology, this cohort needs to be further characterised.  HIV 
infection may accelerate the typical causes of stroke found in the non-HIV infected population.  
Furthermore, the potential impact of HIV treatment and the additive effect of other vascular risk factors 
as the HIV population ages is yet to be realised.  It is possible that in a subpopulation of HIV infected 
individuals, initiating cART exacerbates an ongoing pro-inflammatory state however; a better 
understanding of this subpopulation is urgently needed to guide appropriate interventions. 
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6 Overall discussion 
 
 
6.1 The epidemiology of HIV infection and stroke 
The high incidence of young stroke (age ≤45years) in HIV endemic countries has been largely attributed 
to hypertension but my work has shown that HIV infection also has a role in this population.  Because 
HIV infection is frequently omitted when assessing the global burden of stroke, it has been challenging 
to quantify the true impact of HIV infection on cerebrovascular disease risk (O'Donnell et al. 2010; Feigin 
et al. 2013 ). This also occurs at the hospital level, for example, in a UK based hospital, a 22 year-old man 
was extensively investigated for cryptogenic stroke and it was only on day 12 that a positive HIV result 
was realised (Benjamin et al. 2009).  A concerted effort from both the physician and the researcher is 
essential to address the burden of HIV related stroke.  Work from my thesis supports the idea of routine 
HIV testing in young stroke patients, especially in regions with a prevalence of more than 2 in 1000.  
Furthermore,  requesting appropriate brain imaging (e.g. MRI brain) to confidently exclude mimics of 
stroke, and including HIV infection as a measurable index for stroke surveillance studies will also help 
(British HIV Association 2008) (Chapter 2). Without these simple changes to medical practice the true 
extent of HIV related stroke will not be fully realised.  
 
My findings are consistent with large retrospective datasets in Europe and USA linking HIV infection with 
stroke (Ovbiagele et al. 2011; Rasmussen et al. 2011).  Although the association of HIV infection and 
stroke is not restricted to sub-Saharan Africa, other possible exacerbating factors like the global 
variation in HIV subtype (e.g. predominantly subtype A,C, D in Africa and B in USA and Europe) and the 
effect of other prevalent infectious diseases that are known to exacerbate atherogenesis, cannot be 
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completely ruled out of contributing to the increased burden of stroke in sub-Saharan Africa (Elkind et 
al. 2010).   
 
The phenotype of HIV related stroke in industrialised countries is distinct from my cohort; patients are 
less likely to be immunosuppressed, older than our described cohort but younger than the non-HIV 
stroke population and most are on cART (Ovbiagele et al. 2011; Rasmussen et al. 2011) (Chapter 1). This 
global variation is likely to reflect a shift in the landscape of HIV related stroke; involving a transition 
from non-atherosclerosis HIV-associated vasculopathy, HIV-associated vasculitis and an opportunistic 
infection vasculitis in the young, to an accelerated atherosclerosis in an aging population. Exposure to 
metabolic disorders associated with cART and the overlap of established vascular risk factors in the older 
populations may also exacerbate the latter. In the USA, the rate of older people living with HIV infection 
is rapidly increasing and is estimated to be double by 2015; recent modeling using South African data 
suggests that the number of those over 50 years of age will nearly double in the next 30 years (Hontelez 
et al. 2011; Greene et al. 2013).   
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6.2 Clinical implication of cART and stroke  
Whilst I have shown an association between commencing cART and having a stroke, I have also 
demonstrated that increasing CD4+ T-lymphocyte count (a function of being on cART) is associated with 
a reduction in stroke risk. This emphasises the overall benefit of cART in reducing the risk of stroke 
(Rasmussen et al. 2011). However, there could potentially be public health implications with the 
subpopulation that are at an increased risk of stroke when initiating cART.  In this cohort, ischaemic 
stroke was the predominant stroke type and opportunistic infections only accounted for less than a third 
of cases.  One possible mechanism of stroke after starting cART, as revealed in the histopathology 
supported case report, is that of an underlying HIV-associated vasculitis. Further characterisation of this 
subpopulation is urgently needed, as these patients could potentially benefit from anti-inflammatory 
treatment. 
 
Because 30% of the untreated HIV positive stroke patients were lost to follow-up at 6 months, I was 
unable to fully comment on the outcome of this group. However, with knowledge of their aetiology it is 
plausible that they had died.  This also questions the exacerbating role of starting cART in this cohort. 
 
Overall, the risk of stroke with longer-term (≥ 6 months) cART use was substantially lower overall (aOR 
1.49) and not significantly different from HIV-uninfected individuals.  However, there was suggestion of 
an increased risk of stroke in the younger population (aOR 3.27); this cohort was more likely to survive a 
stroke.  A few studies have reported a link between cART and a high prevalence of dyslipidaemia 
(Behrens et al. 1999; Friis-Moller et al. 2003).  In my study, although the association with stroke was still 
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present after adjusting for hypercholesterolaemia , there is still the possibility of ongoing chronic vessel 
wall inflammation due to HIV infection. 
 
6.3 Other clinical implications of HIV infection and cerebrovascular disease 
People with small vessel disease constituted a small component of our cohort presenting with stroke. 
However, stroke syndromes only form part of the clinical manifestation of small vessel disease, another 
major clinical presentation is neurocognitive impairment (Wardlaw et al. 2013). Although I did not 
assess my cohort for evidence of HIV associated neurocognitive disorder (HAND), there is growing 
evidence to suggest that this is on the rise (Cruse et al. 2012).  The definition of HAND is based on the 
consensus opinion of experts in the field and relies on a battery of neuropsychological (NP) tests 
(Antinori et al. 2007). The classification of HAND includes asymptomatic neurocognitive impairment, 
mild neurocognitive disorder, and HIV-associated dementia (Antinori et al. 2007).  It is specifically 
asymptomatic neurocognitive impairment and mild neurocognitive disorders that account for the 
increasing burden of HAND in the treated HIV infected population (Heaton et al. 2010). HIV encephalitis 
has been closely implicated in HIV-associated dementia but since the introduction of cART, HIV-
associated dementia has diminished and the neuropathology of asymptomatic neurocognitive 
impairment and mild neurocognitive disorders is less certain. Recent evidence suggests that 
cerebrovascular disease has an important role (Wright et al. 2010).  
 
The converging impact of HIV infection, cART and advancing age could potentially increase the burden of 
not only stroke but HAND.  
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6.4 Scope for interventions 
In order for patients and clinicians to make the most informed choices, it is important to risk stratify, at 
several time-points to facilitate primary and secondary prevention Figure 6:1: 
 
1) People with untreated HIV positive stroke 
Opportunistic infection and anti-phospholipid syndrome were the typical aetiology in this 
cohort.   The role for empirical interventions with anti-viral and/or anti-bacterial agents, 
especially in resource-poor settings needs to be explored. Identifying biomarkers with a high 
sensitivity for those with opportunistic infections could also be used to guide the use of such 
empirical interventions. Initiating cART obviously with the caveat of excluding opportunistic 
infections appears to be beneficial. The optimal time point of when to start cART in those with 
proven CNS infection is less clear. Torok and colleagues showed that in TBM, immediate cART 
initiation did not improve outcome and was associated with adverse events (Torok et al. 2011) .  
However, delaying cART initiation by 1 month did no harm (Torok et al. 2011). For APS, the 
priority should be based on a better understanding of the mechanism in HIV positive individuals. 
 
2) People living with HIV infection about to start cART 
Although initiating cART increases the risk of a stroke in a subgroup of individuals, the overall 
benefit still outweighs this risk especially as increasing CD4+ T-lymphocyte count (a function of 
cART) reduces the risk of stroke. Furthermore, advanced HIV infection can be improved if on 
appropriate cART and thus reduces the likelihood of a poor outcome at 6 months.  
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HIV-associated vasculopathy is the most frequently occurring aetiology in those initiating cART.   
Developing clinical biomarkers that can predict those at risk of HIV-associated vasculopathy 
would facilitate risk stratification.  Adjunctive interventions such as anti-inflammatory agents 
(e.g. statins or steriods) could have a role in those initiating cART but needs to be evaluated 
through clinical trials. Furthermore, once a stroke has occurred, the role of high dose 
corticosteroids among those without opportunistic infection should also be explored.    
 
3) People living with HIV infection without cART and without a stroke 
 The World Health Organisation’s timely agenda to reduce transmission of HIV and HIV related 
mortality will theoretically reduce the burden of cerebrovascular disease. However, I believe 
that starting cART irrespective of CD4+ T-lymphocyte count will further delay the chronic 
inflammatory state induced by HIV infection and thus delay the anticipated stroke epidemic 
owing to accelerated atherosclerosis (Mills et al. 2012). 
 
4) People on longer term cART with a stroke 
These patients are generally older and thus likely to overlap with other established vascular risk 
factors (e.g hypertension, hypercholesterolaemia and diabetes).  Furthermore, HIV infection and 
its treatment could exacerbate the burden of these established vascular risk factors e.g. 
hypercholesterolaemia, by independently increasing their prevalence (Friis-Moller et al. 2003). 
The risk of recurrent stroke is therefore high. Regular surveillance and aggressive management 
of these risk factors should be explored in intervention trials. Cardio-thromboembolic stroke is 
also frequent in this cohort and the safety of long-term anticoagulation will need to be 
determined.  In addition to treating the individual risk factors, long term anti-inflammatory 
agents could be of use in reducing HIV-associated chronic inflammation. Non-steriodals and 
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statins are the obvious choice but the novel use of an anti-inflammatory agent such as low-dose 
methotrexate, in secondary prevention of cardiovascular disease is being studied in a non-HIV 
population  and could be beneficial in the HIV context (Everett et al. 2013).   
 
5) People on long term treatment without a stroke 
The surveillance and treatment of risk factors as part of routine HIV care is important at this 
stage.  Metabolic complications (e.g. hypercholesterolaemia) can be related to the class of cART 
used; the phasing out of stavudine for zidovuine or tenofovir will also help (WHO 2013). 
However, the overall safety of the different classes will need to be explored in more detail. This 
is especially true for WHO recommend cART regimens in low-middle income countries (WHO 
2013).
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  Figure 6:1: Scope for primary and secondary interventions to reduce the burden HIV related stroke 
Information in the Grey box is postulated from the literature. 1) People with untreated HIV positive stroke, 2) People living with HIV 
infection about to start cART 3) People living with HIV infection without cART and without a stroke, 4) People on long term cART with  a 
stroke 5) People on long term treatment without a stroke. The risks of stroke associated with each of these numbered stages are 
explained in section 7:4.  cART – combined cART. 
 
 
 
Number 1-5 corresponds to risks described in section 7.4. 
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The overall high in-patient and 6 months mortality seen in my study and another study recently 
performed in Malawi could be related to the high prevalence of advanced HIV disease (Heikinheimo et 
al. 2012).  However, the absence of integrated care for stroke patients (i.e. a stroke unit) could also play 
an important role in the poor outcomes. The benefit of such an intervention or variations of it (i.e. 
nurse-led or guardian-led) will need to be explored. 
 
I have helped to expand our understanding of the mechanisms of HIV related stroke described in 
chapter 1. From the clinical characteristics in Chapter 5 I was able postulate the concept of HIV related 
stroke evolving through an aging population. A better understanding of these mechanisms will help to 
confirm or refute these concepts and thus direct the development of novel therapeutic strategies in HIV 
related stroke Figure 6:2. 
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Figure 6:2: Mechanisms of HIV related ischaemic stroke; redefining the hypothetical model 
cART – Combined anti-retroviral treatment. 
Overall discussion 
184 
 
 
6.5 Concluding remarks 
I have shown that untreated HIV infection and more importantly, recently initiating cART are 
independent risk factors for stroke. The causes of stroke vary but HIV-associated vasculopathy, although 
an evolving aetiology, predominates, especially in those who have recently commenced cART. With the 
advent of effective cART, HIV infection is becoming a chronic disease. HIV positive individuals on cART 
can expect to live longer and, as a result, they are at risk of developing accelerated atherosclerotic 
strokes among other vascular complications such as HIV-associated neurocognitive impairment. The 
consequence is far reaching and is likely to increase death and disability in countries where health 
facilities are already at maximum capacity.  I support the WHO initiative to start cART at a CD4+ T 
lymphocyte count >500 cells/mm3 and the phasing-out of stavudine based cART regimens. I would 
recommend going a step further and initiating cART irrespective of CD4+ T-lymphocyte count to delay 
cerebrovascular complications. As access to cART continues to increase in Malawi, long-term 
cerebrovascular complications are anticipated as seen in the USA. A better understanding of the 
mechanisms in the high risk groups, such as those initiating cART will optimise early recognition and 
diagnosis, and will allow us to implement effective prevention strategies and/or disease interventions. 
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6.6 Future directions 
Improved knowledge about the mechanisms of stroke, especially in those initiating cART and a better 
understanding of the different forms of HIV-associated vasculopathy should lead to improved 
investigations and treatment. 
 
There is growing evidence that HIV related stroke is driven by a pro-inflammatory state. The benefit and 
safety of anti-inflammatory medications in people living with HIV infection such as aspirin, statins, 
steriods and low dose methotrexate will need to be explored through intervention trials (Everett et al. 
2013).   The choice of anti-inflammatory drug is especially important as HIV infection is different from 
other inflammatory conditions because it eliminates CD4+ T lymphocytes but activates other 
components of the immune system. Very specific immune modulatory treatments might be needed. 
 
 Appropriately designed, well powered longitudinal studies are arguably the most useful way of 
developing prediction models, similar to the Framingham Risk Score or the Veterans Aging Cohort Study 
index, for intervention strategies (D'Agostino et al. 1994; Justice et al. 2012).  Such models will alert us 
to those most at risk and therefore, those most in need of an intervention. 
 
6.7 What this study has added to the literature 
My work contributes to the literature on HIV infection and stroke and highlighted an important 
association with starting cART and having a stroke. I have shown that a large proportion of individuals in 
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the UK and Malawi presenting with HIV related stroke are newly diagnosed with HIV infection, thus 
emphasising the need for routine HIV testing especially in the young stroke populations.  The 
heterogeneity of HIV stroke with respect to risk factors for stroke, the degree of immunosuppression 
and HIV activity, and prior or current opportunistic infection has made it difficult to generalise 
epidemiological findings in some studies to populations at large. My study, to some extent unravels 
some of this ambiguity.  I  speculate that HIV related strokes evolves through the introduction of cART 
and then transitions into an aging population, accelerating atherosclerotic stroke and potentially 
contributing to an anticipated stroke epidemic in countries like Malawi. 
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